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1. Scope of the thesis 
This thesis describes the development and application of a miniaturized system for 
continuous subcutaneous glucose monitoring based on m icrodialysis sampling 
coupled with microfluidic glucose analysis. The system incorporates an enzymatic 
microreactor (EMR), a poly(dimethylsiloxane) (PDMS) - glass microfluidic device 
designed for the rapid reaction of glucose with oxygen using the glucose oxidase 
(GOx) enzyme. Fast mixing of GOx with glucose was achieved through integration 
of an array of slanted microgrooves in the PDMS microreactor channel to induce 
chaotic mixing. In in vitro experiments, detection of the hydrogen peroxide 
produced in the reaction was performed using either electrochemical (amperometric) 
measurement at integrated, planar Pt microelectrodes or optical 
(chemiluminescence) detection with a silicon photodiode molded into the EMR.  For 
in vivo application, a microdialysis probe was c oupled to the EMR for the 
continuous measurement of subcutaneous glucose in rats.  
Chapter 1 provides a general introduction to diabetes mellitus and the different 
types of biosensors that have been used for both intermittent and continuous glucose 
monitoring. “Intermittent” monitoring refers to analyses made just a few times per 
day using, for instance, a finger-prick approach to determine blood glucose levels. 
“Continuous” monitoring approaches involve subcutaneous implantation of either 
biosensors or microdialysis probes, which then allow for constant measurement of 
glucose concentrations in the interstitial fluid. The technical requirements for 
continuous glucose monitors (CGM)s are briefly introduced, as ar e the kinetics of 
glucose transport between the blood and the interstitial fluid. Microdialysis sampling 
is described, and its combination with microfluidics proposed for the miniaturization 
and improved performance of CGMs employing microdialysis. Soft lithography is 
presented for the microfabrication of microfluidic devices, as it is the main approach 
used in this thesis. The chapter finishes with a short summary of the broad range of 
applications, particularly in the life sciences, for which microfluidics (or lab-on-a-
chip) is now being considered as an alternative technology to facilitate research and 
development.  
Chapter 2 gives an overview of the physiological processes that influence 
continuous monitoring of subcutaneous glucose, and discusses invasive CGMs 
based on implantable needle-type glucose sensors or microdialysis-based glucose 
sampling. The development of the concept of coupling microdialysis sampling with 
microfluidic devices is also presented. Since CGM implantable sensors or 





physiological factors influencing glucose concentrations measured with these 
systems is extensively discussed. These factors include the relationship between 
blood and interstitial glucose levels, implantation effects, location of the sensor, and 
the duration of measurement periods. 
Chapter 3 presents a new sensing system exploiting the GOx conversion of 
glucose to gluconic acid and H2O2 for continuous glucose monitoring. The system is 
based on a n enzymatic microreactor incorporating chaotic mixing channels to 
rapidly mix a solution containing GOx with a sample solution containing glucose. 
An electrochemical detection method was implemented, using thin-film Pt 
electrodes positioned at the end of the microreactor channel as an  on-chip 
amperometric detector of the reaction product, H2O2. In this study, the glucose 
oxidase concentration required for optimal sensing performance is identified. The 
dependence of EMR operation on flow rate is characterized, and the mixing 
properties of microreactor channels with and without mixing grooves are compared. 
Chapter 4 describes a different type of microfluidic glucose sensing system based 
on an EMR with integrated chemiluminescence detection. A two-reactor system was 
developed for the enzymatic conversion of glucose by GOx, followed by the 
reaction of the H2O2 produced with luminol to produce chemiluminescence. In both 
of these chapters, linear calibration curves for glucose concentrations in the clinical 
range of interest were obtained for in vitro measurements.  
An in vivo application of microfluidic EMR is described in Chapter 5. The EMR 
was coupled with a microdialysis probe which was inserted into the subcutaneous 
tissue of anesthetized rats. The performance of the EMR for in vivo monitoring was 
evaluated by modulation of blood glucose concentrations in the rat with intravenous 
injections of glucose or insulin, with saline as a control. Blood glucose was 
measured every 15 minutes as a reference value for comparison with the EMR. The 
difference between glucose values observed with blood glucose sampling and EMR 
monitoring is also discussed. 
To conclude this thesis, a su mmary of the work and future perspectives for the 
development of CGMs based on m icrodialysis and microfluidics are given in 
Chapter 6.  
 
2. Introduction  
Diabetes mellitus is a widespread chronic metabolic disorder in which blood glucose 
levels are not maintained properly due to the failure of physiological mechanisms 




islets of Langerhans in the pancreas and functions as binding receptor to unlock the 
pathway for glucose penetration into cells. Therefore, insulin plays a crucial role in 
maintaining glucose levels in the blood. There are two main types of diabetes which 
are characterized by the failure of cell uptake of sufficient glucose from the blood. 
The hallmark of diabetes type 1 is insulin deficiency, and this type is also referred to 
insulin-dependent diabetes mellitus (IDDM).[1, 2] The problem with this type of 
diabetes is that the pancreas does not secrete enough insulin so that the tissues in the 
body cannot take up glucose sufficiently, leading to glucose levels which are 
dangerously high. This type of diabetes occurs during childhood and is thought to be 
caused by an autoimmune response of the body, in which the insulin-producing cells 
in the pancreas are actually attacked and destroyed by the body’s own immune 
system. Type 2 diabetes is characterized by insulin resistance, a condition in which 
insulin reduces glucose levels less effectively.[1, 2] Also referred to as non-insulin-
dependent diabetes mellitus (NIDDM), this form of the disease is more common 
than type 1 (about 10 % of patients have type 1 diabetes, whereas 90 % have type 2). 
In type 2 di abetes, the pancreas produces insulin continually, generally in what 
normally would be sufficient amounts. However, cells that require insulin to absorb 
glucose no longer respond adequately to insulin, a condition known as insulin 
resistance, and glucose levels rise. The liver also does not reduce its production of 
glucose as effectively in the presence of insulin, which also contributes to elevated 
glucose levels. Insufficient insulin secretion can also cause this type of diabetes. 
Gestational diabetes mellitus may arise during pregnancy, caused by hormonal 
changes which can affect insulin activation during this period. Maturity onset 
diabetes of the young (MODY; a genetic malfunction) and latent autoimmune 
diabetes in adults (LADA) are also types of diabetes which can occur in some 
individuals, though these forms are uncommon.[3] 
According to the World Health Organization (WHO), more than 220 million 
people are affected with diabetes worldwide, and an estimated 1.1 million people 
died from diabetes-related diseases in 2005. With the number of patients growing 
rapidly, it is expected that there will be some 366 million diabetes patients by 
2030.[4] Moreover, many people who have not been diagnosed will suffer short-
term or long-term complications. The major consequences of diabetes are damage to 
the heart, blood vessels, eyes, kidneys and nerves. Proper management of blood 
glucose levels is a long-term goal to support both diabetes patients and the 
physicians treating them.  
The conventional way in which blood glucose determinations are carried out 





glucose up to four times per day by pricking a finger and applying the resulting drop 
of blood to a portable device. Extensive clinical studies have been done to manage 
blood glucose levels based on self-monitoring of blood glucose (SMBG).[5, 6] The 
trials improved the handling of hyperglycemic episodes significantly with 
intensified insulin treatment. However, SMBG does not provide the whole range of 
information required, with hypoglycemic episodes still tending to go unn oticed.  
Even worse, patients often fail to perform finger-prick checks according to the 
recommended schedule because this method is painful and tedious to perform. A 
more sophisticated approach to determine blood glucose levels is to identify the 
level of glycated hemoglobin (HbA1c), which is a measure of the average plasma 
glucose concentration over a prolonged period of many weeks.[7, 8] This HbA1c 
level is an overall indication of how well glycemia has been controlled the previous 
8 to 10 weeks.  
When compared with the conventional finger-prick method, continuous glucose 
monitoring provides many advantages, including a better capability to check 
metabolic status, gain more insight into daily glucose fluctuations and identify 
episodes of both hypoglycemia as well as hyperglycemia. Obviously, this method is 
more suited to controlling diabetes, especially in the hypoglycemic (low glucose 
levels) regime. Continuous glucose monitoring is often performed by using a 
biosensor (monitoring system) that is inserted into subcutaneous tissue to measure 
interstitial fluid (ISF) glucose levels. Glucose levels can be monitored over days, 
providing very useful information for both diabetic patients and physicians. This 
section provides general information about biosensors, continuous glucose 
monitoring, non-invasive glucose sensing, and the techniques employed for 
continuous glucose monitoring. 
 
2.1. Biosensors 
A biosensor is a device that recognizes a biomolecular compound of interest and can 
convert concentrations of the compound into analytically measurable signals.[9, 10] 
It consists of two components, namely a biomolecular recognition element such as 
an antibody, enzyme, or receptor, and a transducer to convert a chemical signal into 
a quantifiable electrical one (Figure 1). For example, in a biosensor designed to 
detect glucose, the enzyme, GOx, is generally used to catalyze the reaction of 
glucose and oxygen to produce H2O2 and gluconic acid. The glucose concentrations 
can be directly determined by using an oxygen sensor to measure oxygen 
consumption [11], a pH sensor to measure gluconic acid production [12] or an 












Figure 1. Schematic diagram of the general sensing mechanism on which biosensors 
are based. 
 
2.1.1. Different types of biosensors  
Depending on the detection technique used, biosensors can be classified as 
electrochemical biosensors and non-electrochemical biosensors; the latter category 
includes optical, calorimetric, and piezoelectric biosensors. Electrochemical 
biosensors are the most commonly used sensor type in monitoring and diagnostic 
tests in clinical analysis, due to their sensitivity, ease of use and amenability to 
miniaturization.[10, 14] They are based on the principle of chemical interaction 
between a biological recognition element and the species of interest. The 
electrochemical detector measures the output signal produced by the reaction 
process. Electrochemical biosensors can be categorized into amperometric 
biosensors, potentiometric biosensors or conductometric biosensors, depending on 
which parameter (current, potential or conductivity, respectively) is monitored. An 
amperometric biosensor measures the changes in current at a working electrode 
when oxidation or reduction take place, by applying a potential with respect to a 
reference electrode.[15] When substrates such as GOx, lactate oxidase, and ethanol 
oxidase are used to determine these respective substrates, it is the H2O2 produced by 
the enzymatic reaction that is oxidized at the working electrode to produce the 
current signal. High sensitivity and rapid signal response are major advantages of 
amperometric sensors when compared to potentiometric and conductometric 
biosensors. A potentiometric biosensor measures the potential difference between an 
indicating electrode and a r eference electrode. The sensor uses ion-selective 
electrodes (ISE) to detect the accumulated charge due to certain ions in a solution. 
One example is the pH sensitive ion-selective field-effect transistor (ISFET)-based 
enzyme sensor.[16] However, this approach has limitations with respect to in vivo 





substances present in the sample can result in an unstable sensor signal. 
Conductometric biosensors based on conducting polymer coatings containing 
immobilized enzymes were proposed in the early 1990s.[17] Reaction of the enzyme 
with the desired biomolecule leads to a change in local redox potential and/or pH in 
the polymer matrix, which translates to a measurable change in polymer 
conductivity. A glucose nanobiosensor based on this concept was described in 2004 
by Forzani et al.[18] A polyaniline layer coated with GOx formed a bridge over the 
20-60 nm gap between two gold nanoelectrodes. Local oxidation of the polyaniline 
layer in this gap by the H2O2 produced in the enzymatic reaction causes an increased 
polymer conductivity, which is recorded by the Au nanoelectrodes. In this case, the 
reaction is not limited by oxygen or mediators. The concept works also when larger 
interdigitated arrays of Pt microelectrodes are used (see for example the sensor for 
urea detection in ref. [19]). The advantage of these electrodes is the ease by which 
they can be fabricated using a screen-printing process. 
There are a variety of different non-electrochemical biosensors. Optical biosensors 
measure changes in light observed as a r esult of a b iological and/or chemical 
reaction. Various methods for detection of luminescence, fluorescence and surface 
plasmon resonance (SPR) may be involved in this approach. Many technical 
developments and applications of optical biosensors have been reviewed 
elsewhere.[20, 21]  
Fluorescence is a more attractive approach for optical glucose sensing, due to its 
exceptional sensitivity. Affinity-based sensing is generally applied in this type of 
method, which involves the competitive displacement of fluorescein-labeled binders 
with unlabelled glucose. Concanavalin A (ConA) has often been used as a glucose-
specific binding protein, along with fluorescein-labelled dextran as a co mpetitive 
binder.[22] The displacement of bound, labelled dextran by unlabelled glucose 
results in a f luorescent signal due to the fluorescein-labeled dextran which is 
proportional to the concentration of glucose. Unique here was that the ConA was 
immobilized on the inner surface of a microdialysis probe that in turn was coupled 
to an optical fiber for transfer of fluorescent light to a fluorimeter. Glucose diffusing 
over the dialysis membrane could immediately be detected in this way. This 
fluorescence concept was further developed with optical transducer techniques using 
fluorescence resonance energy transfer (FRET).[23, 24] ConA, again immobilized 
on the inside of a microdialysis fiber, was labelled with fluorescent rhodamine dye 
molecules which acted as acceptor molecules. Dextran was labelled with the donor, 
fluorescein isothiocyanate (FITC). When dextran was bound t o the ConA in the 




   GOx 
radiationless way to the rhodamine acceptor molecules of the ConA. The 
fluorescence of the acceptor, rhodamine, increased as a r esult. In the presence of 
glucose, the labelled dextran and ConA moved apart, resulting in a decrease of the 
rhodamine acceptor signal. On the other hand, an increase of the fluorescence due to 
FITC was observed, which occurred at a very different wavelength and thus could 
easily be distinguished from the rhodamine signal. The authors of ref. 44 noted, 
however, that there was an issue with the stability of this sensor, as ConA tended to 
form irreversible aggregates over a n umber of hours, adversely affecting sensor 
response. 
Calorimetric biosensors operate by sensing enthalpy changes in a t hermistor 
resulting from biochemical reactions.[25] The thermistor detects the temperature 
change caused by a reaction such as enzyme catalysis as a change in electrical 
resistance. Piezoelectric biosensors are also non-electrochemical biosensors that 
register changes in the resonance frequency of an oscillating piezoelectric crystal as 
a function of the mass of analyte adsorbed onto the crystal surface.[26]  
Biosensors have several advantages over conventional analytical methods, 
including small size, fast response time, ease of use and cost effectiveness. 
Biosensors have therefore been applied and used in many research fields, such as 
biomedical applications, food industry, and environmental monitoring.[27]  
 
2.1.2. Biosensors for continuous glucose monitoring 
Biosensors for (continuous) glucose monitoring have been under development for 
more than three decades and have become an important part of diabetic therapy. The 
enzymatic reaction of glucose and oxygen on which most glucose monitoring is 
based is shown in equation 1. As shown, GOx catalyzes the reaction to produce 
gluconic acid and H2O2. The H2O2 produced can be detected electrochemically.  
     
 Glucose + O2                     Gluconic acid + H2O2                       (1) 
 
There are several methods that can be used to assess glucose levels in ISF, such as 
cotton wick, microdialysis, microfiltration, and needle-type sensors. Needle-type 
glucose sensors [28-35] and microdialysis-based glucose sensing systems [36-39] 
are commonly used for continuous glucose monitoring. The needle-type sensors use 
GOx immobilized on the surface of an electrode, where the reaction then takes place 
once the sensor is inserted subcutaneously and is exposed to ISF. The microdialysis-
based sensing systems use a microdialysis probe to sample glucose from ISF, which 





continuous glucose monitors can be used either retrospectively to evaluate a 
personal glycemic regimen, or prospectively to monitor glucose levels in real-time, 
depending on the patient’s requirements. (Different technical strategies for 
continuous subcutaneous glucose monitors are described in more detail in Chapter 
2.)  
 
2.1.3. Non-invasive glucose sensing 
Non-invasive glucose sensing encompasses all those techniques which allow 
measurement of glucose concentrations without physical contact to the samples, 
unlike the implantable sensors that measure glucose in blood or ISF. Depending on 
the approach used, non-invasive methods can be categorized as t ransdermal or 
optical. One example of transdermal glucose determination, the GlucoWatch® 
(Cygnus Inc. California), is based on the principle of reverse iontophoresis.[40] This 
involves the movement of ions and glucose from the ISF to the skin surface when a 
small electric current is applied across the skin surface between two electrodes. The 
range of glucose concentrations that is extracted through the skin is very low (on the 
pM level). Glucose is converted to gluconic acid with the concomitant production of 
H2O2 by enzymatic reaction with GOx. H2O2 is  then detected amperometrically at a 
platinum electrode. This device was tested in vivo to monitor hypoglycemia in 
children and licensed by the US Food and Drug Administration (FDA) in 2001.[41] 
Another device using a t ransdermal approach was t he Pendra® system (Pendragon 
Medical Ltd., Zurich, Switzerland), which employed a watch-type device to measure 
the dielectric spectrum of underlying tissue using impedance spectroscopy.[42] 
Though this new technological approach was promising, the device exhibited poor 
accuracy in six subjects with type 1 diabetes.[43] Unfortunately, the Pendragon 
company went out of business in 2005, and watch-type sensors like the Pendra® and 
Glucowatch® are no longer available on the market. 
Optical approaches use various light frequencies to exploit different properties of 
light for non-invasive glucose sensing. Near-infrared (NIR) spectroscopy has been 
investigated over a wide range of wavelengths (750 nm - 1400 nm), since light in 
this portion of the spectrum can penetrate the skin layer and potentially be used to 
monitor glucose.[44, 45] The extent of specific NIR absorption depends on the 
structure of the molecule. Though the peak intensity of glucose absorption is small 
in complex biological matrices, it is possible to quantify the glucose concentration 
by using several wavelengths and multivariate analysis. On the other hand, the use 
of mid-infrared (MIR) spectra (3 µm - 50 µm) yielded higher-intensity glucose 




background absorption by other molecules interferes with the glucose measurement. 
Besides the above-mentioned optical approaches, there are many other non-invasive 
glucose sensing methods based on spectroscopic techniques such as Raman 
spectroscopy,[47] photoacoustic spectroscopy,[48, 49] polarimetry[50] and thermal 
emission spectroscopy [51]. 
Though many non-invasive techniques show great promise, in particular because 
of their user-friendliness, they are still too underdeveloped for clinical use in terms 
of accuracy and precision. In the case of transdermal sensing, many factors can 
negatively influence analytical results. These factors include temperature change, 
tissue thickness, condition of the subject (age, disease state), blood pressure, motion 
artifacts, sweating and  microvascular  blood flow variation.[52] The question then 
arises whether non-invasive techniques can be transferred to patients, or should just 
be used in well-controlled laboratory environments. In order to ensure reliable non-
invasive glucose monitors, further development of standardized procedures to 
eliminate the influence of interfering factors and of clinical applications will have to 
be undertaken.   
 
2.2. Technical requirements of continuous glucose monitors (CGM) 
CGMs provide great insight into daily glucose fluctuations in diabetes patients by 
providing data readout continuously. This allows significant advances with respect 
to better diabetes management, offering important information for insulin therapy 
and metabolic control. However, CGMs still lack reliability and need to be further 
improved. There are fundamental requirements which need to be met for reliable 
continuous glucose measurement. Some technical and clinical aspects are 
highlighted below.[53-55]  (The term ‘sensor’ refers here to an implantable sensor.) 
• Specificity: the CGM should be able to recognize glucose in a co mplex 
medium, with fast and predictable response to changing glucose concentrations. 
• Accuracy (correctness): the measurement should give a value that corresponds 
with high accuracy to actual glucose concentrations.  
• Precision (repeatability of measurement): the measurement should be 
reproducible and less variable with increasing numbers of glucose 
measurements. A coefficient of variance having a value of 5% or less for an 





• Biocompatibility: when a sensor is implanted subcutaneously in the body, there 
should be no (minimal) adverse effects on the host due to toxicity or local 
foreign body reactions caused by the invasive sensor. 
• Response time: the CGM should provide a readout signal in real time and an 
alarm in times of rapid glucose change. 
• Stability: two factors are involved when considering stability. During sensor 
implantation, the sensor may be influenced by the immune response of the 
tissue surrounding the sensor. This might cause biofouling of the sensor and 
affect short-term sensor stability. It is also important that the sensor is able to 
measure glucose concentrations over longer periods of time under physiological 
conditions (days or weeks). 
• Interfering substances: the most commonly occurring electroactive compounds 
found in the body are uric acid, ascorbic acid, acetaminophen, and L-cysteine. 
These substances are also oxidized at the potentials applied for H2O2 detection. 
• Cost-effectiveness: the sensor should be fabricated inexpensively and in a 
reproducible manner on a large scale.  
• User-friendliness: for practical applications, the CGM needs to be a patient- 
friendly device that is portable and easy to handle.  
In order to achieve the long-awaited goal of a reliable CGM, all the above 
mentioned requirements should be fulfilled. The most important parameters for 
further development of continuous CGM are accuracy, signal stability and reliability 
over longer periods (days). The accuracy of a g lucose monitor can be assessed by 
the Clarke error grid [56], the Consensus error grid [57], or the continuous glucose-
error grid analysis (CG-EGA).[58] These statistical approaches are presented in 
detail in Chapter 2 and will therefore not be discussed further here. 
In addition to satisfying the technical requirements mentioned above, it is also 
important to bear in mind the physiological context in which CGMs are employed. 
Commonly, the sensor or microdialysis probe of a CGM is placed in the 
extracellular space to measure interstitial glucose levels. Ideally, continuous glucose 
monitoring should be performed at an intravascular site to give direct measurement 
of glucose levels in the blood. However, this approach has serious risks associated 
with it, such as blood clotting (thrombosis) around the sensor or microdialysis probe 
of the CGM, as well as surgical issues (only a specialist can perform the surgery 
required for the implantation of the CGM probe). It is therefore important to 




since subcutaneous implantation is simpler and safer. The observed differences in 
glucose concentrations between these two compartments are due to glucose kinetics. 
 
2.3. Glucose kinetics 
Since the glucose sensor or microdialysis probe of a CGM is inserted directly into 
subcutaneous tissue, the kinetics associated with the process of glucose diffusion 
between blood and ISF is one of the important factors which influences those two 
levels. Glucose is transported from the blood to the ISF at a rate determined by the 
concentration gradient i.e. the blood glucose level is a major factor controlling the 
interstitial glucose level. Additionally, there are many other compartments that 
change the local interstitial glucose concentration, such as cellular glucose uptake 
rates, local insulin levels, blood flow and permeability of the capillary blood 
vessels.[55] 
The subcutaneous tissue is located below two skin layers, the epidermis and 
dermis. The epidermis is an avascular epithelial membrane, while the dermis 
contains many arterioles, venules and capillaries. The blood glucose level 
determined by a finger-prick uses blood from capillaries in the dermis, which 
consists of a mixture of blood from cut arterioles and venules.[59] ISF is a medium 
that is composed of water, amino acids, sugars, fatty acids, coenzymes, hormones, 
neurotransmitters, salts, and cellular products. The sensor or microdialysis probe for 
continuous glucose monitoring is implanted in this interstitial space. The ISF bathes 
both capillaries and cells, with cell nutrients being taken up from the capillaries and 
made available to the cells. Cengiz et al.[60] described the glucose dynamics 
between plasma and ISF compartments using the following equation (see Figure 2): 
       
         dV2G2/dt = K21V1G1- (K12 + K02)V2G2                                        (2) 
 
where G1 and G2 are capillary blood and interstitial glucose concentrations, 
respectively, K12 and K21 the forward and reverse flux rates for glucose transport 
across the capillary, K02 the glucose uptake into the subcutaneous tissue cells, and 
V1 and V2 the volume of capillary blood and ISF, respectively. Thus, the diffusion of 
glucose into the ISF is proportional to the capillary blood glucose concentration, and 
vice versa. Glucose that is taken up by surrounding tissue cells also directly 
influences the glucose concentration in the ISF.  
Because glucose kinetics are closely associated with physiological conditions, 





In general, interstitial glucose levels correlate well with blood glucose levels under 
steady state conditions (no systemic challenges), if a physiological lag time between 
ISF and blood levels is taken into account.[60-62] (Physiological lag time refers to 
the time interval required for the ISF glucose concentration to reach a v alue 
correlating to the blood glucose level.)  In the case of CGMs, this lag time can be 
attributed in large part to the fact that glucose is taken up by tissue/cells surrounding 
the sensor or microdialysis probe. Under non-steady state conditions, however, 
when glucose levels in the blood are rapidly increased to induce hyperglycemia, 
observed interstitial glucose levels do not reach blood glucose levels.[63, 64] 
Kaptein et al.[65] claimed that there are significant differences between the 
subcutaneous and intravenous compartments. In their ultrafiltration experiments, 
they observed ISF glucose levels which exhibited not just a time delay with respect 
to blood glucose levels, but also a different course over time; the glucose 
concentration versus time curves recorded for the two compartments had different 
shapes. Hence, the relationship between the two compartments is complex, 
reflecting glucose kinetics that vary significantly under non-steady-state conditions. 
Besides differing glucose levels in the blood and ISF, reported values for 
physiological lag times for glucose concentrations in the ISF with respect to the 
















Figure 2. Model for the diffusion of glucose between blood and ISF. The glucose 
concentrations in the ISF and blood compartments are strongly related. (adapted 




ISF glucose levels lag behind those measured in blood, whereas in other instances, 
blood levels actually lag behind ISF levels.[66, 67] According to these authors, this 
variation in lag time may be explained by the so-called push-pull hypothesis. 
According to this hypothesis, glucose is “pushed” into the interstitial space from the 
blood when blood glucose levels are increased. When glucose decreases, on the 
other hand, the tissue/cells surrounding the sensor or microdialysis probe take up 
glucose, effectively “pulling” glucose from the interstitial space to the cells. This 
phenomenon, however, seems to be a matter of debate, as other reports have failed 
to support these observations.[68-70] 
While progress has been made in the search for a more complete understanding of 
the factors governing glucose diffusion between the blood and ISF, existing 
hypotheses are not conclusive. In fact, experimental conditions which can critically 
influence observed results, such as sp ecies used, sensor type, implantation effect, 
implantation depth, and subject condition, vary significantly from one clinical study 
to the next. (This will be discussed in more detail in Chapter 2). However, it is 
generally agreed that invasive glucose monitoring rather than non-invasive glucose 
monitoring is still the most useful approach for clinical studies. The microdialysis-
based sensing method is especially promising, though a number of obstacles need to 
be overcome to improve its reliability.  
 
2.4. Approach to novel technology: microdialysis with microfluidics 
Since microdialysis was introduced by Ungerstedt [71] in 1974 to monitor 
neurotransmitter release in the brain, the technique has been extensively used for 
research to study many other tissues and body compartments. The microdialysis 
probe consists of a se mipermeable hollow fiber membrane which is sealed at the 
end, and is connected to inlet and outlet tubing.[72] The microdialysis probe is 
designed to mimic a b lood capillary and can be placed in any target tissue of 
interest. The lumen of the probe is perfused with an artificial interstitial fluid (ISF; 
usually Ringer’s solution) which is introduced from the inlet. Small pores in the 
membrane allow certain molecules to travel across it along the concentration 
gradient, from higher concentrations in the subcutaneous tissue to low or zero 
concentrations in the perfusing solution, known as the perfusate. However, large 
molecules (including proteins) cannot cross the membrane. The effective pore size 
defines the molecular-weight cut-off (MWCO) of a membrane; molecules having 
molecular weights above the MWCO are prevented from crossing the membrane 





through the outlet reflect the concentrations in the ISF and can be quantified by a 
variety of bioanalytical techniques. 
The molecular concentration gradient across the microdialysis membrane is 
affected by several factors, including the length of probe, membrane material, 
perfusion rate, temperature, analyte species, fraction of free analyte versus protein-
bound analyte, and nature of the external medium.[73] The relative recovery is 
defined as follows:  
 
      R (Recovery) = Cout /Cmedium                                                        (3) 
 
where Cout is the concentration of glucose in the out flow and Cmedium is the 
undisturbed concentration of glucose in the external medium (ISF in the case of 
subcutaneous monitoring). It should be noted that recovery is a strong function of 
perfusate flow rate, with Cout decreasing with increasing flow rate. Increased flow 
rates mean decreased time for diffusion of glucose across the membrane into the 
perfusate, and hence lower Cout. 
Generally speaking, two types of microdialysis-based sensing systems exist. One 
of these, called the subcutaneous glucose monitoring system (SCGM), uses a 
solution-based enzymatic reaction to quantify glucose in the perfusate.[36] A 
Ringer’s solution is perfused through the probe at a flow rate of 0.3 µL/min. The 
glucose which has diffused across the membrane of the probe is moved along with 
the Ringer’s solution and transported to a extracorporeal reaction unit. GOx in 
solution is continuously introduced to this unit, where it is mixed with perfusate to 
convert glucose to gluconic acid and H2O2. An integrated electrode detects the 
produced H2O2 amperometrically. An example of the other type of microdialysis-
based glucose sensing system is the GlucoDay®.[38] This system uses GOx enzyme 
immobilized on an electrode to measure the glucose concentration in the 
microdialysate. However, the microdialysis probe in this system is typically 
perfused at a high flow rate of 10 µL/min, reducing the relative glucose recovery. 
The microdialysis approach has proven to be a safe and reliable technique, as 
tissue in vivo is only exposed to Ringer’s solution, used to perfuse the probe. Sensor 
biofouling is also less of an issue because microdialysis allows the extraction of 
glucose from the ISF; in other words, this is a pre-filtering process that excludes 
protein components from the ISF. However, one drawback of microdialysis can be 
its low temporal resolution. The SCGM system, for example, has a relatively long 
physical lag time (30 min), due to the tubing connecting the probe to the external 




systems being somewhat bulky, though both the SCGM and GlucoDay© are 
portable.   
The long-term goal in CGM development is to realize an autonomous system 
acting as an artificial pancreas. In order to achieve this goal, a fully integrated 
insulin delivery device including a CGM (microdialysis probe, pump and sensing 
system), insulin pump and operating electronics needs to be realized. Reduced 
system size and fast sampling time are critical criteria that require improvement in 
current systems. The combination of microfabrication technology and microfluidics 
represent a very promising opportunity to tackle issues such as glucose sampling, 
analysis time and overall system configuration.  
 
3. Microfluidics  
The field of microfluidics (also referred to as lab-on-a-chip) has over the past two 
decades experienced exponential growth in the development of both the technology 
itself as wel l as ap plications in the chemical and life science realms.[74, 75] The 
concept of microfluidic systems is defined as t he science that involves design, 
control, manipulation and analysis of small amounts of fluids (volumes of nL or 
less) in a microfluidic channel network.[76] It is an interdisciplinary field that 
encompasses engineering, chemistry, physics, biology and bioengineering. Since 
very small amounts of liquids are employed in micro- or nanoscale fluidic devices, 
microfluidics offers many advantages over conventional methods, such as 
dramatically reduced usage of samples and chemical reagents, short reaction times 
(analysis), cost-effectiveness, increased surface-to-volume ratio and portability.  
Solution flow in micrometer-dimensioned channels is typically laminar, that is, 
very well defined, with layers of solution moving past one another in unchanging 
streamlines. It is very predictable flow, in that the velocity at any one particular 
point in the channel remains constant over time. This is in strong contrast to 
turbulent flow, which occurs at higher flow rates relative to laminar flow in flow 
systems. As the name suggests, turbulent flow is characterized by streamlines which 
are not well-defined, with constantly changing velocity over time at any given point 
in the channel. Both laminar and turbulent flows are the result of the interplay of 
viscous and inertial forces in a solution flow. The Reynold’s number, Re, is a 
dimensionless parameter describing the relationship between inertial and viscous 
forces in a flow system.[77] It is defined as: 
     Re = 
𝜌𝑢𝐿
µ





ρ is the density of the fluid, 𝑢 is the linear velocity of the fluid, L is the characteristic 
channel dimension (e.g. diameter of a channel with circular cross-section) and µ is 
the dynamic viscosity of the fluid.  
The use of Re makes it possible to predict the flow rate and solution conditions 
under which a transition from laminar to turbulent flow will occur in any given flow 
system. This transition is observed at Re of between 2000 and 3000, depending on 
the geometry of the flow conduits. For the flow rates typical of microfluidic 
systems, Re is generally less than 1, indicative of the well-defined, laminar flow 
observed in microchannels. In this regime, mixing of solutions is achieved 
predominantly by diffusion, a passive and slow transport process. However, because 
microchannel cross-sections are small, diffusion lengths can be kept short, with the 
corresponding diffusion times necessary for mixing on the order of sub-seconds to 
seconds. Use of a chaotic mixing approach, as in this thesis, augments the contact 
area between the solutions to be mixed, further decreasing diffusion lengths and 
shortening mixing times. In chaotic mixing, mixing is achieved through the 
incorporation of an array of microgrooves into a microchannel. Flow over the 
groove array assumes a helical or corkscrew pattern, in which the contact area 
between two adjacent solutions is increased dramatically to facilitate mixing by 
diffusion.[78]  This microfluidic mixing technique, which is used for solution-based 
enzymatic reaction of glucose, is described in more detail in Chapter 3.  
The technology used to fabricate interconnected microchannel networks in planar 
substrates originates from that used for microelectronics and later, for 
microelectromechanical systems (MEMS).[79] Early microfluidic devices were 
fabricated in silicon or glass, requiring that researchers had access to sophisticated 
cleanrooms. Alternative, less technology-intensive methods to replicate 
microchannels in polymers were introduced in the early to mid-nineties.[80] In 
particular, the development of a process to replicate microchannels in the silicone 
rubber, poly(dimethylsiloxane) (PDMS), has significantly simplified the fabrication 
of microfluidic devices. PDMS is a flexible material that is also optically 
transparent, making it a good material for many microfluidic applications. The 
process for making PDMS devices, known as soft lithography, can be performed for 
the most part outside a cleanroom environment, is easy to learn and is much less 
expensive than silicon or glass devices.[81] The advent of soft lithography in the 
nineties had a dramatic influence on microfluidics research generally, as i t made 




A general procedure for soft photolithography for microfluidic device fabrication 
by replication in PDMS is shown in Figure 3. The process depicted here is the one 
which was used throughout this thesis. To begin, a master or mold containing the 
negative of the microfluidic network was made. In this thesis, the mold was formed 
photolithographically in a layer of photosensitive polymer which had been deposited 
by spin coating onto a silicon wafer. The desired layout and design of the 
microchannels and other features on t he chip were first drawn using a computer-
aided design (CAD) program. This image was then reproduced either in a thin layer 
of chromium deposited on a polished quartz wafer or on a high-resolution 
transparency sheet (resolution 3,810 dpi), to be used as a photomask. This mask was 
used to transfer the two-dimensional microchannel pattern to a layer of 
photosensitive polymer deposited on a silicon substrate. This was accomplished by 
exposing this layer to ultraviolet (UV) radiation (365 nm, 10 m W/cm2) using the 
mask to selectively illuminate some areas of the layer to the exclusion of the rest of 
the layer. Though this is not shown in Figure 3, the photomask was in direct contact 
with the resist layer during the illumination step. The photoresist exposure step is the 
most critical step for defining error-free features having micrometer dimensions, and 
is generally done in a cleanroom or other controlled, relatively dust-free 
environment such as a laminar-flow hood. 
Photoresist is a p hotosensitive material composed of a p olymer, a photoinitiator 
and a casting solvent. Two types of photoresist, positive-type and negative-type, are 
used for photolithographic processes; there are many different variations of both 
which have been developed for a variety of applications. With positive photoresist, 
UV exposure causes the resist in exposed areas to become soluble, whereas 
unexposed resist remains insoluble upon immersion in a developer solution. 
Exposed areas of the resist can thus be removed upon development. The opposite is 
true for negative photoresist, where UV exposure causes the resist to polymerize and 
become insoluble, and unexposed resist remains soluble and can be removed in a 
developer solution. For the work presented in this thesis, a silicon wafer was used as 
the mold substrate, and a relatively thick positive photoresist layer was deposited on 
this wafer as basis for the mold. The thickness of the layer was d etermined after 
development, and was found to be around 35 µm thick. As shown in Figure 3, the 
mold was essentially the negative of the desired microfluidic device, consisting of 
raised features where microchannels were to be formed. The thickness of the 





Figure 3. Schematic diagram for the soft lithography process used to make 
microfluidic devices in PDMS. (Illustration reprinted with permission from 
Sebastiaan Donders, Bionieuws 10-03-2006.)  
 
Replication of microchannels was performed by casting a viscous liquid mixture of 
PDMS prepolymer and curing agent (10:1 ratio) over the mold. The mixture was 
allowed to cure (polymerize) at 50ºC for 4 hours. The PDMS is then smoothly 
peeled off from the master. This replication procedure could be carried out  
numerous times using the same master. Multiple PDMS chips could be formed with 
a single casting, since the master contained multiple designs. The resulting PDMS 
slab could be easily cut into smaller individual devices. To seal the microchannels,  
the surface of the PDMS device containing the microchannels was made hydrophilic 
through oxidation with oxygen plasma or UV-generated ozone. This surface was 
then brought into contact with either an oxidized glass or another oxidized PDMS 
chip containing holes (300 µm in diameter) which aligned with the ends of the 
channels for solution introduction or removal. The assembled chips were then placed 
on a preheated hot plate at 140 ºC. The hotplate was immediately turned off and the 




bond between oxidized surfaces. The chip was then prepared for experiments by 
inserting tubing connections into the inlet and outlet holes. The soft lithography 
process has been thoroughly reviewed elsewhere.[81-83] 
 
3.1. Microfluidic applications 
To data, an enormous number of microfluidic systems have been developed, 
increasing their utilization in many research fields. Many review papers have been 
published, offering different insights into the developments of the last decade. 
Verpoorte [84] reviewed the application of microfluidic chips for clinical and 
forensic analysis. The analytes discussed included endogenous small molecules, 
proteins and peptides, and nucleic acids and oligonucleotides, and their analysis in 
physiological samples was presented where relevant. Manz et al.[74, 75, 85-87]  
have extensively reviewed the literature several times in recent years for 
bioanalytical applications of microfluidic systems. These reviews cover many 
different fields, including cell culture, handling and analysis, clinical diagnostics, 
immunoassays, protein analysis, DNA separation and analysis, polymerase chain 
reaction and environmental monitoring. Whitesides et al.[88-90] have also discussed 
many potential applications of microfluidics in the broad area of the life sciences, 
including biological studies, chemical biology, biological interactions and 
microbiology. Microfluidics has a number of potential advantages for biosensing, 
including increased sensitivity, high-throughput, automation and miniaturization. 
For example, microfluidic-based point-of-care testing devices have opened up new 
possibilities to yield  clinically relevant information in diagnostic applications in a 
simple, fast and low-cost manner.[91] Fully integrated, multifunctional devices are 
increasingly in demand, with many recent reports describing the development of 
components such as micropumps and microvalves,[92] micromixers,[78] 
detectors,[93] and reservoirs for existing and new lab-on-a-chip applications. 
This thesis describes the development and application of a miniaturized system for 
continuous subcutaneous glucose monitoring based on m icrodialysis sampling 
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In patients with diabetes, the manifestation of long-term diabetic complications can 
be largely reduced by maintaining strict glycemic control. Glucose concentrations 
should be measured frequently to adjust therapeutic intervention, e.g. administration 
of insulin. Conventional self-monitoring of blood glucose with fingersticks is not an 
ideal method. Many hypoglycemic episodes may be missed, especially during the 
night. Moreover, this method is difficult to implement in some patients, including 
children, elderly, and people with disabilities. Patient compliance is also reduced by 
the fact that the method is tedious and painful. A new method is needed for 
convenient and continuous monitoring of glucose, which is also the prerequisite for 
the development of an artificial pancreas. 
To date, various approaches are being used to develop continuous glucose 
monitors (CGM). Several CGMs based on different technologies were recently 
brought onto the market. However, the performance of these devices is still sub-
optimal and their feasibility has been questioned. In this paper, we review the 
technical challenges that a C GM typically has to overcome, including the 
physiological influences affecting accuracy, selectivity, sensitivity, and durability.  
Current data regarding CGM performance is only preliminary, as they still await 
evaluation in controlled clinical trials. Each type of CGM has its specific challenges. 
Needle-type electrodes respond rapidly but are most affected by biofouling and 
signal drift, especially during the night. Microdialysis-based CGMs are more stable, 
but these are relatively large systems and there is an inherent time delay between 
microdialysis sampling and analysis. The feasibility of such systems is discussed, 
with particular attention paid to the physiological factors that influence the 

















Diabetes mellitus is a ch ronic and currently incurable disorder of metabolism in 
which blood glucose concentrations cannot be properly maintained due to a lack of 
insulin secretion or a lack of insulin action.[1, 2] Patients with diabetes often have to 
regulate blood glucose by therapeutic intervention, consisting of oral medication or 
exogenous insulin administration. Maintenance of daily glucose balance within the 
narrow range of physiologically acceptable concentrations requires frequent and 
rapid adjustments of the treatment regimen. However, the manifestation of long-
term diabetic complications can be largely prevented by implementing strict 
glycemic control.[3] Intensified insulin therapy, however, warrants the need for the 
patient to monitor blood glucose levels closely. Inappropriate intervention may lead 
to recurrent episodes of iatrogenic hypoglycemia and further impairment of 
endogenous glucose control in the body.[4] 
The conventional way to assess glycemic status is to measure glycated hemoglobin 
(HbA1c) levels as an indicator of average blood glucose over a period of several 
weeks, and to spot-check blood glucose by the fingerstick method for evaluation of 
the acute state. These conventional methods, however, have several disadvantages 
that are limiting to the implementation of good glycemic control. Diabetic patients 
typically measure their own blood glucose levels multiple times per day. The 
frequency of glucose measurements is related to the intensity of the treatment 
regimen and the specific physiological responsiveness of the individual.[5] The 
fingerstick method is generally considered a burden because it is painful and tedious, 
which limits patient compliance.[6] In certain categories of patients, such as i n 
young children, elderly, or patients with disabilities, this method is extremely 
difficult to implement.[7-9] As a result, the frequency of monitoring is often sub-
optimal.[10] Blood glucose levels over the course of a day are very dynamic, and 
even during active control much information may be missed. This is especially true 
during the night, when checks are infrequent and there is increased risk of (severe) 
hypoglycemia.[11-13]  
Continuous glucose monitoring is a relatively new approach aimed at improving 
glycemic control in patients with diabetes by providing a more convenient and 
complete assessment of their glycemic status. In general, a small continuous glucose 
monitor (CGM) is implanted in the patient’s body and this device measures glucose 
levels frequently for prolonged periods of time, ideally up to several weeks. 
Depending on the exact technology, the frequency of measurements may range from 




CGMs have been brought to market. However, the performance of these devices is 
not yet suitable to deploy them on a large scale. Preliminary reports of positive 
findings still need to be corroborated by controlled trials, and it has been questioned 
whether the accuracy was evaluated with appropriate methods.[16-18] This review 
paper covers the technical challenges that the CGMs need to overcome to be suitable 
in healthcare applications. Particular attention is given to the physiological 
influences that potentially affect their selectivity, sensitivity, and durability. The 
impact of the implantation process, exact position of the CGM in the body, and 
relevance of blood-to-interstitial fluid (ISF) glucose kinetics is discussed. 
 
2. Retrospective and prospective applications 
Since the concept of the enzyme-based glucose electrode was first proposed by 
Clark and Lyons in 1962,[19] the development of glucose monitors has received 
much attention. In recent years, CGMs have proven to be a m ajor asset in many 
healthcare applications, especially in diagnosis and treatment of diabetes. The aim of 
a CGM is to provide a continuous sequence of frequently measured glucose 
concentrations for prolonged periods of time. This data can be used retrospectively 
to establish the optimal and personal treatment regimen for the patient, to diagnose 
and prevent the occurrence of hypoglycemia, and to assess impact of lifestyle 
modifications on glycemic control.[7] In this mode, the data is usually evaluated by 
the physician. In addition to retrospective use, in some CGMs the data can also be 
used prospectively to alert the patient in real-time to take immediate corrective 
action. In prospective mode, the output from the CGM is primarily used by the 
patients themselves to assess glycemic status in real-time, although it has also been 
argued that CGM findings should first be confirmed by a physician to avoid 
therapeutic errors.[18] In this mode it is imperative that analysis is rapid and the lag 
time between physiological changes and corresponding sensor output is short. 
Patients also need to be well educated in the use of the CGM.[8] 
Clinical outcome studies have suggested that the use of CGMs improve mean 
glycemia (mean blood glucose concentration), especially in patients with difficult-
to-control diabetes.[7, 20] CGMs have also been found to effectively register 
hypoglycemic excursions that would otherwise go unnoticed, for example in 
preschool children or during the night.[9, 21] It is particularly difficult to maintain 
euglycemia in preschool children, because they are more sensitive to insulin, and 
they have variable eating habits and unpredictable levels of physical activity. In 
adult patients, approximately 33% of cases of hypoglycemia during the day occur 
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without symptoms, and 55% of cases of severe hypoglycemia occur during sleep.[13] 
Some studies showed that the use of CGMs effectively shortened the duration of 
hypoglycemic episodes, although there was no statistical improvement of metabolic 
control compared to frequent capillary glucose measurements.[22, 23] It was 
therefore concluded that CGMs are particularly useful to prevent complications from 
recurrent hypoglycemia. However, there is no f urther improvement of glycemic 
control compared to frequent self-monitoring with fingersticks. In addition to 
diabetes, CGMs are also useful in other diseases where glycemic control is at risk, as 
in glycogen storage disease or insulinomas.[24] 
The ultimate goal of prospective CGM use in diabetes therapy is to integrate the 
monitor into a closed-loop system that functions as an  artificial pancreas. The 
automated continuous dosing of insulin in such a system is based on glucose data 
provided by the CGM.[25, 26] Model-based predictive control algorithms are 
needed to convert sensory input to direct appropriate insulin delivery, because 
personalized control is needed that adapts to individual-specific kinetic factors, 
system- and physiology-based time delays, and to daily life events. Use of CGMs in 
prospective mode, more so than in retrospective mode, requires the devices to at 
least be able to detect a glucose decline of 0.6 mM in 5 min.[27] This defines lower 
limits for accuracy, precision and data sampling frequency. It has been reported that 
CGMs may incorrectly detect hypoglycemia during the night. The needle-type 
sensors seem to be particularly susceptible to nocturnal signal drift.[28, 29] 
Although this phenomenon cannot yet be explained, it may be remedied by 
additional and separate calibrations using fingersticks during the night.[28, 30] 
However, this solution reduces the level of convenience, one of the goals for CGM 
development in the first place.  
 
3. Technical strategies 
3.1. Needle-type electrodes 
A common approach to continuously monitor glucose is by means of an implantable 
enzyme-coated electrode. This technique has been developed into a major analytical 
tool to monitor concentrations of many different biomolecules, both in vitro and in 
vivo.[31] Glucose is measured by coating the electrode with the enzyme glucose 
oxidase, which converts glucose and oxygen into gluconolactone and hydrogen 
peroxide. The amount of hydrogen peroxide is subsequently assayed 
amperometrically by oxidizing it at the electrode surface at an applied potential 




they have a high temporal resolution and a very short response delay. In addition, 
the size of the electrode and the potentiostat can be kept small. 
The largest disadvantage of needle-type CGMs is a l ack of specificity caused by 
the presence of other electroactive biomolecules, such as uric acid and ascorbic acid, 
which are oxidized at the potential used for H2O2 detection. A lower potential may 
be used when a redox mediator is incorporated in the biorecognition layer to help 
shuttle electrons between the enzyme and the electrode.[31] Biosensors with 
mediators are considered second-generation sensors, as opposed to the ones that 
require oxygen. Some commercially available CGMs use mediators, including the 
FreeStyle Navigator.[32, 33] This is also the prevailing method in teststrips for 
measurement of blood glucose. The working principle of both types of sensors is 
outlined in Figure 1. However, successful use of mediator molecules depends on 
their positionwith respect to the redox center of the enzyme. Mediators degrade after 
repeated cycling, are often chemically unstable in either reduced or oxidized form, 
and are prone to leaching. Moreover, mediators generally have difficulty competing 
with freely diffusible oxygen, and are sensitive to inhibitors.[34, 35] 
For implantable biosensors, common alternative strategies to increase specificity 
for glucose is the affixing of a permselective layer onto the electrode to prevent  
 
Figure 1. Schematic diagram of the enzymatic reaction on the surface of the 
electrode. 
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potential interferents from reaching the electrode surface,[34] and/or the addition of 
a background electrode (without glucose oxidase) for differential recording.[36] 
Differential recording eliminates interferences by subtracting the current caused by 
interferents at the background electrode from the total current generated at the 
working electrode. After implantation in the body, needle-type CGMs are vulnerable 
to biofouling, to a large extent due to the presence of enzyme in the interface 
between electrode and tissue. They have also been reported to suffer from signal 
drift, especially during the night.[29, 37] 
 
3.2. Microdialysis probes 
A different strategy is to measure glucose ex vivo after a small amount of ISF-related 
sample has been recovered from the body, for example by means of microdialysis. 
Microdialysis was introduced in the early 1970s to monitor neurotransmitter release 
in vivo in the brain,[38] and has since evolved into a common method in biomedical 
research to acquire samples derived from ISF in almost any tissue.[39, 40] The 
microdialysis probe, like a small catheter, is inserted into the tissue and serves to 
mimic a blood capillary. The probe has a semi-permeable hollow fiber at its tip that 
separates the tissue from the probe’s lumen. The lumen of the probe is continuously 
perfused with an aqueous solution that resembles the ionic composition of the 
surrounding ISF. Small molecules, including glucose, can pass through the pores of 
the membrane by diffusion along their concentration gradient. Depending on the 
molecular weight cut-off of the membrane, most of the larger biomolecules, like 
proteins, are excluded from the dialysate. The dialysate emerges from the probe’s 
outlet at a typical flow rate of 0.1 – 5.0 µL/min and can be collected for analysis. 
Analysis of glucose in the dialysate can be carried out by various optical and 
electrochemical techniques. Figure 2 shows an example of a microdialysis-based 
CGM.[41] 
There are fewer biocompatibility issues with microdialysis compared to enzyme-
coated electrodes, as co ntact with the tissue is made only by the semi-permeable 
membrane and no hydrogen peroxide leaks into the tissue. In addition, the 
membrane keeps proteins and cellular debris out of the dialysate, thereby reducing 
biofouling of the detector. However, there are also a few disadvantages. It may take 
up to 30 min for the sample to travel through the tubing from the probe to the 
detector, which creates a response delay that is unacceptable in a prospective 
application when the CGM should alert the patient during acute hypoglycemia.[41-









Figure 2. Schematic diagram of the Subcutaneous Continuous Glucose Monitoring 
(SCGM) system: a) Ringer’s solution; b) glucose oxidase; c) peristaltic pump; d) 
sensor; e) microdialysis probe (reprinted with permission from Schoemaker et 
al.[41]). 
 
3.3. Coupling microdialysis with microfluidics 
In the past decade, the use of microfluidics has increased enormously in 
interdisciplinary research fields comprising chemical, biological, biomedical and 
other life science applications.[45, 46] Notable advantages of this approach include 
sample handling in the µL-to-pL range, fast analysis and/or reaction times and cost-
effectiveness with small, disposable devices. Coupling microdialysis with 
microfluidics thus combines the long-term stability of microdialysis probes with 
substantially reduced lag times, as they occur with needle-type CGMs. Soft 
lithography, the replication of microchannel networks in elastomeric materials, 
provides a rapid-prototyping approach for the realization of devices within a few 
days.[47-49] Not surprisingly, a significant amount of research has been conducted 
in recent years on coupling microdialysis sampling with the development of 
microfluidic chips. This will be discussed below.  
However, it is important to recognize that there is a body of literature predating the 
use of microfluidics which describes the use of microdialysis for glucose monitoring. 
In the early 1990s, for instance, Schmidt et al. developed a glucose monitoring 
system using microdialysis, in which dissolved enzyme was perfused through the 
hollow fiber to oxidize glucose. The resulting changes in oxygen concentration were 
monitored with an oxygen electrode.[50] It was demonstrated that this system could 
monitor changes in subcutaneous glucose concentrations in vivo.[50, 51] Laurell 
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developed a continuous glucose monitoring system where microdialysate was 
passed through an immobilized enzyme reactor.[52] An oxygen electrode positioned 
at the end of the reactor was used to monitor fluctuations in dissolved oxygen 
concentrations due to changing glucose concentrations in the microdialysate. This 
system was used to perform an in vivo subcutaneous glucose measurement in a 
patient.[53] An amperometric glucose measurement was performed by Meyerhoff et 
al. to monitor subcutaneous glucose using microdialysis in real-time.[54, 55] Other 
glucose sensing systems coupling microdialysis and electrochemical detection have 
been presented for in vitro and in vivo experiments in animals[56, 57], comparative 
studies of different types of microdialysis probe[58], and the evaluation of a thin 
layer flow cell detector for in vivo monitoring.[59] Glucose and lactate 
determination in microdialysate using microfabricated biosensors incorporated into a 
microfluidic system coupled to a microdialysis probe was described in 1997.[60, 61] 
The advantages of small-volume fluid handling systems were immediately clear, as 
lag times of less than 5 min between sampling and analysis were made possible 
using this approach. Shortly thereafter, Böhm et al. presented a micromachined 
double lumen microdialysis probe connector with incorporated sensor for on-line 
sampling, a diagram of which is shown in Figure 3(a).[62] Two etched silicon chips 
formed this device, which incorporated not only the probe connector but also a 
chloride sensor in a microchamber located behind the connector.  
The first example of a microchip electrophoresis device coupled with 
microdialysis was reported in 2004 by Huynh et al., who monitored an enzymatic 
reaction producing a fluorescent product.[63] A continuously flowing dialysate 
stream from a microdialysis probe was introduced into the microchip, and discrete 
injections into the separation channel on chip were achieved using a valveless gating 
approach. Fluorescence detection was used to detect separated sample components. 
Other examples of microchip electrophoresis for on-line analysis of microdialysate 
have used poly(dimethylsiloxane)(PDMS)-glass bonded devices, interfaced to 
microdialysis probes with silica capillary tubing. Martin’s group described the use of 
on-chip pneumatic valve(s) for discrete plug samplings from a hydrodynamic flow 
channel into a separation channel (Figure 3(b)).[64, 65] The microdialysis probe was 
inserted directly into the sample inlet, S, and microdialysate was introduced 
continuously to the chip. With valve 1 normally open (NO) and valve 2 normally 
closed (NC), microdialysate runs from the inlet to the sample waste, SW, o utlet. 
Periodically, valve 2 w as opened, valve 1 c losed, and a small amount of 
microdialysate was i njected into the separation channel. Stimulated dopamine 




in this way, using electrochemical detection. Wang et al. reported a segmented flow 
microfluidic device interfaced with a microdialysis probe in order to improve the 
temporal resolution of in vivo glucose monitoring (Figure 3(c)).[66, 67] Segmented 
flow was produced by flowing perfluorodecalin (oil) from one arm of a T-junction,  
 
Figure 3. (a) A double lumen microdialysis probe connector micromachined in 
silicon. The connector has an incorporated sensor for on-line sampling (reprinted 
with permission from Böhm et al.[62]) (b) Poly(dimethylsiloxane)(PDMS)-based on-
chip pneumatic valves for hydrodynamic flow control. (reprinted with permission 
from Mecker et al.[65]) (c) Microfluidic chip with a microdialysis interface based 
on segmented-flow (above) and continuous flow (below). (reprinted with permission 
from Wang et al.[66]) (d) Schematic diagram of microfluidic chip for glucose 
sensing and insulin injection. Micropumps, microvalves, microchannels and 
reservoir were incorporated to control fluids.(reprinted with permission from 
Huang et al.[68]). 
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while microdialysate from a probe was introduced continuously from a second arm.  
The resulting microdroplets were then directed onto a co nventional fused-silica 
collection capillary. By adding reagents to the microdialysate containing glucose, a 
reaction could be performed in the droplets, producing a fluorescent signal 
proportional to glucose concentration which was detected at the end of the collection 
capillary. A couple of papers have been reviewed elsewhere for development and 
applications of microdialysis-microfluidic system.[69-71] 
Microfluidics technology provides a route to completely integrated systems for 
(continuous) glucose monitoring.[72] Huang et al. presented a microfluidic system 
with compartments of control modules such as valves, pumps, fluidic channels, and 
reservoir and monitoring modules including glucose and flow sensors (Figure 
3(d)).[68] This system is particularly interesting, since both in vitro results for 
glucose measurement and automatic insulin injection were demonstrated, with 
minimal amounts of reagents consumed. Hsieh et al. developed an on-chip 
microdialysis system with in-line sensing electrodes.[73, 74] A microdialysis 
membrane sealed a 1 5-µm-deep microchannel formed photolithographically in an 
SU-8 epoxy layer and containing electrodes for electrochemical detection. 
Ultimately, the device was designed to function as a microdialysis probe, with the 
outer surface of the membrane in direct contact with tissue, and the inner surface 
perfused by medium containing GOx, pumped through the microchannel. Glucose 
diffusing across the membrane into the microchannel reacts with the GOx to 
produce H2O2, which is then detected at the electrodes. For the studies reported in 
[73, 74], the outer membrane surface was p laced in contact with a r eservoir 
containing a glucose solution. 
In our group, we have reported an enzymatic microreactor incorporating a chaotic 
mixing channel with an on-chip electrochemical detector for continuous glucose 
monitoring.[75] This microreactor was used in an in vivo application, in which a 
microdialysis probe was interfaced with the device for subcutaneous glucose 
monitoring  in anesthetized rats.[Chapter 5 of this thesis] Having demonstrated the 
feasibility of using this type of microfluidic chip system in conjunction with 
microdialysis, a micro CGM combining both an enzymatic microreactor and on-chip 
electrochemical detector is envisioned. 
 
4. Currently available CGMs 




To date, various approaches are being used to develop continuous glucose monitors 
(CGM). Several CGMs with different technologies were recently brought to market. 
Some of these rely on noninvasive transdermal methods to measure glucose, such as 
reversed iontophoresis or optical techniques. Noninvasive techniques are thoroughly 
reviewed by W ilkins et al.[76] The GlucoWatch (Cygnus Inc), based on 
iontophoresis,[77] was commercialized in 2001.[78] The Pendra (Pendragon 
Medical) uses impedance spectroscopy to measure glucose, and was introduced onto 
the market in 2003.[79] Although noninvasive transdermal approaches are appealing 
due to their high degree of convenience and user friendliness, they are still too 
underdeveloped in terms of accuracy.[28] Accuracy is negatively affected by 
variation in temperature, tissue thickness, sweating, blood pressure, motion artifacts, 
and microvascular blood flow variation.[80] As a result, the prospect of noninvasive 
CGMs is still elusive. 
In contrast to the noninvasive techniques, rather promising results have been 
obtained with invasive methods like needle-type and microdialysis-based CGMs. In 
this review we therefore mainly focus on invasive techniques, such as needle-type 
electrodes[32, 33, 81-86] and microdialysis-based CGMs.[41-44] Characteristics of 
several commercially available systems are summarized in Table 1. Needle-type 
CGMs with glucose oxidase immobilized onto an implantable electrode are a 
successful approach. This technology is currently used by several CGMs, including 
the CGMS Gold, Guardian REAL-Time and Paradigm REAL-Time 
(Medtronic),[81-84] Dexcom STS (Dexcom),[85, 86] and Freestyle Navigator 
(Abbott Diabetes Care).[32, 33] 
Commercially available CGMs based on microdialysis include the SCGM 
(Roche),[41, 42] and the GlucoDay (Menarini Diagnostics).[43, 44] The SCGM uses 
enzyme in solution rather than using immobilized enzyme on the electrode to react 
with glucose and produce H2O2. A small peristaltic pump perfuses Ringer’s solution 
and glucose oxidase at a flow rate of 0.3 µL/min. The glucose which diffuses across 
the probe membrane and into the microdialysate is transported to the sensor unit. 
The glucose and glucose oxidase in solution are then mixed/reacted. The electrode 
detects the produced H2O2 amperometrically using an applied potential. The 
GlucoDay uses glucose oxidase immobilized on the working electrode. Glucose 
from the microdialysis fiber is conveyed to the sensor at a flow rate of 10 µL/min. 
This flow rate results in relatively poor glucose recovery, as a result of the reduced 
contact time of perfusion solution with the internal membrane surface. Compared to 
needle-type CGMs,  the microdialysis-based approach is considered a safe technique 
for in vivo applications, as the reaction takes place outside of the body. Sensor 
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biofouling is also less of an issue, as microdialysis plays a role as a prefiltering tool 
to remove proteins and other biological complexes from the glucose sample. 
However, a low temporal resolution (long system lag time) and the requirement of 
an external pump are drawbacks of this approach. Microfluidics offers an excellent 
opportunity to reduce reaction and lag times and miniaturize microdialysis-based 
systems. 
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4.2. Main challenges 
Technology for CGMs has been under development for over three decades, and 
several lines of research have produced proofs-of-principle with promising results. 
However, in spite of all these scientific advances, CGMs are still awaiting their 
widespread use in diabetes therapies. It has been acknowledged that proliferation of 
CGM in healthcare applications is currently hampered by a lack of reimbursement 
from private and government health insurance agencies, and the presence of several 
technical challenges that still need to be overcome.[17, 87] CGMs currently on the 
market should be upgraded for higher accuracy, signal stability, and reliability of 
longer period of days. Frequent calibrations by the fingerstick method, especially 
during the night, and regular replacement of the implants are still major burdens to 
the patient and limit applicability.  
The most important criterion for reliable CGMs is that they exhibit a high degree 
of accuracy. The accuracy of CGMs in clinical applications is usually evaluated by 
means of error grid analysis. Error grid analysis takes into account that in the 
clinical context the required degree of accuracy is co-determined by the blood 
glucose concentration. In the error grid, glucose concentrations obtained from the 
CGM are plotted against concurrent blood glucose values obtained by the fingerstick 
method. Various zones in the grid are defined that are considered indicative of a 
certain degree of accuracy. The most common methods are the Clarke Error 
Grid,[88] established in 1987, and the updated version named the Consensus Error 
Grid (see Figure 4).[89] While the Consensus Error Grid does not have boundaries 
that skip risk categories, it has also been argued that this method is too forgiving 
when assessing accuracy during systemic hypoglycemia.[16] The Continuous 
Glucose-Error Grid Analysis was developed in 2004, which also takes into account 
that a certain time delay may exist between glucose changes in ISF compared to the 
blood.[90] However, the delay rate in this method is arbitrary and there currently is 
no consensus about the underlying physiological mechanism.[91] 
The Clarke Error Grid has been used in many clinical studies to evaluate the 
accuracy of commercially-available CGMs. Typically, more than 93% of 
measurements fell in zones A or B in patients with type 1 or type 2 diabetes.[32, 92-
94] Although the accuracy is sufficient, these positive findings were obtained under 
well controlled laboratory conditions. Accuracy was found to be much lower when 
patients used the CGMs at home, indicating that real-life situations and proper 
patient training largely affect CGM performance.[18, 93] CGMs generally have the 
lowest degree of accuracy when monitoring glucose during systemic 
hypoglycemia.[37, 95] Part of this effect may be explained by the dynamic 
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relationship between blood and ISF compartments under these conditions. Whatever 
the reason may be, it is sufficient grounds to question the reliability of CGMs in 
both improving glycemic control and avoiding hypoglycemia. 
Another major challenge for all types of CGMs is the lag time between a change in 
blood glucose concentration and the measurement provided by the CGM. This lag 
time includes a physiological delay between the blood and the tissue site where the 
CGM is implanted, a phenomenon discussed in Section 5. Microdialysis-based 
CGMs also have considerable system delays that originate within the device itself. A 
wide range of lag times have been reported, ranging from 6 to 30 min.[96, 97] 
 
Figure 4. (a) Clarke Error Grid and (b) Consensus Error Grid, zone A: clinically 
accurate, zone B: benign errors, zone C: overcorrect, zone D: failure to detect, zone 
E: erroneous (reprinted with permission from Wentholt et al.[16]). 
 
5. Physiological factors 
5.1. Glucose in ISF versus in blood 
For historical reasons, therapeutic decisions in the treatment of diabetes are made on 
the basis of blood glucose values. Intravascular placement of CGMs is very 
tempting, because it would negate issues about glucose transfer through tissues. 
However, there are obvious difficulties and health risks related to the placement of 
CGMs in the intravascular compartment for prolonged periods of time. Initial 
placement and then replacement of CGMs in a b lood vessel always requires the 




and thrombosis.[98, 99] Formation of blood clots on the CGM may also reduce its 
lifespan and therefore necessitate frequent replacement, although Wientjes et al. 
demonstrated good long-term stability of their intravascular microdialysis-based 
CGM in human patients.[100] Invasive CGMs are typically placed in extracellular 
compartments, such as t he subcutaneous adipose tissue in the abdomen or the 
forearm. These devices measure glucose concentrations in the ISF. Noninvasive 
optical techniques measure a co mbination of intravascular, intracellular, and 
extracellular concentrations. The use of either approach poses the question whether 
glucose concentrations in the ISF truly reflect blood glucose. It has been postulated 
that ISF may more adequately reflect overall tissue homeostasis compared to blood 
glucose measurements, which would have important clinical relevance concerning 
hypoglycemic symptoms and diabetic complications.[101, 102] Moreover, in a 
principle site for endogenous regulation of glucose homeostasis, the endocrine 
pancreas, ISF glucose is used by the body to adjust release of insulin and 
glucagon.[27] To date the dominant method has been to calibrate ISF glucose values 
against concurrently obtained blood glucose, with varying degrees of success, to be 
able to relate to existing literature on daily glycemic dynamics. 
In human skin, approximately 40% of tissue volume is ISF and approximately 5% 
consists of blood vessels.[103] Subcutaneous adipose tissue has less ISF compared 
to skin, largely impacted by the degree of obesity.[104] The relationship between 
ISF and blood glucose is complex and not well understood. There is disagreement 
among the outcomes of the various studies that have investigated this relationship, 
which we b elieve to be attributable to differences in methodology. Under 
physiological conditions, there is a f ree and rapid exchange of glucose between 
blood and ISF.[105] During steady-state, glucose concentrations in blood and ISF 
will therefore be equal when glucose uptake by the tissue surrounding the CGM is 
negligible, and there will be a gradient when glucose is taken up by the surrounding 
tissue.[30] It has been reported that ISF glucose in subcutaneous adipose tissue is 
nearly identical to the blood[101, 106], although others reported ISF glucose to be 
15-30% lower.[107-109] The blood-ISF gradient is dependent on the tissue,[101] 
and seems to be larger during systemic hypoglycemia.[110, 111] Conflicting reports 
also exist about the rate of equilibration between blood and ISF during increasing or 
decreasing glucose concentrations. Some studies revealed rapid equilibration[110, 
112], whereas others demonstrated a delayed physiological response in the ISF by 
18-30 min.[14, 94, 106, 113, 114] Moreover, Moberg et al. showed that the delay 
was larger in skeletal muscle compared to adipose tissue, and also larger during 
decreasing than during increasing glucose levels.[101] 
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There is general agreement in the literature that recovery from insulin-induced 
glucoprivation lasts longer in ISF compared to blood, both in healthy and in diabetic 
subjects.[106, 111, 115] It is interesting to note that some studies revealed glucose 
concentrations in ISF decrease earlier compared to the blood during insulin-induced 
hypoglycemia, both in rats[116] and in humans.[108] This so-called push-pull 
phenomenon, first described in anesthetized rats in 2000,[105] is suggestive of a 
dynamic relationship between blood and ISF which depends on changes in local 
glucose uptake. However, in diabetic dogs it was found that the delay of 
approximately 5-10 min was independent of circulating concentrations of insulin.[30] 
Diabetes may also affect the blood-ISF relationship, as hypoglycohistiosis preceded 
systemic hypoglycemia by approximately 15 min in diabetic rats, but not in healthy 
ones.[116] 
The various findings described above illustrate the complexity of the relationship 
between glucose concentrations in blood and ISF. Especially during systemic 
hypoglycemia, when accuracy of measurements is most critical, ISF values obtained 
by any CGM have to be treated with great care. Unfortunately, it has not been 
possible toestablish a systematic pattern in the outcomes that could be attributed to a 
specific technical aspect of electrode-type or microdialysis-type CGMs. A high 
degree of variation between individuals has been observed with both systems.[102, 
112] Therefore, it seems that the exact conditions at the tissue site of implantation 
may influence the outcomes. 
 
5.2. Implantation effects 
In addition to technical challenges that deal with accurate analysis of glucose 
concentrations, there are also physiological challenges that may affect the 
concentration of glucose to which the CGM is exposed. These physiological factors 
can be divided into acute processes that accompany CGM implantation, intermediate 
processes that involve wound healing, and long-term processes such as 
inflammation, encapsulation, and angiogenesis.[97, 117-119] In addition, these 
processes may also impair the performance of the device itself. The changes in 
tissue morphology alter diffusion parameters of the tissue, such as the endothelial 
barrier and tissue tortuosity. There may also be disturbances in microcirculation and 
local rate of metabolism. Implantation of a CGM produces signs of trauma. 
Therefore it is important that the tissue is given sufficient time to recover after a 
probe has been implanted. On the other hand, slow-onset tissue reactions may render 




opportunity exists in which reliable measurements can be obtained. The goal is then 
to limit these reactions and maintain favorable conditions. 
Implantation of a CGM into subcutaneous tissue causes acute damage to blood 
capillaries and cells immediately surrounding the CGM. Local supply of blood and 
glucose to the site of implantation is impaired.[120] On the other hand, multicellular 
structures that may normally form a barrier for diffusion of glucose from capillaries 
to more distant tissue are disrupted, allowing glucose to reach the CGM more 
efficiently. In the first days following CGM implantation, the tissue surrounding the 
CGM shows morphological changes, including signs of hemorrhage and edema.[119] 
At the intracellular level, major tissue disruptions have been reported 40 hours after 
implantation.[121] Increased rates of metabolism caused by tissue trauma and 
wound healing processes have been implicated in decreasing ISF glucose levels 
relative to the blood within the first 12 hours after CGM implantation.[97, 122] 
Lutgers et al. showed that it takes up to four days after implantation before a 
reasonable recovery of at least 70% is obtained.[123] This is consistent with 
inflammation effects, because those last for three days after CGM implantation.[124, 
125] Activation of the complement system induces vasodilatation, changes the blood 
flow to the region, and increases vascular permeability.[126] 
In chronically implanted CGMs, substantial deposits of fibrin-like polymer were 
found to cause a physical barrier to the diffusion of glucose, which may increase the 
response delay between changes in glucose concentration in the ISF compared to the 
blood.[127, 128] Fibrin is a si gn of vascular endothelial cell damage and 
inflammation. A biofilm coating may form on the CGM, consisting of fibrin, 
proteinaceous deposits, and infiltrated granulocytes and monocytes. This biofilm 
hampers CGM response to changes in local glucose concentration, thereby further 
impairing continuous glucose monitoring in ISF. At a later stage after CGM 
implantation, in part stimulated by trophic factors released in the inflammatory 
response, angiogenesis in the damaged tissue restores local blood glucose supply but 
may even enhance glucose transport and thereby partially compensate negative 
effects caused by fibrous encapsulation.[118] The extent to which implantation 
disrupts the surrounding tissue is related to the shape, dimensions, and surface 
material of the probe as well as the exact implantation procedures.  
 
5.3. Location of the CGM 
In most applications, CGMs are implanted in subcutaneous tissue to measure 
glucose in the ISF (see Figure 5). The amount of glucose present in the ISF 
immediately surrounding the CGM depends on the concentration of glucose in the 
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blood, the rate of glucose diffusion from the capillary to the ISF, and the rate with 
which glucose is taken up by the adjacent cells. These parameters are affected by the 
rate of glucose metabolism at the site of implantation, the amount of insulin that is 
present, sensitivity of the tissue to insulin, the blood flow to the local area, and the 
permeability of the nearby capillaries.[27] Lutgers et al. showed that glucose 
recovery by microdialysis was negatively correlated with abdominal wall skin-fold 
thickness, probably due to heterogeneity in capillary density.[123] The vascular bed 
in the subcutaneous tissue is richly vascularized, but it c ontains less ISF than the 
skin layers above. Therefore, higher skin-fold thickness results in lower ISF glucose 
levels. The size of the adipocytes might affect the amount of available ISF, which 
would be a mechanism for the degree of adiposity to influence measurable glucose 
concentrations.[129] Adiposity is particularly relevant to type 2 diabetes. In addition, 
Korf et al. postulated that changes in metabolism in adipocytes surrounding the 
CGM also impact local glucose concentrations by modulation of local blood flow to 
the area.[130] During a period of increased physical activity, the CGM might 
register hyperglycemia even though blood glucose levels are normal. 
 
Figure 5. A close-up image of the composition of the skin and a magnified schematic 
view of the interstitial space: a) a sensor/microdialysis probe is inserted in the 
subcutaneous tissue. b) a representation of the diffusion model of blood-to-ISF; the 
glucose concentration in ISF is proportional to the concentration in each 
compartment; G1 and G2 are capillary blood and interstitial glucose concentrations, 




Considering the factors that influence glucose concentrations in ISF, we propose 
here that the exact location of CGM implantation is an important factor in 
determining whether registered ISF glucose values will match those in the blood. 
Moreover, anatomical and physiological differences between species at the level of 
subcutaneous adipose tissue may complicate the interpretation of translational 
studies.[131, 132] Humans have considerably more subcutaneous fat than rats. The 
more fat cells, the more tortuous the path is for glucose in adipose tissue.[132] It is 
therefore recommended for testing purposes that CGMs be implanted in more fatty 
regions of the rat. Tiessen et al. reported that, during an oral glucose tolerance test in 
healthy humans, glucose values obtained by microdialysis from the loose connective 
tissue layer in the abdominal subcutis correlated much better with the blood than 
those obtained from subcutaneous adipose tissue.[133] This difference between 
tissues can be explained by the difference in interstitial structures, and by increased 
insulin-mediated glucose uptake in adipocytes. This is further supported by the 
increase in glucose gradient observed during systemic hyperglycemia. Papers 
reporting CGM performance in humans or animals are not always the same site and 
depth of location where CGM is implanted. Seemingly controversial findings in 
literature about the correlation between glucose levels in blood and ISF may very 
well be explained by differences in interstitial structure immediately surrounding the 
CGM between the various studies. Systematic investigation regarding the best site of 
implantation, i.e. a convenient site from which reliable glucose concentrations may 
be obtained, still need to be carried out. 
 
6. Future perspectives 
Implantable CGMs are instrumental in the treatment of diabetes by helping to 
prevent hypoglycemia, especially under conditions where self-monitoring with 
fingersticks is inadequate. Currently existing CGMs, however, are still hampered by 
a lack of accuracy, and have not yet been approved for long-term use. Future 
development of CGMs will be aimed at improving long-term stability and 
biocompatibility. It is important that the performance of CGMs is evaluated in a way 
that foreshadows their performance in patients. Proper test conditions should involve 
the use of animal models that are more analogous to humans than rats. Skin anatomy 
and physiology of subcutaneous ISF in pigs and dogs bear closer resemblance to 
humans. Humans have more adipose tissue than rats, and may not be affected to the 
same extent as r ats by physical and vascular factors, such as en capsulation, 
biofouling, and wound healing.[132] 
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It is also important that the accuracy of CGMs are evaluated in an appropriate way. 
A common approach to test in vivo performance is to administer a high 
concentration of glucose either into the peritoneal cavity or directly into the blood 
through a venous catheter.[134] This typically results in a C GM response that is 
delayed compared to rapid changes in blood glucose. CGM performance is much 
more accurate when glucose changes in blood are more gradual, for example 
following oral glucose administration.[135] Oral administration of glucose results in 
a more physiologically relevant response that better reflects the conditions under 
which CGMs are used in clinical applications. 
It is our opinion that the timeframe of experimental evaluation of CGMs is an 
important, and yet often overlooked, factor that has major influence on the outcome. 
Experiments that test in vivo performance often last no m ore than a few days. 
Considering the large array of physiological factors that influence CGM 
performance after it has been implanted into the body, ranging from acute tissue 
damage, intermediate term wound healing and inflammation, and long-term 
processes such as en capsulation and angiogenesis, it should be clear that it takes 
considerable time before the tissue environment immediately surrounding the CGM 
has been stabilized. It has been suggested that a “break in” period of approximately 
4-18 days should be observed before reliable glucose recordings can be 
obtained.[131] After that, the physiological properties of the implantation site 
remain stable for months. Prolonged monitoring is then only limited by deterioration 
of the CGM itself. 
Reliable glucose monitoring with an implantable CGM for prolonged periods of 
time requires that the implanted device has as little interaction with the hostile 
environment in the body as possible. For this reason, we propose that microdialysis 
probes intrinsically are more resistant to biofouling than needle-type electrodes. 
Microdialysis probes offer the advantage that only the semi-permeable membrane 
forms the outer surface that comes into contact with the tissue, and the enzyme 
glucose oxidase and the electrode are not exposed to the hostile environment of the 
body. From a m aterials perspective, several strategies exist to use surface 
passivation and/or thin film modification in order to improve biocompatibility.[132, 
136] Further development of these techniques can be combined with lab-on-chip 
technology to miniaturize all CGM components and to optimize response time and 







Continuous glucose monitoring offers potentially excellent guidance for insulin 
intervention therapies in the treatment of diabetes. The use of CGMs can provide 
accurate and continuous registration of blood glucose concentrations, both in 
retrospective and prospective applications. In the near future, a CGM could even be 
part of a cl osed-loop system in which the delivery of insulin is automatically 
adjusted based on the sensory data generated by the CGM (i.e. an artificial pancreas). 
In healthcare applications, the performance of CGMs currently on the market is still 
severely hampered by various technical challenges that to date have prevented their 
widespread deployment. There is particular need for higher accuracy, signal stability 
and reliability of longer period of days, because frequent calibrations and regular 
replacement of the implants are major burdens to the patient. Several physiological 
factors critically affect CGM performance. The most prominent factors include 
disturbance of the tissue in which the CGM is implanted, damage to the CGM by 
biofouling, and disruption of CGM function by biofilm formation and tissue 
encapsulation. In addition, to accurately and timely monitor changes in blood 
glucose levels with a device that is exposed to the ISF of abdominal or subcutaneous 
adipose tissue requires the CGM to be carefully positioned. The exact location, size 
and surface properties are very important. The glucose kinetics relationship between 
blood and ISF is delicate. Efforts to improve CGM performance should therefore 
chiefly aim at optimizing biocompatibility. 
Placement of a C GM into subcutaneous tissue is probably the most practical 
position for general use in healthcare applications. Techniques designed for that site 
are much more accurate compared to transdermal techniques, and unlike 
intravascular methods, implantation can be carried out without the help of a 
physician. Moreover, in the ISF there are fewer issues with biofouling or hemostasis, 
and fewer risks for hemorrhages. However, placement into subcutaneous tissue 
warrants the need to carefully consider glucose kinetics between blood and the ISF. 
From reviewing the biomedical literature on this relationship, we have concluded 
that this is not straightforward but in fact rather complex. The present dogma is that 
of the push-pull theory, which states that a p ostprandial glucose increase in the 
blood is followed by a similar increase in the ISF after a short delay.[108] However, 
a decrease in circulating glucose (e.g. by insulin-induced clearance) would be 
preceded by a glucose decrease in the ISF.[116] Many studies have been reported 
that either support or refute the push-pull theory. Moreover, there is a great degree 
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of variation among studies in the reported lag times, ranging from nearly 
instantaneous equilibration to a delay of 45 min.[129]  
From our meta-analysis, we conclude that the observed glucose kinetics between 
blood and ISF is largely dependent on the size and design of the CGM, CGM 
implantation in superficial subcutis versus loose connective tissue of deeper layers, 
and on t he species under investigation. Other predictive factors are degrees of 
adiposity and skin fold thickness, and the level of physical activity. It is therefore 
very difficult to make a definitive statement about the relevance of a p ush-pull 
phenomenon for CGM function in any particular patient. We recommend that 
evaluation of this phenomenon be included in the calibration procedures that are 
already being carried out, in particular after each placement of a new CGM implant. 
In the near future, further development of CGM technology is to result in higher 
accuracy and signal stability of these instruments. In addition to their enhanced 
applicability in diabetes intervention therapies per sé, technological improvements 
of CGMs will also enable us to examine blood-to-ISF kinetics more thoroughly, 
hence indirectly making the use of CGMs in patients even more reliable. 
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The development of continuous glucose monitoring systems is a major trend in 
diabetes-related research. Small, easy-to-wear systems which are robust enough to 
function over many days without maintenance are the goal. We present a new 
sensing system for continuous glucose monitoring based on a microreactor 
incorporating chaotic mixing channels. Two different types of chaotic mixing 
channels with arrays of either slanted or herringbone grooves were fabricated in 
poly(dimethylsiloxane) (PDMS) and compared to channels containing no grooves. 
Mixing in channels with slanted grooves was characterized using a f luorescence 
method as a function of distance and at different flow rates, and compared to the 
mixing behavior observed in channels with no gr ooves. For electrochemical 
detection, a thin-film Pt electrode was positioned at the end of the fluidic channel as 
an on-chip detector of the reaction product, H2O2. Glucose determination was 
performed by rapidly mixing glucose and glucose oxidase (GOx) in solution at a 
flow rate of 0.5 µL/min and 1.5 µL/min, respectively. A 150 U/mL GOx solution 
was selected as t he optimum concentration of enzyme. In order to investigate the 
dependence of device response on flow rate, experiments with a premixed solution 
of glucose and GOx were compared to experiments in which glucose and GOx were 
reacted on-chip. Calibration curves for glucose (0 ~ 20 mM, in the clinical range of 
interest) were obtained in channels with and without grooves, using amperometric 
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1. Introduction 
Diabetes mellitus is a widespread disease causing heart disease, weight loss, blurry 
vision, neurological disorders, and even death.[1] Proper management of blood 
glucose is thus of crucial importance for diabetic patients. The conventional way 
blood glucose determinations are carried out involves the finger-prick method. 
Usually, diabetic patients measure their own blood glucose several times per day by 
applying a drop of blood to a portable device. However, this intermittent monitoring 
does not yield the full range of information necessary to effectively control glucose 
levels 24 hours a day. The current research trend is thus towards real-time in vivo 
monitoring over longer periods (days).[2-5] Type 1 diabetic patients in particular 
could benefit from a portable glucose sensor to keep their glucose values within a 
reasonable range. Theoretically, a portable glucose sensor could include an insulin 
pump in a feedback loop to serve as an artificial pancreas. 
Electrochemical detection is commonly used for glucose analysis.[6] The 
advantages of electrochemical detection include sensitivity and ease of interfacing 
with detection electronics. Several reports incorporating electrochemical detection 
on a microchip have been published for the detection of glucose.[7-9] The principle 
of the enzymatic reaction involved is shown in Equations (1) and (2). Glucose, O2 
and glucose oxidase (GOx) react to generate hydrogen peroxide (H2O2) at 
concentrations proportional to the original glucose concentrations. The H2O2 is then 
oxidized under applied potential into O2 and H
+, with the resulting electrons being 
recorded as an electrical current. 
     
 Glucose + O2                     Gluconic acid + H2O2  (GOx: glucose oxidase)    (1) 
 
   H2O2                            2H
+ + O2 + 2e
-                                                                                                   (2) 
The reaction may be carried out by mixing the reagents in solution to produce 
H2O2 which is then subsequently detected by integrated electrodes[7, 8], or by 
immobilizing GOx directly onto the detection electrode surface to react with glucose 
in solution.[9] The electrochemical detectors in these microchips displayed fast 
response times and low detection limits. Immobilizing GOx certainly reduces its 
consumption significantly compared to devices in which GOx is added in solution. 
However, the major disadvantage of this approach is that the enzyme layer is prone 
to biofouling in in vivo applications, which might cause a decrease in activity over 




Over the last decade, a number of glucose sensor designs have been developed and 
become available for continuous monitoring purposes.[12-16] Mastrototaro et 
al.[14] reported an in vivo needle-type continuous glucose monitoring system 
(CGMS), which is currently being used by consumers as a kit (MiniMed). The 
detector in this system is based on the reaction of immobilized glucose oxidase on 
the electrode with glucose. Schoemaker et al.[15] and Wientjes et al.[17] have both 
reported a subcutaneous continuous glucose monitoring system (SCGM) based on a 
microdialysis probe and using the solution-based enzymatic reaction with glucose. 
They reported reliable measurements in diabetes patients over periods of four 
days[18] up to two weeks.[19, 20] However, due to their bulky size and the need for 
connecting tubes between system components, these systems exhibited relatively 
long physical lag times of 30 min or more. Pickup et al.[13] reviewed the clinical 
use of glucose monitoring systems and introduced new technology for non-invasive 
glucose sensing, based on near-infrared spectroscopy and fluorescence. Wentholt et 
al.[21] reported an overview of the current applications and clinically relevant 
aspects of continuous glucose monitors (CGMs), with emphasis on the calibration 
procedure, interpretation of continuous glucose data, and some important 
limitations. Overall, these authors concluded that improved accuracy, reliability for 
longer periods of time, miniaturization, and cost-effectiveness are the main issues 
which need to be considered in the further development of continuous glucose 
monitoring systems.[21] 
Chip-based microfluidic technologies are a good alternative to improve on 
conventional monitoring approaches such as the SCGM described above. 
Microfluidic systems, also termed “miniaturized total analysis systems (µTAS)”[22] 
or “lab-on-a-chip”, are now widely used in analytical chemistry and biological 
applications. Advantages of these systems include dramatically reduced 
consumption of chemical reagents, faster reaction times and cost-effectiveness. 
Micro SCGM systems can thus be envisaged which exploit the solution-based 
reaction of GOx with glucose in nL volumes in micrometer-sized channels for 
glucose sensing. The overall speed of the analysis will therefore depend in part on 
the efficiency of mixing reagents in the microfluidic channels.  
Mixing at the micrometer scale is a c hallenge, as f lows are generally extremely 
well-defined and laminar. Mixing of two solution streams in a straight microchannel 
is possible only through means of diffusion, a passive molecular transport process 
which is very slow. There has therefore been an enormous amount of research done 
in the past decade or so on how to implement efficient mixing at the nL scale. So-
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called passive micromixers are generally preferred for many micro analytical flow 
systems, since these elements do not require the application of an external force to 
achieve mixing. A large number of passive micromixers have been reported, 
including a planar laminar flow mixer,[23] a cross-shaped micromixer[24] and a 
droplet mixer.[25] The approach chosen for our work is one based on chaotic 
mixing, first described by S troock et al.[26, 27]. Mixing is achieved through the 
incorporation of an array of microgrooves into a microchannel. Flow over the 
groove array assumes a helical or corkscrew pattern, in which the contact area 
between two adjacent solutions is increased dramatically to facilitate mixing by 
diffusion. Depending on device dimensions, complete mixing can be achieved in just 
a few seconds. Since reaction of glucose with GOx occurs upon mixing, integrated 
microelectrodes positioned at the end of the mixing channel will record a signal due 
to the oxidation of the H2O2 produced. 
Ultimately, the overall analysis time is determined by both the mixing/reaction 
time in the microchannel and the time it takes for microdialysate containing glucose 
to be transported from the implanted probe to the sensing component. In fact, the 
physical lag time of glucose transport from the probe to the sensing element in 
conventional systems is generally on the order of tens of minutes. A seco nd 
objective of miniaturization of microdialysis-based CGMs is therefore to 
substantially reduce the physical lag times of these systems. 
The long-term goal of the present project is to realize an autonomous, portable 
sensing system for continuous in vivo glucose monitoring, based on the reaction in 
solution of GOx with glucose to produce H2O2. To accomplish this, we have 
designed a miniaturized glucose sensing system based on microdialysis sampling 
and lab-on-a-chip technology. In this system, nL amounts of sample and enzyme 
rapidly mix and react. As high-recovery microdialysis requires flow rates in tissue 
less than 1 µL/min[17], we have adapted the microreactor dimensions according to 
these conditions. In this paper, we describe a new application for chaotic mixing, 
that is, the efficient and fast mixing of GOx and glucose for reaction. To that end, 
either slanted or herringbone grooves were fabricated in poly(dimethylsiloxane) 
(PDMS) chips, and the mixing characteristics of these channels  co mpared to 
channels without grooves. A thin-film Pt electrode at the end of the fluidic channel 







2. Materials and methods 
2.1. Chemicals and reagents 
All chemicals were analytical reagent-grade. Fluorescein and potassium iodide (KI) 
were purchased from Sigma-Aldrich (Germany) and used to prepare 0.002M 
fluorescein solution and 0.2M KI solution, respectively. Potassium ferricyanide 
(K3Fe(CN) 6) and potassium ferrocyanide (K4Fe(CN) 6) were supplied by Sigma-
Aldrich (Germany) and used to prepare a 1 mM solution in a 20 m M phosphate 
buffer  (pH = 7.2). pH was measured using a pH meter (inoLab® pH 720, WTW, 
Germany). The phosphate buffer was prepared by mixing solutions of 
NaH2PO4·H2O (63 mL) and Na2HPO4·2H2O (100 mL) containing 0.1 M potassium 
nitrate (KNO3) as a supporting electrolyte. H2O2 (30%) was supplied by VWR (The 
Netherlands) and prepared freshly every day at various concentrations in phosphate 
buffer. D-glucose and GOx were supplied from Merck (Germany) and used to 
prepare 100 mM and 5000 U/mL stock solutions, respectively. D-glucose was stored 
in a refrigerator at 2 ºC and used for 1 month. GOx was stored at - 20 ºC and used 
for 3 months. All solutions were prepared with 18 ㏁ ultrapure water purified in an 
Arium® 611 (Sartorius Stedim Biotech, Germany).  
 
2.2. Microfluidic chip fabrication 
The first microchannels were constructed by standard microfabrication and 
replicated in the silicone rubber, PDMS (Sylgard 184, Dow Corning, U.S.A.). The 
chip layout and design were drawn using the program, Clewin (Wieweb software, 
Hengelo, The Netherlands). The structure on the silicon master, which served as a 
mold, was processed with two steps of standard photolithography (Figure 1, right 
column).[28] A 4-inch p-type (100) silicon wafer (Si-Mat, Germany) (525µm 
thickness) was employed as a substrate. The silicon wafer was first cleaned 
sequentially with acetone, isopropyl alcohol, and deionized water, and dried with N2  
gas. The wafer was t hen treated with hexamethyldisilazane (HMDS) (Sigma-
Aldrich, Germany) in a vacuum desiccator for 30 min to improve adhesion of the 
photoresist (PR). A thick positive PR, AZ4562 (Microchemicals GmbH, Germany), 
was coated on the silicon wafer using a spin-coater at 1000 rpm for 3 sec and baked 
at 100 ºC for 30 min. The resulting PR layer was 35 µm thick. After rehydration at 
ambient temperature for 3 hours, the coated wafer was exposed to ultraviolet (UV) 
light (365 nm, 10 m W/cm2) using a photomask printed on a high-resolution 
transparency to pattern the microchannels (resolution 3,810 dpi; Pro-Art BV, 
Groningen, The Netherlands). The exposed PR was then removed by dipping in a 
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developer solution (AZ351B: deionized water (DI) = 1:3, Microchemicals GmbH, 
Germany) and agitating the beaker for 20 m in, leaving behind PR ridges for 
microchannel replication. The wafer was then rinsed in DI water and dried with N2 
gas. Contrary to usual protocol, no postbake step was undertaken for this layer. 
Rather, the substrate was again exposed to UV light for 10 sec using a second 
transparency photomask to pattern the groove arrays. The patterned PR was ag ain 
immersed in a developer (AZ351B: DI = 1:4) solution for 6 min to form groove 
structures on top of the microchannel structures. 
PDMS resin and a curing agent were used for microchannel replication in a PDMS 
slab. The two liquids were mixed at a weight ratio of 10:1 PDMS: curing agent, and 
the solution left to stand at ambient conditions for 20 min to remove air bubbles. 
Afterward, the mixture was poured over the prepared silicon master. A 
polycarbonate alignment piece was used together with fused-silica capillaries to 






















µm in diameter) were drilled in the polycarbonate using a CNC machine (Sherline, 
USA) at points corresponding to the locations of the required inlets/outlets when this 
piece was aligned with the silicon master. Fused-silica capillaries were then inserted 
through the holes and aligned on the microchannel structures on the silicon master. 
The prepolymer mixture was allowed to cure against the master at 50 ºC for 4 hours. 
 
2.3. Thin-film electrode formation 
Platinum (Pt) sensing electrodes were formed on a g lass wafer by a standard 
photolithography and lift-off process (Figure 1, left column). A 4-inch, 525-µm-
thick borofloat glass wafer (Telic, USA) was used as a substrate for the electrode 
patterning. The glass wafer was first cleaned using a piranha solution (96% H2SO4:  
30% H2O2 ratio of 3:1), then thoroughly rinsed in DI water and dried with N2 gas. 
(WARNING: Piranha solution must be handled with extreme caution, as it is highly 
oxidizing and reacts explosively when it comes into contact with easily oxidized 
organic solvents. This solution must be used in a well-ventilated fumehood with 
absolutely no organic solvents in the vicinity. Explosive reactions also occur in the 
presence of trace amounts of metals such as Pt, Ag, and Mn. Metal tweezers must 
not be used when cleaning wafers in piranha.) The wafer was t hen treated with 
HMDS in a vacuum desiccator for 30 min. An image reversal PR 5214E 
(Microchemicals GmbH, Germany) was coated using a spin-coater at 2000 rpm for 
20 sec, and the substrate was placed on a hotplate at 105 ºC for 50 sec to soft-bake 
the resist and remove solvents. Subsequently, the substrate was exposed to UV light 
(365 nm, 10 m W/cm2) for 2 s ec using a photomask with electrode pattern. After 
reversal baking of the substrate at 115 ºC for 2 min, a flood exposure was performed 
for 20 sec without mask to solubilize unexposed areas, resulting in a negative image 
of the mask. Finally, the substrate was immersed in a developer solution (AZ351B: 
DI water, ratio 1:4) to remove soluble PR and expose the glass surface where the 
electrodes were to be formed. 
 A lift-off process was performed to obtain Pt sensing electrodes on the patterned 
glass wafer. A Ti thin-film layer (20 nm) was deposited over the entire wafer by E-
beam evaporation (Temescal, USA) under a high vacuum of 9 × 10-6 Torr. Ti was 
deposited first, as it adheres better to glass than Pt, and in turn, Pt adheres well to Ti. 
Subsequently, a Pt thin-film layer (150 nm) was grown by E-beam evaporation at 2 
× 10-5 Torr. The glass substrate was then immersed in acetone to dissolve the 
remaining PR layer, thereby simultaneously lifting off the thin Pt/Ti film on top of 
it. The metal remained behind in the predefined electrode regions. Groups of three Pt 
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electrodes were patterned; the patterned electrode dimensions were 100 µm × 1500 
µm and the distance between two electrodes was 30 µm.  
 
2.4. Chip integration 
The dimensions of the channel and grooves on t he structured silicon master were 
determined using a st ylus profilometer (Veeco Instrument BV, The Netherlands) 
before casting PDMS. There are two inlets and one outlet (waste) to the 
microreactor channel. The two inlet channels are half as wi de as the microreactor 
channel after the Y-junction, to ensure a constant linear flow velocity throughout the 
device upon introduction of two solutions at the same flow rate. A 1:1 dilution of 
solutions will also result under these conditions of operation. The inlet channels are 
both 100 µm wide, 35 µm deep and 5 mm in length. A ruler is located along the 
channel to show the distance from the Y-junction. The total length of channel from 
the Y-junction is 22 mm, while the width and depth of the channel are 200 µm and 















                (a)                                               (b)                                                 (c)      
Figure 2. (a) Photograph of the detection region of a fabricated microfluidic chip. 
(b) Three different types of PDMS channels with integrated electrodes: from top to 
bottom, channels with no grooves, slanted grooves, and herringbone grooves. (c) 
Schematic diagram of grooves in a channel structure. Note that the grooves were 6 - 





channel were 6~8 µm deep and were patterned at an angle of 45º with respect to the 
central axis of the channel. The total volume of the mixing/reaction channel is about 
150 nL. 
In order to bond the PDMS slab to the glass chip with the electrodes, the PDMS 
was smoothly peeled off from the master and cut. The two devices were first treated 
with UV-generated ozone for 15 min to oxidize the PDMS surface, which creates 
hydrophilic properties and improves bonding strength.[29] Subsequently, the PDMS 
slab and glass were immediately aligned under a microscope and brought into 
contact with each other. The assembled chip was then placed on a hot plate at 140 ºC 
and allowed to cool down to room temperature, after which the chip was irreversibly 
bonded. The whole bonding procedure was carried out in the cleanroom. Figure 2 
shows a fabricated microfluidic chip and examples of the three different types of 
PDMS channels with integrated electrodes investigated in this study, containing 
either no grooves, slanted grooves, or herringbone grooves.  
 
2.5. Experimental setup for fluorescence 
In order to characterize mixing, fluorescence detection was used to gain quantitative 
information about the degree of mixing along the length of the channel. A 
fluorescence microscope, Model ‘DMIL’ (Leica Microsystems, The Netherlands), 
was equipped with a 10× objective, a mercury arc lamp, and a CCD camera. The 
mixing process was visualized using a fluorescein filter, which is made for 488 nm 
excitation and 518 nm emission. Fluorescence quenching was car ried out for 
quantitative analysis using 2 mM fluorescein and 200 mM potassium iodide (KI). KI 
quenches the fluorescence produced by fluorescein when it is excited at 488 nm. 
Fluorescein and KI were introduced separately through the inlets into the Y-junction 
at various flow rates, and the image was captured with a CCD camera using a 20.1 
ms exposure time, a gamma setting of 1.0, and a gain of 1.0. The images were 
acquired at different distances from the Y-junction and analyzed by determining the 
standard deviation (SD) of the intensity distribution across the entire channel using 
Lx95P image analysis software. Flow rates were controlled by syringe pumps 
(ProSense, The Netherlands) connected with silica capillaries to the chip inlets using 
350-µm-o.d. and 250-µm-i.d. silica capillaries.  
 
2.6. Experimental setup for electrochemical detection  
Cyclic voltammetry and chronoamperometry were carried out using a potentiostat, 
“Electrochemical Analyzer” (CH Instrument, USA), interfaced to a computer. Two 
thin-film Pt electrodes were used, one as a wo rking electrode (WE), the other as a  
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counter electrode (CE). The Pt electrodes were located 21 mm downstream from the 
Y-junction. The active area of the Pt WE was 0 .02 mm2 (200-µm-wide channel × 
100-µm-wide electrode). A Ag/AgCl wire was used as a reference electrode (RE) 
and positioned in the reservoir at the end of the device. The RE was prepared by 
dipping a short piece of Ag wire (250-µm-diameter) for 5 sec into a crucible 
containing melted silver chloride (Sigma-Aldrich, Germany). For the glucose 
analysis experiments, a 1:3 flow rate ratio of glucose sample to GOx solution was 
introduced through the two inlets, and measurements were carried out under 
continuous flow conditions controlled by the syringe pumps. (For microdialysis 
experiments, the microdialysis probe outlet will be connected to the glucose sample 
inlet of the device using a si mple, low-dead-volume tubing connection.) For the 
comparison of system response to premixed glucose-GOx solutions and direct 
reaction of glucose and GOx in the channel, premixed solution was prepared using a 
1:3 volume ratio of 5.6 mM glucose and 150 U/mL GOx in a vial. After adding the 
two solutions, the vial was gently shaken 10 t imes and introduced in the reactor 
channel through both inlets approximately 5 min later after shaking. A two-position 
actuator switching valve (Valco Instrument Co., Inc) was adapted to alternatively 
introduce buffer solution and glucose sample solution to measure background and 
sensing signals, respectively. Once the flow rate had been set each time, the valve 





















for measurements at each flow rate, and current measurements were made 
continuously as flow rate was v aried. All experiments were carried out at room 
temperature, and data were saved directly on a computer. A schematic diagram of 
the electrochemical detection experimental set-up is shown in Figure 3. 
 
3. Results and discussion 
3.1. Characterization of the micromixers 
A fabricated micromixer was characterized by capturing images at different 
distances from the Y-junction using a fluorescence microscope and determining the 
variation in fluorescence intensity across the width of the channel. The standard 
deviation (SD) was calculated using the following Eq. (3)[30]: 











                                                    (3)            
where ix  is the gray-scale intensity value of pixel i, and x is the mean intensity 
value of pixels across the entire channel. Quantitative values of the SD of mixing 
efficiency varied between 0.5 for completely unmixed solutions (variation of 
intensity from 0 f or KI solution to 100 % fluorescence for fluorescein) and 0 f or 
completely mixed solutions (intensity equal across the channel).  
Figure 4 shows the SD of intensity versus distance as a function of flow rate, 
comparing channels with slanted grooves and no grooves. Flow rates that fall in the 
range required to achieve high glucose recoveries in microdialysis sampling of 
subcutaneous tissue were considered. The results showed that grooved channels 
have a higher mixing efficiency compared to channels without grooves. In fact, 
mixing in channels with slanted grooves is almost complete at a distance of 1 cm 
along the channel at total flow rates ranging from  0. 4 µL/min to 2 µL/min 
(Reynolds number = 0.08 at 1 µL/min). This result confirms that grooves formed in 
the channel ceiling at an oblique angle with respect to flow direction enhance the 
mixing rate of two adjacent solution streams. Differences in measured standard 
deviations of fluorescence intensity at shorter distances along the channel are most 
likely due to the reproducibility of the experiment itself. The depth and width of the 
grooves were designed based on Stroock’s geometric parameters (relative groove 
height to channel height, α < 0.3; channel height, h ≪ width of the channel, w) and 
have values of 6-8 µm and 50 µm, respectively, as shown in Figure 2 (c).[27] These 
initial results of mixing characterization were used as important information for 
further mixing and reaction experiments. 
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Figure 4. Comparison of microfluidic mixers having no grooves and slanted grooves 
as a function of distance from the Y-junction and at different flow rates (one device, 
n=3). The flow rate in each case is the total flow rate in the mixing channel. The 
flow rates of fluorescein and KI at the inlets are each half of the total flow rate. 
 
3.2. Cyclic voltammograms of three different types of microfluidic channel 
Cyclic voltammograms were carried out to check the electrochemical properties of 
the microfluidic chip. A ferri/ferrocyanide couple provides an ideal electrochemical 
model for a preliminary chip test with integrated electrodes. The redox couple 
ferri/ferrocyanide reaction is as follows (Eq. (4)): 
 
           Fe(CN)6
3-  + e-                  Fe(CN)6
4-                      Eº = 0.356 V                 (4) 
 
Firstly, the redox curve was examined with a stationary flow when 1 mM 
(K3Fe(CN)6) was introduced in the channel at a scan range of -0.3 V to 0.7 V. The 
oxidation and reduction peaks were observed at 0.21 V (35 nA current) and 0.10 V 
(56 nA current) respectively, at a scan rate of 100 mV/s (data not shown). For cyclic 
voltammetry under continuous flow conditions, 1 mM Fe(CN)6
3- / 1 mM Fe(CN)6
4- 
was prepared in 20 mM phosphate-buffered solution (pH = 7.2) containing 0.1 M 




rate of 1 µL/min and a scan rate of 20 mV/s. The cyclic voltammograms recorded 
over an applied potential range of 0 V to 0.6 V versus Ag/AgCl are shown in Figure 
5. In these early devices, the array of mixing grooves extended over the entire length 
of the channel, including the integrated electrodes. Higher oxidation and reduction 
currents were observed for channels with slanted or herringbone grooves than for 
unstructured channels. This was probably caused by higher local velocities over the 
electrode surfaces in the chaotic mixers, leading to thinner diffusion layers at these 
surfaces and thus improved analyte delivery and higher currents. Because of the 
observed, rather uncontrolled local flow effect on detector response, grooves were 
not structured over the electrodes in later devices used in the rest of this study. 
Instead, the groove patterns ended more than 1 mm upstream from the electrodes to 
reduce the flow effect on the electrode surface, as shown Figure 2(b). Comparing 
structured channels, the herringbone grooves did not yield a significant improvement 



















Figure 5. Comparison of cyclic voltammograms for the three different types of 
microfluidic channel. A 20 mM phosphate-buffered solution (pH = 7.2) containing 1 
mM Fe(CN)6
3- /Fe(CN)6
4- in 0.1 M potassium nitrate was used at a f low rate of 1 
µL/min and a scan rate of 20 mV/s. 
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therefore decided to focus further studies on comparing channels with no grooves to 
channels containing slanted grooves. This was b ecause channels with slanted 
grooves were easier to fabricate than channels with herringbone grooves; aligning 
the photomask for slanted grooves in the second photolithographic step was simpler 
than aligning the mask for herringbone grooves. 
A linear sweep voltammogram was recorded by introducing 6 mM H2O2 in 0.1 M 
KNO3 solution, in order to decide on an applied potential for glucose measurement. 
The onset of oxidation current was observed at 0.3 V and showed a plateau around 
0.7 V, at a total flow rate of 1 µL/min and a scan rate of 100 mV/s (data not shown). 
Therefore, this applied potential was selected for subsequent glucose experiments. 
 
3.3. Optimization of GOx concentration 
Prior to the optimization of GOx concentration, electrode variation from one chip to 
the next was characterized using a p remixed solution of 20 mM glucose and GOx 
solution. One example of each mixer type (grooved and ungrooved) was selected, 
and signal variation was t ested three times with each device. The results of these 
experiments showed that although current values varied from one device to the next, 
current values fell within the same range. Two devices, one with a g rooved 
micromixer, the other an ungrooved micromixer, were selected for subsequent 
experiments to compare the effect of no gr ooves versus slanted grooves in the 
channel.  
Since the concentration of GOx plays an important role in the reaction, various 
concentrations of GOx solutions were tested in the two channel types. To date, only 
a few papers have reported on-chip glucose sensing by mixing glucose sample and 
free enzyme in solution rather than using immobilized enzyme on electrode 
surfaces.[8, 31-33] Pijanowska et al.[32] developed a flow-through amperometric 
sensor implemented in a silicon-glass sandwich construction having a volume of 5 
µL. The glucose sample was r eacted in a r eaction cell using only two different 
enzyme activities, 22 and 132 U/mL GOx, with a higher sensitivity being obtained 
with the latter concentration. Wang et al.[7] proposed a microchip capillary 
electrophoresis (MCE) approach for glucose sensing, in which GOx solution was 
injected together with glucose sample from separate reservoirs into the separation 
channel. A 75 U/mL GOx solution proved sufficient for these researchers to obtain a 
calibration curve.  
Figure 6 shows the result of amperometric response arising from reaction of 20 




slanted grooves. The flow rates were set at 0.5 µL/min glucose and 1.5 µL/min GOx 
(1:3 mixing ratio) in order to avoid the oxygen depletion effect.[34] This is an effect 
which has been observed at higher concentrations of glucose for both 
electrochemical sensors utilizing immobilized GOx and devices based on the 
reaction of GOx and glucose in solution.  The sensitivity of sensor response 
decreases because the amount of oxygen available in the solution is not sufficient for 
full conversion of glucose conversion to H2O2 with enzyme (see also Equation (1)). 
In effect, oxygen is depleted from the solution by the enzyme reaction. To prevent 
the effect of oxygen depletion in measurements employing immobilized enzymes on 
electrodes, electrodes have been prepared with a semi-permeable coating to reduce 
the amount of glucose diffusing to the electrode. Other approaches have involved the 
use of mediators, molecules which take on the role of oxygen in the reaction.[3, 35] 



















Figure 6. Amperometric response arising from reaction of 20 mM glucose with GOx 
at different concentrations in channels without grooves and w ith slanted grooves 
(one device, n=3). The flow rates of glucose and GOx were 0.5 µL/min and 1. 5 
µL/min, respectively; an example of raw data showing background signal and 
sensing signal is shown in the inset. 
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and calibration curves were not linear at higher concentrations of glucose when the 
mixing ratio between glucose and GOx was 1:1; instead, the signal tended to level 
off. It was decided to increase the flow rate of GOx with respect to glucose sample 
to a ratio of 3:1, diluting the effective glucose concentration in the channel by a 
factor of 4 to prevent oxygen depletion.  
All experiments were performed three times and a r epeatable output signal was 
observed (as shown in the inset of Figure 6). As the concentrations of GOx solution 
increased, oxidation current gradually increased from approximately 20 nA (10 
U/mL) to reach a maximum of 100 nA and 120 nA (150 U/mL) in channels with no 
grooves and slanted grooves, respectively. At higher GOx concentrations, the 
current leveled off and then decreased in both channels with no grooves and slanted 
grooves. These results indicated that increasing concentrations of enzyme provided 
better conversion to H2O2 and product within a reaction time of approximately 4 sec. 
However, at concentrations of GOx greater than 150 U/mL, the system exhibited 
less stable signal, as r eported elsewhere[8]; this could be due to the interaction of 
GOx and H2O2 produced. Therefore, a 150 U/mL concentration of GOx solution was 
chosen as an optimum condition for further experiments. Compared with slanted 
grooves in the channel, the absence of grooves in the channel resulted in lower 
current values. It can be concluded that the chaotic flow pattern results in more 
efficient mixing caused by transverse flow in the channel.  
 
3.4. Comparison of system response for premixed glucose-GOx solutions and 
reaction of glucose and GOx in the channel 
In order to investigate dependence on flow rate, the response measured for premixed 
glucose-GOx solutions was compared with that measured for the reaction of glucose 
and GOx in the mixing/reaction channel as a function of flow velocity. For the latter 
experiments, a 5.6 mM glucose sample and a 150 U/mL GOx solution were 
introduced at a 1:3 mixing ratio in a slanted grooves channel and the flow velocity 
was varied from 0.95 mm/s (0.4 µL/min) to 14.3 mm/s (6 µL/min). The 
amperometric responses for premixed solutions and reaction in the mixing channel 
are presented in Figure 7. There are two dominant factors in this continuous flow-
through reaction system which affect detector response, namely flow velocity and 
reaction time. The effect of flow velocity was m easured by introducing premixed 
solution (5.6 mM glucose sample and 150 U/mL GOx solution had already reacted 
to produce H2O2) in both inlets and varying the flow rate. The results showed that as 




was also observed that current values increased as a function of flow velocity when 
experimenting with 0.5 mM H2O2 solutions (data not shown). This is very different 
from the decreasing signal observed for GOx immobilized on e lectrodes at higher 
flow rates, which Lowry et al. ascribed to the removal of H2O2 from the electrode 
surface.[36] On the other hand, Wu et al.[37] observed currents which increased as a 
function of flow rate at two closely spaced oxygen sensors in a microchannel. This 
latter report supports our hypothesis that the observed increase in current values for 
premixed solutions is due to the thinner diffusion layers at the electrode surface 
which result at higher flow rates. These layers are stagnant, and molecules must 
diffuse through them to reach the electrode surface. As diffusion layers decrease in 
thickness, the time required for diffusion to the electrode surface also decreases, 
resulting in the delivery of analyte to that surface to be less limited by diffusion. 




















Figure 7. Amperometric response in a channel with slanted grooves, arising from a 
1:3 reaction ratio of 5.6 mM glucose and 150 U/mL GOx as a f unction of flow 
velocity (from 0.4 µL/min to 6 µL/min). The response due to premixed solution (5.6 
mM glucose and 150 U/mL GOx) was compared with the glucose-GOx reaction in 
the mixing channel (a single device was used for both curves, n=3 for each point).  
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In the case o f glucose reaction with GOx in the mixing channel, a d ecreasing 
signal as a f unction of flow velocity was observed. This decrease in current is 
primarily due to lower H2O2 concentrations, the result of shorter reaction times. The 
maximum reaction of glucose and GOx was observed at very low flow rates (lower 
than 0.4 µL/min). Thus, based on reaction times of 22 sec and 4 sec (0.4 µL/min and 
2 µL/min, respectively) from the Y-junction to the electrodes, the most efficient 
conversion of glucose with GOx can be achieved either at very low flow rates and/or 
in longer reaction channels. 
 
3.5. Calibration curve 
A calibration curve was obtained when a 150 U/mL GOx solution was reacted with 
glucose sample in a channel at a total flow rate of 2 µL/min, with a 1:3 flow rate 
(and thus 1:4 dilution) ratio of glucose and GOx. Figure 8 shows the amperometric 
response as a function of glucose concentration in channels with either no grooves or 
slanted grooves. The data exhibit a linear relationship between current and glucose 
concentrations of 0 to 20 mM, with a sensitivity of 5.3 nA/mM and 6.9 nA/mM in 
channels with no grooves and slanted grooves, respectively.  The current density 
was calculated by dividing sensitivity by the active area of the working electrode, 
yielding 26.5 mA/M·cm2, and 34.5 mA/M·cm2 for channels with no grooves and 
slanted grooves, respectively. The linearity of the curves was tested by plotting 
observed current values versus predicted current values and examining the 
distribution of points around the resulting diagonal line (data not shown). In both 
cases, points were very symmetrically distributed around the line. The slope of the 
plot for the no-groove case was 0.9992, with an R2 of 0.9983. In the groove case, the 
slope was 1.0032, with an R2 of 0.9989. In both cases, excellent linearity was thus 
observed.  
In our approach, the flow velocity and time for reaction of glucose sample and 
GOx enzyme strongly affect the sensitivity of the sensor signal, allowing flow 
conditions to be tuned to obtain optimal results. One of the big advantages of this 
microfluidic reactor approach is that by varying flow rates of glucose and GOx, it is 
possible not only to avoid the oxygen depletion effect without any electrode 
treatment but to tune the sensitivity for the application. However, continuous 
perfusion of glucose and GOx to the device does lead to a slightly decreased signal 
over time. This might be caused by GOx adsorbing either onto the microchannel or 
electrode surface as described elsewhere.[38] This effect will be further investigated 
as part of the development of systems for long-term measurement of glucose in in 





Figure 8. Calibration curves obtained using 150 U/mL GOx solution at a total flow 
rate of 2 µL/min (0.5 µL/min glucose: 1.5 µL/min GOx) in two channel types, 
without grooves and with slanted grooves (one device, n=3). Glucose concentrations 
were in the clinical range of interest. 
 
4. Conclusion 
We have successfully demonstrated an enzymatic glucose reactor based on chaotic 
mixing in a microfluidic channel network for continuous glucose monitoring. 
Together with another recent report describing improved lucerifase detection in a 
chaotic mixer[39], our example of glucose detection is one of the first examples of 
this type of mixer being applied to the enhancement of a biochemical reaction at the 
nL scale. A linear calibration curve was obtained in both microchannels with slanted 
grooves and no grooves, using a 150 U/mL GOx enzyme solution. Higher sensitivity 
was obtained with slanted groove arrays compared to micromixers with no grooves, 
due to enhanced mixing. The factors which determine sensitivity are flow velocity 
and extent of reaction. Though there is a loss of GOx due to the continuous flow to 
the outlet, this disadvantage is alleviated by the use of micofluidics for nL liquid 
handling and the application of low flow rates (2 µL/min for the optimized system). 
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The low flow rates used are also compatible with microdialysis sampling and are 
required to achieve a h igh recovery of glucose from the subcutaneous tissue and 
reduce solution consumption. The possible influence of interfering substances such 
as ascorbic acid, uric acid and acetaminophen on glucose determination are now 
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Portable systems for continuous monitoring of glucose in biomedical applications 
still tend to be relatively large. The use of amperometric detection has helped to 
reduce the volume and weight of these systems, as this mode of detection requires 
only small electrodes and little peripheral equipment. However, (micro)electrodes 
that are in direct contact with the sample may have shortened lifespans, due to 
electrode fouling which in turn leads to signal drift and decreased reproducibility as 
a result. To address these disadvantages, we have designed a new microfluidic 
system for glucose sensing based on chemiluminescence (CL) detection, as a route 
to integrated, portable systems. A two-reactor system was developed for enzymatic 
conversion of glucose by glucose oxidase (GOx) to H2O2 in the first reactor, with 
further reaction of H2O2 with luminol in the second reactor to produce light at 425 
nm. A CL microfluidic chip was fabricated in poly(dimethylsiloxane) (PDMS) and 
bonded to a g lass slide. A silicon photodiode was then cast into a seco nd PDMS 
layer, which was reversibly bonded to the glass surface of the CL chip so that the 
diode was p ositioned directly over the second reactor. A chaotic mixing channel 
with slanted groves in its ceiling was incorporated into the first microreactor channel 
to enhance mixing efficiency. The performance of the fabricated CL microfluidic 
chip was characterized to establish optimal reaction conditions with respect to flow 
rate, pH, and concentrations of L/I and catalyst, HRP. To obtain a useful calibration 
curve for glucose sensing, the two inlet flow rates of glucose and GOx solutions 
were determined to be 0.5 µL/min and 1.5 µL/min, respectively. A solution 
consisting of 4 mM luminol/ 4 mM iodophenol in a carbonate buffer solution (pH 
10.1) and containing 7 U/mL HRP was introduced at the third inlet at a flow rate of 
0.5 µL/min, to react with H2O2 produced in the first reactor. The calibration curve 
obtained showed that CL light intensity was proportional to glucose concentration. 
The system exhibited a linear curve for current response as a f unction of glucose 
concentration in the clinically relevant range between 2 and 10 mM, with a 
sensitivity of 39 pA/mM (R = 0.9963, one device, n=3) and a limit of detection of 












The main goal of glucose monitoring is to provide better information to diabetes 
patients and support them in the proper management of their condition. The 
development of continuous glucose monitoring approaches is one of the main 
directions in the field of glucose sensing for diabetic patients. Portability, long-term 
stability, and improved accuracy are the main issues in the further development of 
continuous glucose monitors (CGM). Over the last decade, an enormous and 
growing amount of research in the field of microchip-based microfluidic systems, 
also known as Lab-on-a-Chip, has been carried out.[1, 2] These systems make 
substantial reductions in the amounts of sample and chemicals used, analysis times, 
and reaction times possible, by applying micro- or nanoscale fluidic channels for 
ultra-small-volume liquid handling. Due to the fact that small amounts of solutions 
and chemical reagents are introduced and manipulated in microchannel networks, 
miniaturized, portable sensing systems can become a reality.  
PDMS microfluidic systems are compatible with the use of optical components as 
on-chip detectors.[3, 4] PDMS is optically transparent down to wavelengths around 
230 nm[5], so it can be used over a wide range of the visible spectrum in 
conjunction with optical detection. The major challenge is the integration of the 
optical detector in the PDMS microfluidic device to achieve a d evice with optical 
detection functionality. Recently, Kuswandi et al. reviewed optical sensing systems 
for microfluidic devices.[6] Various detection methods are described in which 
optical sensing systems are coupled and/or integrated into microfluidic devices. The 
detection principle varies from UV absorbance[7], to fluorescence[8], laser-induced 
fluorescence (LIF)[9], and chemiluminescence (CL) [10]. Detectors such as charge-
coupled devices (CCD) or photomultiplier tubes (PMT) can be located either under 
the bottom of the fluidic chip or implanted into the device to achieve successful 
integration and high sensitivity.[11] Alternatively, optical fibers can be aligned in 
specially formed grooves or otherwise in a device to transport light to the chip from 
an external source, and on from the chip to an external detector. Compared to 
electrochemical detection, where electrodes in contact with complex samples can be 
subject to biofouling, optical detection methods are less prone to signal drift, 
because the reagents are generally not in direct contact with the detector.  
CL detection has been extensively studied with respect to its incorporation in 
microfluidic chips.[12-18] The merit of CL detection is that it does not require an 
excitation source, as does fluorescence, or a monochromator for sensing the photons 
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   GOx 
long been popular for H2O2 analysis in general, with CL applications for 
microfluidics emerging more recently.[12] For determination of H2O2 concentration, 
the CL reaction between luminol and H2O2 is commonly catalyzed by Cu(II), Co(II), 
or horseradish peroxidase (HRP) to produce the emission of light. The main reaction 
principle of CL is as follows (using the example of glucose determination): 
 
 
Glucose + 2O2                      Gluconic acid + H2O2   (GOx: glucose oxidase)      (1) 
 
Luminol + 2H2O2                       Aminophthalate + 4H2O + N2 + hυ                    (2) 
                                                                 
 (hυ is light at 425 nm wavelength)    
 
 Most CL detection systems have used a PMT located over the fluidic channel to 
allow very sensitive detection of the emitted light.[13-15, 18] However, PMTs need 
a high voltage power and an external mounting support (block). In contrast, 
photodiodes can be easily built into microfluidic devices and compactly integrated to 
provide portable sensing systems. Previously reported CL detection systems have 
been reported in which photodiodes have been employed as detectors. Nakamura et 
al.[19] developed a flow injection system (FIA) with CL detection based on a 
commercially available silicon photodiode in order to measure mM lactate 
concentrations in serum. Jorgensen et al.[16] fabricated a planar silicon photodiode 
detector on the back-side of a bulk micromachined microfluidic device. This 
microfluidic channel network consisted of an enzyme chamber, mixer and detection 
region. The reaction of hydrogen peroxide and luminol was performed in the 
microreactor and the resulting chemiluminescent light detected at the monolithically 
integrated photodiode at a detection limit of 5 µM H2O2. However, this in-house 
silicon photodiode required a ser ies of complicated fabrication steps. Hofmann et 
al.[17] integrated a copper phthalocyanine–fullerene organic photodiode in a PDMS 
microfluidic device and demonstrated a preliminary limit of detection of 1 mM H2O2. 
Later on, this group further developed the organic photodiode with an active layer of 
the conjugated polymer poly(3-hexylthiophene) and [6,6]-phenyl-C61-butyric acid-
methylester, a soluble derivative of C60. The LOD of this device was 10 µM H2O2 
detection.[20] 
The long-term goal of this project is to realize a fully integrated system of fluidic 
channels, mixers, pumps and a detector for continuous glucose monitoring in vivo. 
The main idea of this approach is to retain the advantages of the Subcutaneous 
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Continuous Glucose Monitoring (SCGM) system[21], which is based on 
microdialysis sampling and has been studied for clinical use. Glucose sensing in this 
system exploits the reaction of glucose in the microdialysate with GOx in a second 
solution, with the electrochemical detection of the resulting hydrogen peroxide. This 
solution-based glucose monitoring principle is well suited for transfer into a 
microfluidic system as basis of a totally portable system for diabetes-related 
research. In a first approach, we demonstrated an enzymatic microreactor based on 
chaotic micromixing for the fast reaction of glucose with GOx, followed by the 
amperometric detection of hydrogen peroxide using microfabricated electrodes.[22] 
However, electrode-based sensing technology still has a major challenge to 
overcome with respect to electrode biofouling and signal drift, particular in in vivo 
applications.  
As an alternative approach for this project, we have realized a new microfluidic 
sensing system based on CL detection. Commercially available silicon photodiodes 
have been used to detect the CL signal, as they are small and easily integrated into 
microfluidic devices. In this paper, we have designed a two-reactor system, the first 
for the enzymatic conversion of glucose by GOx, the second for the reaction of H2O2 
with luminol for CL detection. A CL microfluidic chip was fabricated by 
PDMS/glass bonding, with a silicon photodiode fixed in a seco nd PDMS layer 
directly positioned underneath the microfluidic channel. Chaotic mixing channels 
were incorporated in the microreactor to enhance mixing efficiency and accelerate 
the reactions. The performance of this system was evaluated in a ser ies of in vitro 
tests to establish optimal reaction conditions, including flow rate, pH, and 
concentrations of the various reactants and catalysts. 
 
2. Materials and methods 
2.1. Chemicals and reagents 
All chemicals were analytical reagent-grade. Luminol and 4-iodophenol (L/I) were 
purchased from Sigma-Aldrich (Germany) and used to prepare solutions of various 
concentrations. The L/I solutions were left for 24 hours to yield better activity and 
hence enhanced chemiluminescence. The solutions could be used for one month 
when stored at 2 ºC in a refrigerator.[23] H2O2 (30%) was supplied by VWR (The 
Netherlands) and used to prepare sample solutions in a phosphate buffer (PB) 
solution (pH = 7.2). The 20 mM PB solution was prepared by mixing solutions of 
NaH2PO4·H2O (63 mL) and Na2HPO4·2H2O (100 mL). D-glucose was obtained 




0.2 M carbonate buffer solution was used to prepare buffer solutions of varying pH, 
adjusted using 4 M NaOH. GOx and horseradish peroxidase (HRP) were supplied by 
Sigma-Aldrich (Germany) and used to prepare 5000 U/mL and 2500 U/mL stock 
solutions in ultrapure water, respectively. These solutions were stored at -20 ºC. All 
solutions were prepared with 18 ㏁  ultrapure water purified in an Arium® 
611system (Sartorius Stedim Biotech, Germany). 
2.2 Fabrication of microfluidic chip 
The microchannels and reactors were replicated in the elastomer, 
poly(dimethylsiloxane) (PDMS) (Sylgard 184, Dow Corning, Germany) using 
masters formed in a p ositive photoresist layer by standard microfabrication on a 
silicon wafer. The chip layout and design were drawn using the mask-design 
program Clewin (Wieweb software, Hengelo, The Netherlands). The structure on the 
silicon master was processed with two steps of standard photolithography.[22, 24] A 
4-inch p-type (100) silicon wafer (Si-Mat, Germany) was employed as a su bstrate. 
The silicon wafer was first cleaned sequentially with acetone, isopropyl, and 
deionized water, and dried with N2 gas. The wafer was then treated with 
hexamethyldisilazane (HMDS) (Sigma-Aldrich, Germany) in a v acuum desiccator 
for 30 min to improve photoresist adhesion to the Si wafer. A thick layer of positive 
photoresist (PR) AZ 4562 (Microchemicals GmbH, Germany) was then coated onto 
the Si wafer using a spincoater and re-hydrated at ambient temperature for 3 hours, 
leaving a 35-µm-thick layer. The coated wafer was exposed to ultraviolet (UV) light 
(365 nm, 10 m W/cm2) using a microchannel photomask reproduced on a  
transparency sheet (resolution 3,810 dpi; Pro-Art bv, Groningen, The Netherlands). 
The exposed PR was then removed by dipping in a developer solution (AZ351B, 
Microchemicals GmbH, Germany) and rinsing in deionized water, to leave the 
ridges which form the molds for the microchannels. Subsequently, the substrate was 
again exposed to UV light for 10 sec using a second photomask with patterns for the 
groove arrays on the ridges. The patterned PR was developed once more in order to 
form groove structures on top of the microchannels.  
 The PDMS monomer solution and a curing agent were mixed at a weight ratio of 
10:1 PDMS: curing agent, and the solution left to stand at ambient conditions for 20 
min to allow the air bubbles introduced during the mixing process to dissipate. 
Afterward, the mixture was poured over the prepared silicon master. A 
polycarbonate alignment piece was used together with fused-silica capillaries to 
form access holes to the microchannels during the replication process. The holes 
(300 µm diameter) were drilled in the polycarbonate at the points of inlets/outlets 
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using a C NC machine (Sherline, USA). Finally, the microchannels on the silicon 
master were aligned with the 260-µm-diameter capillaries, and the mixture was 
cured on the master at 50 ºC for 4 hours. The PDMS was then smoothly peeled off 
from the master and cut into individual devices. 
In order to bond the PDMS slab and glass slide (Menzel-Gläser GmbH, Germany), 
the glass slide was cleaned with acetone, isopropyl, and deionized water, and dried 
with N2 gas. The two devices were treated with UV-generated ozone for 15 min to 
oxidize the PDMS and glass surfaces. Subsequently, the PDMS slab and glass slide 
were immediately aligned under a microscope and brought into contact with each 
other. The assembled chip was then placed on a hot plate at 140 ºC and cooled down 
to room temperature, after which the chip was i rreversibly bonded. The whole 
bonding procedure was performed in a Class 1000 cleanroom environment. 
 
2.3. Silicon photodiode fixation and bonding with microfluidic chip 
To measure the emitted CL, a silicon photodiode was bonded to the microfluidic 
chip and used as a detector. There are a variety of photodiodes available that provide 
high sensitivity at low cost; the photodiodes used in this study were from 
Hamamatsu (S2387, spectral response range: 320 to 1100 nm). Chabinyc et al.[3] 
reported the integration of a microavalanche photodiode (µAPD) into a PDMS 
device for direct in-channel fluorescence detection. The µAPD was embedded in 
PDMS and placed adjacent to the microfluidic channel. In a si milar manner, we 
fixed the silicon photodiode in a PDMS mold. A 10:1 mixture of PDMS and curing 
agent was cast around a silicon diode which had been placed in a Petri dish. After 
curing, the PDMS slab was cu t to have the same outer dimensions of the 
microfluidic chip. The PDMS slab with fixed silicon photodiode was reversibly 
bonded to the outer surface of the glass slide, with careful positioning of the 
photodiode directly under the section of the device in which CL is generated (Figure 
1(a)). The silicon photodiode could be reused simply by detaching the PDMS with 
diode from the microfluidic chip and re-attaching this piece to another microfluidic 
device.  
Figure 1(d) shows a f abricated device. The device has two flow-through 
microreactors, the first one for the reaction of GOx and glucose, and the second one 
for the reaction of H2O2 and luminol. The length of the
 first reactor was 43 mm, 
while the width and depth of this channel were 200 µm and 35 µm, respectively. As 
shown in Figure 1(b), this channel had slanted grooves incorporated into the top 
along its entire length to enhance mixing using a chaotic mechanism. The grooves 




in the second reactor was optimized to cover the entire photodiode active area to 
increase the detection sensitivity, as this is the channel in which CL was generated. 
No grooves were patterned in this second reactor. The width, length and volume of 
the second reactor channel were 200 µm, 16 cm and 1.2 µL, respectively. The 
thickness of the glass slide sealing the microchannels was 100 µm.  
 
Figure 1. a) Schematic diagram of microfluidic chip. b) Groove structure 
incorporated into the first reactor to enhance chaotic mixing of the two solutions 
containing glucose and GOx. c) Emission of light at 425 nm in the second reactor 
upon reaction of H2O2 with luminol. d) A device with two flow-through 
microreactors. 
 
2.4. CL experimental set-up  
Figure 2 shows a schematic diagram of the CL detection experimental set-up. The 
syringe was connected to the chip inlet using silica capillaries (365 μm OD, 75 μm 
ID), and two microdialysis syringe pumps (CMA, Sweden) controlled the flow rates. 
Oxygen concentrations in solution were measured using ‘Micro Dissolved Oxygen 
Electrode’ (Lazarlab, Inc., CA) To obtain a calibration curve, glucose sample and 
GOx solution were introduced at a 1: 3 flow rate ratio using flow rates of 0.5 µL/min 
(Figure 2, inlet 1) and 1.5 µL/min (Figure 2, inlet 2), respectively. The flow rate of 
the glucose sample was chosen to be 0.5 µL/min so as to be compatible with high-
recovery microdialysis sampling.[22, 25] The H2O2 produced and L/I were reacted 
at a 4:1 flow rate ratio, with a flow rate of 2 µL/min for H2O2 sample, and 0.5 
µL/min for L/I reagent (Figure 2, inlet 3), respectively. A two-position actuator 
switching valve (Valco Instrument co., Inc) was used to switch between buffer 
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solution and glucose sample for acquisition of background and sample detector 
signal, respectively. The silicon photodiode was wired to a multifunctional 
transimpedance amplifier (107A/V gain) (Sglux, Germany), which converts current 
to voltage. A multimeter (Agilent) displayed the output signal value and the data 
was recorded with a LabVIEW (National Instruments, TX) program. All 


















Figure 2. Chemiluminescence experimental set-up. Dashed line delineates the light-
tight black box.  
 
3. Results and discussion 
3.1 Flow effect and response of L/I sample 
The performance of the fabricated CL microfluidic chip was ch aracterized to 
establish optimal reaction conditions e.g. flow rate, pH, and concentrations of L/I 
and catalyst, HRP. First, the effects of flow rate and various concentrations of L/I 
reagent on CL response were studied.[14] The preliminary study was performed by 
introducing H2O2 at inlet 2 (Figure 2, inlet 2) and L/I  at inlet 3 (Figure 2, inlet 3). 
The reaction of H2O2 and luminol causes the emission of blue light, starting at the 
point of flow confluence at the Y-junction and then throughout the entire second 




Figure 1(c). Figure 3(a) shows representative sigmoidal curves comprising 
background signal recorded for a 1:1 mixing ratio of buffer solution and L/I (initial 
parts of the curves), followed by increasing CL signal due to a 1:1 mixing ratio of 10 
mM H2O2 sample and 4 mM L/I; the switching valve in Figure 2 was used to switch 
from buffer to H2O2 sample. The photodiode output signal was plotted as a voltage 
value, which was proportional to the CL intensity. The “rise time” is defined as the 
time it takes for the CL signal to increase from baseline (background signal) to 95% 
of its final value. This corresponds to the total time required for the two analytes to 
flow from start to finish through the second reactor to reach the outlet reservoir. A 
maximum CL signal is recorded when the reaction mixture fills the entire length of 
the long serpentine channel from the Y-junction to the outlet. The rise times are 
approximately 95 sec an d 50 sec at  a total flow rate of 1 µL/min and 2 µL/min, 
respectively, which corresponds to the length of the second reactor, viz., 16 cm. As 
the flow rate was increased from 0.4 µL/min to 4 µL/min, the CL intensity also  
 
Figure 3. (a) Example of background and sensing signal arising from 1:1 mixing 
ratios of buffer (initial parts of the curves) or 10 mM H2O2 and 4 mM 
luminol/iodophenol (L/I). The rise times were approximately 95 sec and 50 sec at a 
total flow rate of 1 µL/min and 2 µL/min, respectively. The rise time was defined as 
the time required for the CL signal to change from baseline to 95% of the final 
steady-state output signal. (b) Curve of CL intensity as a function of L/I 
concentrations arising from the reaction of 10 mM H2O2 and L/I reagent at a total 
flow rate of 2 µL/min. L/I concentrations were always the same i.e. a value of 4 mM 
along the x-axis means that both luminol and iodophenol concentrations were 4 mM 
for this experiment. 
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increased (data not shown). This can be explained by the fact that the brightest 
emission occurs at the beginning of the reaction, which takes place in the upstream 
part of the channel. At higher flow rates, a larger portion of the photodiode detecting 
area is exposed to this bright emission as more of the initial CL reaction takes place 
downstream in the long serpentine channel that covers the photodiode. 
Figure 3(b) shows the photodiode current response arising from the reaction of 10 
mM H2O2 and varying concentrations of L/I reagent at a total flow rate of 2 µL/min. 
L/I reagent was prepared at concentrations ranging from 0.5 mM to 8 mM in a 0.2 M 
carbonate buffer (pH 10.3) containing 20 U/mL HRP (both L and I had the same 
concentration). The output signal increased with increasing L/I concentration, 
reaching its maximum value at 4 mM. Therefore, 4 mM L/ 4 mM I was chosen for 
further experiments. Additionally, the reaction was monitored in the second reactor 
in order to check for interference of the nitrogen gas produced by the reaction. 
Inspection under a microscope showed that nitrogen gas bubbles were observed not 
in the channels but in the outlet reservoir, where nitrogen gas bubbles collected. 
 
3.2. Effect of pH and oxygen depletion 
The CL microfluidic chip was sp ecifically designed with a t wo-reactor system to 
first allow GOx to produce H2O2 at an optimal pH between 5 and 7[26], before L/I is 
added under more alkaline conditions where the CL reaction is most efficient.[27] 
This current microchip design compensated for the pH discrepancy between 
reactions by adding an additional inlet, inlet 3 (Figure 2), for introduction of the L/I 
reagent after the reaction of glucose and GOx. Since luminol is not easily dissolved 
in solutions having a pH lower than 8, a pH range of 8.5 to 11.2 was taken into 
account for the experiment. Complete dissolution was observed at pH values higher 
than 9. For maximum activation of L/I, the solution was left for one day prior to 
use.[23] Figure 4 shows the effect of L/I solution pH on reaction efficiency, using 10 
mM H2O2 and 4 mM L/ 4 mM I. The mixing ratio of H2O2 and L/I was 1:1 at a total 
flow rate of 1 µL/min and 2 µL/min; two of the three chip inlets were used (Figure 2, 
inlet 2) and (Figure 2, inlet 3). The maximum output signal value was obtained 
around pH 10.1. 
The enzymatic production of H2O2 in the first reactor requires oxygen (see Eq. (1)), 
so a l ack of oxygen may affect the sensitivity of our CL microfluidic system. In 
previous reports, the negative influence of low oxygen was alleviated by either 
coating polymer membrane on t he electrode surface[28] or using a solution 
containing higher levels of dissolved oxygen to increase oxygen concentration.[29] 




which is continuously supplied at a 3:1 ratio with glucose sample, is generally 
sufficient to allow conversion of all glucose present. Ultrapure water at room 
temperature has approximately 0.29 mM of oxygen, similar to concentrations used 
in other sensing applications.[30] In addition, PDMS is permeable to oxygen and 
may allow supplemental oxygenation while the fluids are traveling through the 
channels. We tested rate limitations of oxygen on CL output in our microfluidic 
system by mixing glucose sample at a 1:1 ratio with 300 U/mL GOx. The CL output 
signal was stable at glucose concentrations below 15 mM. However, at 15 and 20 
mM the output signal decreased over time (Supplementary Information, Figure S1, 
at the end of this chapter). This decrease did not occur when the glucose samples 
were premixed with GOx well before their introduction into the microfluidic system. 
This indicates that oxygen does not become rate limiting at glucose concentrations 
















Figure 4. Effect of luminol/iodophenol buffer solution pH. Separate buffer solutions 
containing either 10 mM H2O2 or 4 mM luminol/4 mM iodophenol with 20 U/mL 
HRP were introduced at inlets 2 and 3, respectively, at a total flow rate of 1 µL/min 
or 2 µL/min. 
 
3.3. Activities of HRP and GOx in solution 
The effect of the HRP enzyme catalyst on CL signal output was further evaluated by 
varying the HRP concentrations in the second reactor of the microfluidic chip from 0 
to 100 U/mL. The three solutions introduced at the three inlets were as follows: 1) 4 
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mM or 20 mM glucose samples at a flow rate of 0.5 µL/min (Figure 2, inlet 1; 2) > 
1000 U/mL GOx solution at a flow rate of 1.5 µL/min (Figure 2, inlet 2); 3) 4 mM 
L/ 4 mM I contained HRP sample at flow rates of 0.5 µL/min or 1 µL/min (Figure 2, 
inlet 3). A preliminary study was performed by reacting 10 mM H2O2 in buffer with 
4 mM L/ 4 mM I containing varying amounts of HRP in buffer at a total flow rate of 
2 µL/min (inlets 2 and 3 were used). The highest output signal resulted from a 1:1 
mixing ratio of H2O2 with L/I reagent with  20 U/mL HRP added (data not shown). 
Figure 5(a) shows the measured photodiode response when various concentrations 
of HRP in 4 mM L/4 mM I were reacted with glucose. With 4 mM glucose, the 
highest CL output signal was obtained at 5 U/mL HRP, whereas with 20 mM 
glucose, the maximum signal was observed at 20 U/mL HRP. Apparently, more 
HRP is required to convert all the H2O2 that is produced at higher glucose 
concentrations. Moreover, the L/I flow rate also played a defining role in the final  
output current value, with 0.5 µL/min producing the higher current value in the 4 
mM glucose sample case, and 1 µL/min in the 20 mM glucose case. This can be 
explained by the fact that the amount of HRP, delivered concurrently with the L/I 
solution, is varied by the L/I flow rate. For 1 µL/min L/I solution, a 2:1 mixing ratio 
of produced H2O2 to L/I is achieved; for 0.5 µL/min L/I solution, a 4:1 mixing ratio 
of H2O2 to L/I is established. Thus, the dilution of H2O2 also influences the recorded 
output signal. This means that at higher L/I flow rate, a lower concentration of HRP 
is sufficient to generate the maximum signal. A L/I flow rate of 0.5 μL/min and 20 
U/mL HRP were sufficient for good sensitivity at clinically relevant glucose 
concentrations. Therefore, these conditions were selected for further experiments. 
It is interesting to note in Figure 5(a) that HRP concentrations higher than 20 
U/mL resulted in decreasing output signal with increasing HRP concentration. This 
can be explained as follows, by first noting that in the absence of catalyst, the 
reaction speed is slow, yielding less CL light emission within the reaction channel 
over the photodiode active area. As the amount of catalyst increases, the reaction 
producing light proceeds more rapidly. This means that at a given flow rate, more 
light is produced further upstream from the detector. To achieve a maximum 
photodiode response, it is desirable to have the reaction producing a maximum 
amount of light directly over the photodiode’s active surface. This can in effect be 
tuned by optimizing the amount of HRP catalyst added to the H2O2 solution at any 
given flow rate ratio. At higher catalyst amounts, the reaction takes place too far 
upstream in the second reactor. The amount of CL that goes undetected due to its 




the amount of catalyst involved in the reaction.  (see Supplementary Information, 
Figure S2, at the end of this chapter). 
Figure 5(b) shows the CL output signal as a function of GOx concentration 
between 25 and 300 U/mL. The test conditions were 4 mM L/ 4 mM I containing 20 
U/mL HRP (pH 10.1), introduced at a flow rate of 0.5 μl/min (Figure 2, inlet 3); 
glucose sample (4 mM or 20 mM) at a flow rate of 0.5 μL/min (Figure 2, inlet 1), 
and GOx solution at a flow rate of 1.5 μL/min (Figure 2, inlet 2). As GOx 
concentration was increased, the output signal also increased up to 150 U/mL GOx 
solution for both 4 mM and 20 mM glucose, with the signal leveling off at higher 
GOx concentrations. It can be concluded that 150 U/mL GOx is sufficient for rapid 
conversion of all glucose, so this concentration was used for further experiments. 
 
 
Figure 5. (a) Response to glucose recorded for various concentrations of HRP in 4 
mM L/4 mM I. Conditions: 4 mM or 20 mM glucose sample (0.5 µL/min); > 1000 
U/mL GOx (1.5 µL/min); and 4 mM L/ 4 mM I containing varying concentrations of 
HRP (0.5 µL/min or 1 µL/min). (b) Study to determine the optimal GOx 
concentration. Conditions: 4 mM and 20 mM glucose sample (0.5 µL/min); 4 mM L/ 
4 mM I containing 20 U/mL HRP (0.5 µL/min); GOx sample (1.5 µL/min). 
 
3.4 Calibration curve  
Figure 6 shows the calibration curve of photodiode output signal as a function of 
glucose concentration. The test conditions were the same as described in Section 3.3, 
except that here 7 U/mL HRP and 150 U/mL GOx were used. The lower 
concentration of HRP of 7 U/mL was chosen in favor of the previously established 
optimum of 20 U/mL because a pilot experiment revealed that the calibration curve 
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was more linear and more consistent at this lower HRP concentration (data not 
shown). Moreover, the use of 5 U/mL HRP resulted in good linearity only at lower 
glucose concentrations, whereas the use of 10 U/mL HRP resulted in good linearity 
only at higher glucose concentrations (data not shown). Therefore it was decided to 
use the intermediate value of 7 U/mL instead. One set of raw data is shown in the 
inset in Figure 6. A linear curve was observed for  current as a function of glucose 
concentration between 2 and 10 mM, with a sensitivity of 39 pA/mM (R = 0.9963, 
one device, n=3). The limit of detection was approximately 230 µM glucose 
concentration, based on a signal-to-noise ratio of 3 (S/N = 3). For the clinical 
application of monitoring subcutaneous glucose in patients with diabetes, high 
accuracy and precision are required only in the narrow physiological range of 
around 3 mM to 10 mM.[31] Thus, the linear range that we have established with 
















Figure 6. Calibration curve obtained using 150 U/mL GOx solution (1.5 µL/min); 4 
mM L/ 4 mM I in carbonate buffer (pH = 10.1) containing 7 U/mL HRP (0.5 
µL/min); glucose sample in PB (pH = 7.2) (0.5 µL/min). Raw data are shown in the 
inset. 
 
4. Conclusion  
We developed a n ew microfluidic system with CL detection for continuous 




output signal by a silicon photodiode. In this contribution, the performance of the 
microfluidic system was evaluated and several important parameters were optimized 
to establish the best reaction conditions, including flow rate, pH, and concentrations 
of the various reactants and catalysts. The best performance was achieved with 
simultaneous flow rates of 0.5 μL/min glucose, 1.5 μL/min GOx, and 0.5 μL/min L/I 
solution introduced into the three respective inlet channels of the device. Minimum 
required enzyme concentrations were established at 150 U/mL GOx and 7 U/mL 
HRP, while optimal L and I concentrations are 4 mM each at a pH of 10.1. The 
system generated a linear calibration curve for glucose concentrations between 2 and 
10 mM (R = 0.9963, one device, n=3), with an observed sensitivity of 39 pA/mM 
and a LOD of 230 μM (S/N=3).  
The use of GOx in solution for each assay can be regarded as an advantage only if 
the enzyme solution itself has not been stored for a long (several days) period of 
time before use. Ozyilmaz et al. show that immobilized GOx stored at 25ºC actually 
loses its activity much less rapidly than GOx stored in solution at the same 
temperature when monitored over 20 days.[32] Use of a f reshly prepared enzyme 
solution is thus a prerequisite for implementation of this approach, with daily 
replacement of this solution when operating the system over periods of several days. 
Furthermore, it was demonstrated that oxygen supplied via the delivery of fresh 
GOx solution and from diffusion through the PDMS was not rate limiting. The 
microfluidic system had a short reaction time of less than 1 min at a total flow rate 
of 2.5 µL/min (calibration curve) with a reaction volume of 1.2 µL in the second 
reactor. Based on these results, it can be concluded that this new CL microfluidic 
system is well suited for sensing glucose, and that its clinical application is feasible. 
A few studies have been reported on the in vivo use of CL systems in rabbits, in 
combination with microdialysis-based sample acquisition.[33, 34] However, these 
involved a PMT as detector, instead of the much smaller photodiode that we used 
here. Further research is needed to explore the application of this device as a small, 
portable continuous glucose monitoring system for biomedical purposes. 
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Figure S1. Oxygen depletion effect in high-concentration glucose samples. 15 mM 
and 20 mM glucose samples exhibited CL signals that, once having reached a 
maximum, decreased over time. Photodiode signal was generated by mixing glucose 
and 300 U/mL GOx solution in a 1:1 mixing ratio, while 4 mM L/ 4  mM I was 
infused into the third inlet.  
 
 
              (a)                                             (b)                                      (c)  
Figure S2. Effect of HRP concentration. CL light was emitted in the second reactor 
by the reaction of 10 mM H2O2 and 4 m M L/ 4 m M I containing different 
concentrations of HRP (a) 0 U /mL, (b) 20 U /mL and ( c) 100 U/mL. As the 
concentration of catalyst is increased from 0 U/mL to 100 U/mL, the faster the 
reaction proceeds, with maximum light emission occurring earlier in the second 
microreactor. The amount of CL detected therefore decreases at higher HRP 
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Continuous glucose monitoring provides additional insight into how blood glucose 
levels vary over the course of a day or days, important information for diabetes 
patients and physicians from both a diagnostic and prognostic point of view. 
However, optimized methodologies and further technical improvements are still 
needed. We present an application of a n ewly-designed microfluidic chip, 
incorporating an enzymatic microreactor (EMR) for continuous glucose monitoring 
in rats. The EMR is a microfluidic device designed for the rapid reaction of glucose 
with glucose oxidase in nL volumes of solution. The hydrogen peroxide produced is 
detected with integrated microelectrodes. In this study, the EMR is coupled to a 
microdialysis probe which is inserted into the subcutaneous tissue of anesthetized 
rats. The performance of the EMR was evaluated by modulating blood glucose 
concentrations with intravenous injections of 20 % glucose (w/v) or 5 U/kg insulin, 
with saline as a co ntrol. Dynamic changes in glucose levels were recorded, with a 
1.5 mM (15 %) increase and an 8.6 mM (85%) decrease modulated by glucose and 
insulin administrations, respectively. Blood glucose was frequently measured 
colorimetrically using the Accu-Chek® method as a reference value for comparison 
with results obtained using the EMR. Differences between glucose values 
determined by blood sampling and EMR monitoring are also discussed. This is the 
first example of the use of a chaotic mixing approach in a microfluidic device for an 
in vivo glucose sensing application. Based on in vitro and in vivo results, we 
conclude that the feasibility of using the coupled microfluidics-microdialysis system 
for continuous subcutaneous glucose monitoring has been successfully demonstrated 


















Continuous glucose monitoring is a relatively new approach to assist patients with 
diabetes mellitus to maintain blood glucose concentrations within near-normal 
levels.[1] The manifestation of well-known diabetic complications such as 
retinopathy, nephropathy and neuropathy can be prevented by using intensified-
insulin therapy to lower baseline glucose levels.[2, 3] This treatment regimen, 
however, predisposes patients to frequently experience episodes of severe 
hypoglycemia.[4] Hypoglycemia is the main limiting factor for good glycemic 
control in diabetes therapy, and should be therefore be avoided.[5] Continuous 
glucose monitoring provides great insight into glucose levels throughout the day 
compared to the intermittent measurements by the finger-prick method. It can be 
used retrospectively to assess blood glucose during the night or perhaps as a tool for 
the physician in addition to patient anamnesis.[6] It can also be used prognostically 
to warn the patient of developing hypoglycemia and, when integrated into an 
artificial pancreas, to direct automatic adjustment of insulin dosing.[7] 
In vivo microdialysis is a powerful technique for continuous monitoring of 
subcutaneous glucose.[8] The microdialysis probe consists of a s emipermeable 
hollow fiber membrane which is sealed at the end, and is connected to inlet and 
outlet tubing. The microdialysis probe is designed to mimic a blood capillary and 
can be placed in any target tissue of interest. The lumen of the probe is perfused 
with an artificial interstitial fluid (ISF; usually Ringer’s solution) which is 
introduced from the inlet. Small pores in the membrane allow certain molecules to 
travel across it along the concentration gradient, from higher concentrations in the 
subcutaneous tissue to low or zero concentrations in the perfusing solution, known 
as the perfusate. However, large molecules (including proteins) cannot cross the 
membrane. Glucose concentrations in the perfusate collected through the outlet 
reflect the concentrations in the ISF and can be quantified by a variety of 
bioanalytical techniques. 
Microdialysis-based and needle-type sensing systems have both proven to be 
biocompatible and safe for the patient. However, using microdialysis to sample 
glucose from subcutaneous tissue has advantages over implanting a needle-type 
probe directly in this tissue. Microdialysis is a v ery effective sample pretreatment 
approach, since the probes are made of low-molecular-weight cut-off materials 
which do not allow the passage of large molecular species like proteins or proteases 
from tissue into the perfusate. This facilitates detection of glucose in the 




many interfering species from entering the sample. This is particularly advantageous 
for electrochemical detection of glucose, since the detection electrodes are far less 
prone to biofouling in the relatively clean microdialysate matrix than in more 
complex physiological fluids. Since the sensing electrodes are not in direct contact 
with cells/tissue, a higher degree of analytical accuracy can be obtained compared to 
needle-type sensors.[9]  
However, microdialysis does require external components such as pumps for 
liquid transportation, which can make the system somewhat large and bulky. System 
lag time, that is, the time delay between dialysis of analyte and actual analysis result 
caused by the length of connecting tubing between probe and analytical device, is 
another disadvantage of this technique. Low perfusion flow rates on the order of 
hundreds of nL to just a few µL per minute are often not compatible with the 
internal volumes (tens of µL or more) of connecting tubing in these systems. 
Transport of microdialysate from the probe to the analysis component in the system 
can take many minutes as a result. The implanted probe is also much bigger than a 
needle-type sensor. Despite these potential disadvantages, however, microdialysis 
sampling has proven to be an attractive alternative to implanted needle-type sensors.   
Among those microdialysis-based sensing systems reported,[10-13] the 
Subcutaneous Continuous Glucose Monitoring (SCGM) system[11] appears to be a 
good candidate to monitor glucose in patients with diabetes. Microdialysate 
containing glucose is mixed with reagent solution containing glucose oxidase 
(GOx), which catalyzes the oxidation of glucose to hydrogen peroxide (H2O2) and 
gluconolactone. The amount of H2O2 can be detected amperometrically through 
oxidation at a detection electrode, with the amount of current produced being 
directly proportional to the H2O2 concentration and thus also to the original amount 
of glucose in the sample. This approach for glucose sensing is unusual, in that most 
electrochemical glucose sensors employ GOx immobilized to the electrode for 
detection of H2O2. While more than adequate for short-term experiments, sensors 
based on immobilized GOx tend to lose sensitivity and exhibit a drift in response 
over longer periods of time as the enzyme slowly loses its catalytic activity. A 
solution-based glucose reaction with GOx in a continuously flowing system has the 
advantage that fresh enzyme is continuously provided, circumventing sensor drift 
and sensitivity loss. Free GOx in solution also loses its activity over a period of 
several days, so it is important to use freshly prepared GOx solution in this 
application, and to replace the GOx reagent daily for multi-day experiments. 
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A prototype of the SCGM has been studied for clinical use and shown to be 
reliable for continuous glucose monitoring over longer periods of days.[14] 
However, the overall configuration of this system is also rather bulky, and system 
lag times are long (over 30 min). Thus, the concept of a miniaturized SCGM is an 
approach with good prospects for reducing system size and lag time while retaining 
the advantages of the solution-based reaction of GOx with glucose for glucose 
sensing. 
Chip-based microfluidic technologies provide an excellent alternative for 
conventional glucose monitoring approaches such as the SCGM mentioned above. 
The advantages of microfluidic systems include dramatically reduced consumption 
of chemical reagents, enhanced cost-effectiveness and substantially shortened 
reaction times. Micrometer-sized fluidic channels enable the solution-based reaction 
of GOx and glucose in nL volumes. The nL volumes characteristic of microfluidic 
devices are also compatible with microdialysis sampling, which is generally carried 
out at low-microlitre or even sub-microlitre per minute flow rates. The lower the 
flow rate, the higher the recovery of glucose from the subcutaneous tissue being 
sampled.  
To date, significant research efforts have been expended on coupling microdialysis 
sampling with microfluidic devices. Several recent reviews discuss the possible 
integration of microdialysis with microfluidic detection components for on-line 
measurement of dialysate.[15-17] There have been few reports, however, of  
microchip-based sensing systems linked with microdialysis for continuous glucose 
monitoring. Hsieh et al. developed an on-chip microdialysis system with an in-line 
sensing electrode.[18, 19] A microdialysis membrane was i ntegrated directly into 
the fluidic channel in order to reduce system dead volumes such that lag times were 
just a couple of minutes. The membrane sealed a 15-µm-deep microchannel formed 
photolithographically in an SU-8 epoxy layer. This channel contained two 
microfabricated Pt electrodes and a Ag/AgCl pellet electrode. Ultimately, the device 
was designed to function as a microdialysis probe, with the outer surface of the 
membrane in direct contact with tissue, and the inner surface perfused by medium 
containing GOx, pumped through the microchannel. Glucose diffusing across the 
membrane into the microchannel reacts with the GOx to produce H2O2, which is 
then detected at the electrodes. For the studies reported in [18, 19], the outer 
membrane surface was placed in contact with a r eservoir containing a g lucose 




recovery of 99 % at a 0.5 µL/min flow rate, and fluctuating glucose concentrations 
in the clinically relevant range were tracked using electrochemical detection. 
 The aim of this study is to evaluate the performance of a new microfluidic system 
coupled to microdialysis sample acquisition for continuous monitoring of 
subcutaneous glucose in rats.  Recently, we reported a new enzymatic microreactor 
(EMR) incorporating a chaotic mixing channel with microfabricated electrodes for 
the continuous-flow measurement of glucose.[20] The mixing channel had an array 
of small, slanted parallel grooves formed in its top surface along the length of the 
channel. Chaotic mixing of two side-by-side flowing solution streams is induced 
when the solutions flow over the groove array, as flow is forced to turn towards the 
sidewall of the channel in the direction of the grooves. Solution streams rapidly 
begin to twist around each other in a helical fashion, and the flow pattern becomes 
chaotic. This in turn enlarges the contact area between solutions, reducing diffusion 
lengths and increasing mixing rates as a r esult. In the EMR, a solution containing 
glucose was mixed with a solution containing glucose oxidase, with the resulting 
H2O2 detected amperometrically at the end of the channel. The EMR with slanted-
groove array demonstrated superior mixing and hence enhanced glucose detection 
sensitivity compared to a non-grooved EMR.  
Here we sh ow the in vivo application of the EMR with slanted-groove array for 
continuous monitoring of subcutaneous glucose. Glucose sampling is achieved using 
a microdialysis probe, the outlet of which is coupled to one of the EMR inlets to 
enable analysis of glucose in the microdialysate. The monitoring system was f irst 
thoroughly characterized in vitro with respect to glucose recovery (probe) and 
glucose response (EMR). To demonstrate the performance of EMR in vivo, a 
microdialysis probe was inserted subcutaneously into a rat.  Glucose concentrations 
in the ISF were then monitored in response to intravenous injections of saline, 
glucose and insulin, with frequent sampling of blood for blood glucose analysis as a 
reference. Microdialysate glucose levels obtained using the EMR were compared 
with blood glucose levels. The observed differences between glucose concentrations 
measured in ISF using microdialysis sampling and in blood are also discussed. 
 
2. Materials and methods  
2.1. Chemicals and reagents 
All chemicals were analytical-reagent grade. Ascorbic acid was obtained from 
Merck (Germany). Uric acid and acetaminophen were purchased from Sigma-
Aldrich (Germany). Pyrrole was purchased from Sigma-Aldrich and used to prepare 
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a 200 m M solution in phosphate-buffered saline solution (PBS). The PBS was 
prepared in-house by mixing Na2HPO4 and NaH2PO4 in water to final 
concentrations of 0.04 M and 0.01 M, respectively. NaCl was added to this buffer to 
a final concentration of 0.10 M. Ringer’s solution, also prepared in-house, was used 
as the microdialysis infusion solution, and had a composition of 147.0 mM NaCl, 
3.0 mM KCl, 1.2 mM MgCl2, and 1.2 mM CaCl2. Saline solution (0.9%, sterile) was 
purchased from Baxter and stored at 2 ºC. Insulin (recombinant human insulin, 100 
IE/mL) was purchased from Eli Lilly  (Indianapolis, U.S.) and stored at 2 ºC. D-
glucose and GOx were supplied by Merck (Germany) and used to prepare 1 M and 
5000 U/mL stock solutions, respectively. D-glucose was stored in a refrigerator at 2 
ºC while GOx was stored at - 20 ºC. All solutions were prepared with 18 MΩ⋅cm 
ultrapure water purified in an Arium® 611 system (Sartorius Stedim Biotech, 
Germany).  
 
2.2. Fabrication of microfluidic chip 
The fabrication of the microchannel in polydimethylsiloxane (PDMS) by replication 
using a st ructured silicon wafer as master was described in detail in a previous 
paper.[20] Briefly, a 4-inch, p-type, polished (100) silicon wafer (Si-Mat, Germany) 
(525 µm) was employed as a substrate. After wafer cleaning, it was treated with 
hexamethyldisilazane (HMDS) (Sigma-Aldrich, Germany) to improve adhesion of 
the photoresist. The structure on the silicon master was p rocessed in a thick 
photoresist layer with two steps of standard photolithography. A thick layer of 
positive photoresist AZ 4562 (Microchemicals GmbH, Germany) was co ated onto 
the silicon wafer using a sp in coater, and then re-hydrated at ambient temperature 
for 3 hours. The coated wafer was exposed to ultraviolet (UV) light (365 nm, 10 
mW/cm2) using a photomask made on a transparency sheet (resolution 3,810 dpi; 
Pro-Art bv, Groningen, The Netherlands) to structure the ridges which are the 
negative of the microchannels. The exposed photoresist was then removed by 
dipping in a developer solution and rinsed in deionized water. Subsequently, the 
substrate was again exposed to UV light for 10 s using a photomask to structure the 
grooves on top of the microchannel-ridges and developed. For microchannel 
replication in PDMS, a mixture of PDMS resin and curing agent (Sylgard 184, Dow 
Corning, U.S.) was prepared and cast onto the silicon master. The mixture was 
allowed to cure at 50 °C for 4 hours. Once hardened, the PDMS slab was peeled off 
of the silicon master. Microfabricated thin-film platinum (Pt) electrodes were 




formed on a 4-inch Pyrex glass wafer using a standard photolithography and lift-off 
process. Groups of threes electrodes were prepared onto one wafer (active area 100 
µm x 1500 µm). The PDMS slab was cut into individual devices for bonding to the 
glass chip with electrodes. After UV-ozone treatment, the PDMS slab and glass chip 
with electrodes were immediately aligned under a microscope and brought into 
contact with each other to form an irreversible bond. The whole bonding procedure 
was done in a cleanroom.  
In order to prevent protein adsorption and reaction with interfering substances, the 
thin-film Pt electrodes were coated by electrodeposition of overoxidized polypyrrole 
(PPy). A solution of 200 mM PPy was prepared in 100 mM PBS (pH 7.4, 
composition as above) solution and used for electrode coating.[21] The PPy solution 
was first bubbled for 20 min with nitrogen (N2) gas in order to lower the oxygen 
concentration in solution. The electrodes were then coated by introducing the PPy 
solution into the microfluidic channel and applying a constant potential of 0.85 V for 
5 min. Subsequently, the PPy was overoxidized by maintaining a potential of 0.85 V 
for 6 hours in PBS solution. The chip was then cleaned with ultrapure water.  
 
2.3. Evaluation of in vitro microdialysis recovery 
A cannula microdialysis probe (Brainlink B.V., Groningen, The Netherlands) was 
used in this study. The shaft was made of concentric fused silica tubes (not rigid but 
quite flexible), and the semi-permeable membrane at the tip made of 
polyacrylonitrile (PAN). This material has a 4 5-50 kDa molecular-weight cut-off.  
Membrane lengths of 1 or 3 cm (ID of 250 µm, OD of 340 µm) were used for this 
study. The inflow of perfusion solution was down the center of the concentric shafts, 
with outflow up the peripheral channel. In order to evaluate in vitro microdialysis 
recovery, relative glucose recovery was d etermined using a colorimetric method. 
Prior to microdialysis use, the probe was cleaned with 70% ethanol and ultra-
purified water. A 1 0 mM glucose sample solution was prepared in DI water in a 
beaker as a reference solution, and a probe was immersed in this glucose solution. 
The probe was perfused with Ringer’s solution using a syringe pump which was 
connected to the inlet of the probe with silica tubing. The glucose solution was 
stirred and maintained at 37°C. Microdialysate samples were collected for 30 min in 
vials at the outlet of the probe at various perfusion flow rates (0.3 µL/min - 20 
µL/min). For the quantitative colorimetric determination of glucose recovery in the 
microdialysate, 6 µL dialyste samples were mixed with 50 µL of glucose reagent 
(CMA, Sweden) and allowed to react for one hour in a 60-well plate. This reaction 
is catalyzed by peroxidase and yields the red-violet colored quinoneimine. The 
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amount of compound formed is measured photometrically at 546 nm wavelength 
and is proportional to the glucose concentration. After reaction, the 60-well plate 
was placed on a Microplate reader (Molecular Device, CA) and SoftMax Pro 
Software displayed the absorbance. Relative recovery was expressed as percent of 
beaker glucose content. 
 
2.4. In vitro evaluation of performance of microdialysis probe coupled to EMR 
Figure 1 shows a sch ematic diagram of the experimental set-up used for in vitro 
evaluation of the microdialysis probe coupled to the EMR. The microdialysis probe 
was perfused with Ringer’s solution at 0.5 µL/min. The resulting microdialysate was 
then transported from the probe outlet to one of the EMR inlets. A 150 U/mL GOx 
solution was introduced at 1.5 µL/min into the other EMR inlet. The length of the 
mixing channel in the EMR was 10 cm long.  
Glucose was detected electrochemically as described previously.[20] Two thin-
film Pt e lectrodes were used as working and counter electrodes, respectively. A 
Ag/AgCl electrode was used as a reference electrode and prepared by using a silver 
wire (Ag) (250 µM diameter, Sigma-Aldrich). The Ag wire was immersed in 1 M 
HCl solution saturated with NaCl. The AgCl layer was coated by connecting the 
wire to the positive terminal of a 9-V battery for 10 min to oxidize silver at the 
surface of the wire to form AgCl. With respect to the electrochemical detection, 
signal fluctuation and damping noise originating from pulsation of the syringe 
pumps were observed in the pilot experiments. To alleviate this problem, a 
pulsation-dampening set-up was introduced into our continuous measurement 
system, as shown elsewhere.[22] Briefly, a 20-µL air bubble was entrapped in each 
gastight syringe next to the piston. Because air is far more compressible than liquid, 
this bubble served as a cushion capable of absorbing piston pulsation without 
transfer of this pulsation to the surrounding liquid. The syringe pumps used for the 
remaining experiments were from Harvard Apparatus Ltd. (UK). 
The in vitro EMR evaluation was performed by injecting varying volumes of 1 M 
stock glucose solution into the beaker, which contained a known amount of water, to 
achieve different concentrations of glucose (2.1 mM, 5.6 mM, 10.1 mM, 15.0 mM, 
20.6 mM). The microdialysis probe was i mmersed in this glucose solution, which 
was kept at 37ºC and stirred by placing on a stirring hotplate. (Note that the chip and 
tubing were not heated.) The H2O2 produced by the reaction between glucose and 
GOx (150 U/mL) was oxidized at the integrated microelectrode at an applied 




current was recorded as a function of glucose concentration. The output current 
value was displayed on a PC. The data acquisition rate was every 2 sec. 
 
 
Figure 1. Experimental set-up used for the evaluation of the in vitro performance of 
the microdialysis probe coupled to the EMR. 
 
2.5. Experimental set-up and procedure for in vivo glucose monitoring 
This study was approved by the Institutional Animal Care and Use C ommittee 
(IACUC) of the University of Groningen. Male Wistar rats (350-410 g, Harlan, 
Horst, The Netherlands) were singly housed in Plexiglas cages (30 x 30 x 40 cm) in 
a room in which light (12 h:12 h light cycle; lights on at 07: 00) and temperature (21 
± 1 °C) were controlled. The animals had free access to fresh water and standard 
rodent chow. The animals were acclimated for one week before surgery and the start 
of the experiments.  
On the day of an experiment, the rat was anesthetized with isoflurane gas (5% 
isoflurane in O2 to induce anesthesia, followed by 2% isoflurane in O2 to maintain an 
anesthetized state). The level of anesthesia was monitored and maintained at an 
appropriate level throughout the surgery and experimental procedures. A cat heter 
was placed in the jugular vein to accommodate the collection of blood samples. A 
10-cm segment of silicone tubing (0.50 mm ID; 0.90 mm OD) was inserted into the 
right jugular vein. The catheter was exteriorized from the neck and fitted onto a 21-
gauge stainless steel (0.80 mm OD; 40 mm length) connector. The catheter was kept 
 
In vivo application of an enzymatic microreactor 
 
 125 
patent by infusing 30 µL of heparin (20 U/mL in saline) every 15 minutes 
(immediately after collecting each blood sample). A second incision was made in 
the dorsal part of the thorax and a microdialysis probe (1 mm open surface) was 
placed in a deep subcutaneous tissue layer. Both wounds were carefully closed with 
suture. 
In vivo glucose monitoring in the rats was started immediately after surgery. 
During the experiments, the animals were kept under anesthesia, body temperature 
was maintained at 37°C, and dehydration was prevented by hourly subcutaneous 
injections of saline at a site distant from the microdialysis probe. The microdialysis 
probe was perfused with Ringer’s solution at a flow rate of 0.5 µL/min. The outlet of 
the probe was connected to one of the EMR inlets by 10 cm of silica tubing (0.005 
in ID; 0.02 in OD) (see Figure 1). GOx (150 U/mL) was continuously introduced by 
a second syringe pump to the other EMR inlet at a flow rate of 1.5 µL/min. The 
connection between this syringe pump and the EMR was realized using a 30-cm-
long piece of silica tubing. The microelectrode signal in the EMR was allowed to 
stabilize for 90 min. After a stable signal had been established, glucose 
concentrations were modulated by consecutive intravenous injections of saline (1 
mL; control), 20% (w/v) glucose in saline (1 mL), and 5 U/kg insulin in saline (1 
mL), administered at one-hour intervals. Samples for determination of blood glucose 
levels were collected (70 µL) via the jugular vein at 15 min intervals. Loss of fluid 
volume in the animals was compensated by replacement with saline injected hourly. 
Blood glucose was co lorimetrically quantitated with an Accu-Chek® analyzer 
(Roche Diagnostics, Switzerland). After completion of the experiment, the rats were 
immediately sacrificed with 20% Euthasol® (AST Beheer BV, The Netherlands). 
 
2.6. Data analysis 
The acquired in vivo raw data was further processed for EMR evaluation and 
comparison with blood glucose values (Microsoft® Excel 2007). Data points 
obtained using the EMR were displayed as 1-min average values of raw data. The 
dynamic change of glucose levels was plotted with respect to baseline levels. In 
order to transform EMR signal into “blood” glucose values, a one-point in vivo 
calibration was performed using an average blood glucose value obtained at steady 
state, after saline solution administration but before administration of glucose.[23] A 
conversion factor, k, was first calculated by equating the product of k multiplied by 






                                          k · iEMRss = [BG]ss                                        (1) 
 
All measured values of iEMRss were then transformed to blood glucose concentrations 
through multiplication by k. The maximum values of transformed EMR signal and 
experimentally determined blood glucose concentrations achieved by injection of 
glucose were compared for statistical significance. The statistically significant 
difference was analyzed by one way ANOVA, followed by a B onferroni-Holm’s 
post-hoc test. The significance was set at p < 0.05.[24] 
 
3. Results and Discussion 
3.1. In vitro interference study 
Electroactive molecules can diffuse through the microdialysis membrane and be 
oxidized electrochemically at the surface of the bare Pt working electrode, thus 
increasing the output current and interfering with glucose determination. The most 
electroactive interfering substances present in physiological samples are ascorbic 
acid, uric acid and acetaminophen.[25] The extent to which these substances could 
adversely affect observed signal must therefore be addressed prior to in vivo glucose 
analysis. Much effort has been spent to eliminate the effect of interfering substances 
on sensor response.[26] Permselective coating layers such as n afion, polypyrrole 
(PPy)[27], overoxidized PPy[21], polyphenylenediamine[28] and cellulose 
acetate[29] have been coated on bare electrode surfaces to prevent undesirable 
contributions to the measured current. 
In this study, the effects of interfering substances on electrochemical 
measurements in the microfluidic chip made with bare electrodes were compared 
with electrodes coated with overoxidized PPy. Separate samples containing 5.6 mM 
glucose and either 150 µM ascorbic acid, 500 µ M uric acid or 150 µM 
acetaminophen were prepared. The concentrations chosen for the interfering species 
are typical maximum values in physiological sample.[11] These solutions were 
introduced into the channel and the resulting current compared with that produced 
by a 5.6 mM glucose sample alone. The results, shown in Figure 2, indicate that all 
three electroactive substances increase electrode response by less than 10 % when a 
bare electrode was used. With the PPy-coated electrode, the interference was 
decreased to less than 5 %  in all cases, with uric acid exhibiting almost no 
measurable interference. Interestingly, the bare electrode shows less interference 
compared to previous electrochemical biosensor reports.[30, 31] This could possibly 
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be explained by a high enzymatic conversion of glucose in the reaction channel. The 
enzyme is continuously converting glucose as the reaction mixture travels along the 
mixing channel to the sensing electrode. In fact, the current produced for a 5.6 mM 
glucose solution is equivalent to that measured for an approximately 3 m M H2O2 
sample (data not shown). The contribution to overall electrode signal from 
interfering substances is thus relatively small.  
Figure 2. Interference study (n = 4 devices). The current recorded for solutions 
containing 5.6 mM glucose with 150 µM ascorbic acid, 500 µM uric acid or 150 µM 
acetaminophen added was compared to that of a solution containing only 5.6 mM 
glucose. Observed differences are expressed as a percentage (%). 
 
3.2. In vitro microdialysis probe recovery 
In vitro microdialysis recovery was ch aracterized as a function of flow rate and 
probe length. The molecular weight cut-off of the semipermeable microdialysis 
membrane dictates the extent to which different molecular species can diffuse across 
it. A high-precision syringe pump is used to transport the analyte compounds which 
have diffused over the membrane into the microdialysate to the probe outlet. When 
the analyte concentration reaches equilibrium across the membrane, 100 % relative 





% Recovery = Cout / Cbeaker × 100 (%)                                      (1) 
 
where Cout is the concentration of glucose in dialysate and Cbeaker the undisturbed 
concentration of glucose in the stirred medium in which the microdialysis probe is 
immersed.   
It is well known that the relative recovery is increased when flow rate is decreased. 
Relative recovery can be regulated by adjusting perfusion flow rate and length of 
probe membrane; recoveries of 100 % are also possible. The effects of flow rate and 
probe length were investigated in this study, since these are the parameters that 
dictate in vitro recovery. 
Figure 3 shows the in vitro recovery of glucose at different flow rates with 
microdialysis probes having lengths of 1 cm and 3 cm. The results showed that as 
















Figure 3. In vitro recovery of glucose at flow rates between 0.3 and 20 μL/min (n=3 
probes, 3 experiments per probe). The recovery of 1-cm probe and 3-cm probe were 
obtained and compared as a function of flow rate. 
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reduced times for diffusion of glucose over the membrane.  Comparing the 3-cm 
probe to the 1-cm probe, it is clear that the 3-cm probe showed higher recovery at 
higher flow rates.  This is because of the greater contact area with medium afforded 
by the longer membrane, resulting in more molecules diffusing through the 
membrane. The recovery for the 1-cm probe was, however, still very good at a flow 
rate of 0.5 µL/min with a v alue of 95%, while the longer microdialysis probe 
exhibited a 1 00% recovery at this flow rate. Damage to cells and tissues during 
probe insertion for in vivo application is greater for the longer probe, however. The 
1-cm probe was t hus deemed more appropriate with respect to minimizing the 
adverse side effects of probe insertion. In addition to optimal recoveries, flow rates 
of less than 1 µL/min also result in a reduced requirement for perfusion medium. 
This is in keeping with the use of a microfluidic sensing device in this application to 
reduce reagent consumption for the eventual development of a portable monitoring 
system. Therefore, a 1-cm-long  membrane and a flow rate of 0.5 µL/min allowing 
for nearly 100 % recovery were chosen for further experimentation. 
 
3.3. Calibration of the EMR coupled to the microdialysis probe  
Prior to performing an in vitro evaluation of the EMR coupled to a microdialysis 
probe, possible backpressure effects caused by connection to the probe which could 
result in altered flow rates were considered. When tubing, microchip, and 
microdialysis probe are all coupled, perfusion fluid might be lost at the EMR inlets, 
a weak point in the system which could be subject to leakage upon applied pump 
flow (see Figure 1). Theoretically, the expected pressure drop over the system can 
be calculated using the Poiseuille equation.[33] This pressure drop was calculated to 
be approximately ~10 kPa under the given conditions, described in Section 2.4. 
Possible changes in set flow rates due to backpressure were then experimentally 
determined for the pumps operating individually, and for the pumps coupled to the 
chip and microdialysis probe (see Figure 1). Each experimental configuration was 
run for 30 min at a perfusion flow rate of 0.5 µL/min and/or 1.5 µL/min. The liquid 
collected at the tubing outlet of the pumps or chip outlet during this time was 
weighed, and the flow rate was calculated. The pumps delivering Ringer’s solution 
and GOx reagent were tested separately and found to operate at their set flow rates 
of 0.5 µL/min and 1.5 µL/min, respectively, with no observed backpressure effects. 
There were also no adverse effects noted when the two pumps were coupled directly 
to the two inlets of the EMR chip and operated at their set flow rates (total flow rate 




Ringer’s solution pump (0.5 µL/min ) was connected to  the microdialysis probe, 
which in turn was connected to one inlet of the EMR, while the other pump 
introduced buffer at a flow rate of 1.5 µL/min to the other chip inlet.The results 
showed an approximate 5 % loss of fluid at a total flow rate of 2 µL/min when two 
pumps were operated simultaneously under these conditions. 
Figure 4 shows the result for the in vitro calibration of an EMR in line with a 
microdialysis probe as a function of glucose concentration. The experimental set-up 
depicted in Figure 1 was employed for these measurements. Changes in electrode 
current in response to glucose concentrations up to 20.6 mM were measured. A 
linear relationship between current and glucose concentration was shown in the 
range between 2.1 mM and 20.6 mM, with a sensitivity of 7.8 ± 1.0 nA/mM  (n = 6 
devices, 1 experiment per device, as shown in the inset of Figure 4) and correlation 


















Figure 4. In vitro calibration of the EMR coupled to a 1 -cm long microdialysis 
probe (n = 6 devices). An example of a recorded current-time trace is shown in the 
inset, exhibiting current values that increase stepwise over time as the glucose 
concentration in the beaker was increased. Current was recorded for 15 min at each 
concentration. Each value of current in the calibration curve is an average of data 
acquired over a 15-min period. 
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inset, exhibiting current values that increase stepwise over time as the glucose 
concentration in the beaker was increased. Current was recorded for 15 min at each 
concentration. This result confirms that the microfluidic chips were reproducible 
from one device to the next. During the in vitro evaluation, the physical lag time, or 
delay between microdialysis and analytical signal, was estimated to be about 18 to 
19 min (time after concentration change at which the steady-state current had 
increased by 10%), due mainly to the tubing connecting the probe to the chip inlet 
and the dead volume of the microdialysis probe. In principle, this physical lag time 
can be reduced through further miniaturization of the sensing system to bring it 
closer to the probe insertion site. 
 
3.4. In vivo study  
The performance of the in vivo glucose monitoring microsystem in rats was 
evaluated by modulating blood glucose concentrations with intravenous injections of 
glucose or insulin, using saline as a control. In a previous study in humans, a rapid 
increase in blood glucose concentrations was achieved by administration of an oral 
glucose load (75 g glucose), and a r apid decrease was ach ieved by intravenous 
insulin administration (6-40 units).[34] Capillary blood samples were collected 
every 15 min for 3-5 hours and glucose was an alyzed by different commercial 
glucose monitors. In rats, fast and robust changes in blood glucose can be induced 
by intraperitoneal injection of 1g/kg glucose[35] or intravenous injection of 5 U/kg 
insulin.[36] Here we have chosen to modulate glucose levels by consecutively 
injecting saline (1 mL/kg), 200 mg/kg glucose, and 5 U/kg insulin intravenously at 
one-hour intervals.  
The effect of these treatments on glucose concentrations in the blood and in 
subcutaneous ISF are shown in Figure 5. Blood glucose levels are expressed as 
change in glucose concentration over time relative to the baseline concentration 
within the same animal. Recorded EMR current, which reflects subcutaneous ISF 
glucose concentrations, was calibrated to in vivo blood glucose values by a one-
point calibration against blood glucose at baseline (an average of blood glucose 
concentrations at 3:00 and 3:15).[23] Continuous registration of subcutaneous ISF 
glucose was converted into one-minute averages, and expressed as ch ange in 
glucose concentration over time relative to the baseline concentration within the 
same animal. Arrows indicate the time points of the saline, glucose and insulin 
administrations. 
Baseline blood glucose concentration was measured to be 10.2 ± 2.3 mM by using 




the effects of anesthesia. Our approach does not allow us to directly compare 
glucose levels in blood and ISF at steady-state. The correlation between glucose in 
blood and ISF has often been debated. In some studies it has been shown that under 
steady-state conditions ISF glucose levels were similar to blood glucose in healthy 
subjects.[37, 38] However, others reported ISF glucose to be ~15-30% lower.[39, 
40] Despite this, we have chosen to report our measured ISF glucose signal trends in 
terms of baseline blood glucose concentration, as i t is generally accepted that ISF 
glucose trends will mirror blood glucose trends, though with a physiological lag 
time. As seen in Figure 5, the physiological lag time in our experiments is between 5 
and 9 minutes, which agrees with the literature.[41] 
 
Figure 5. Dynamic changes in subcutaneous glucose concentration with respect to 
the baseline concentration by administration of glucose-modulating substances (n = 
5 rats) Arrows indicate consecutive administrations (saline, glucose and insulin) at 
one-hour time intervals. Plotted EMR data points are 1-min averages of the 
recorded data and blood glucose are every 15 min intervals. * indicates a 
statistically significant difference compared to baseline at 3:30. (p < 0.05; ANOVA)  
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Approximately 5 min after glucose injection, but not after saline administration, 
ISF glucose values started increasing to a maximum increase of 1.5 mM (15%). In 
contrast, ISF glucose decreased by 8.6 mM (85%) in total after insulin 
administration, starting about 15 min after insulin injection. These dynamic changes 
in glucose levels can be explained by the different mechanisms that exist for glucose 
kinetics in subcutaneous tissue.[42] When glucose is injected into the jugular vein, it 
is quickly spread to all capillaries. Glucose is then transported from the blood to the 
interstitial fluid of the subcutaneous tissue and ISF glucose rapidly 
equilibrates with the blood. Insulin is also rapidly distributed to all capillaries after 
being injected into the jugular vein. However, insulin affects glucose concentrations 
in an indirect manner, namely by activating glucose transporter proteins, mainly 
GLUT4, that clear glucose into muscle cells and adipocytes. In this way, glucose is 
removed from the ISF into cells surrounding the microdialysis probe. 
The relationship between ISF and blood glucose is complex and not well 
understood. Under physiological conditions there is free and rapid exchange of 
glucose between blood and ISF.[35] However, there will be a gradient between 
blood and ISF when glucose is taken up by the tissue surrounding the microdialysis 
probe.[43] It has been reported that the blood-ISF gradient seems to be larger during 
systemic hypoglycemia[44, 45], however, our results indicate that the amplitude in 
blood and in subcutaneous ISF is identical.  
Here we d emonstrated a p hysiological lag time between blood and ISF of 
approximately 5-9 min, independent of the direction of glucose change. Conflicting 
reports exist in the literature about the rate of equilibration between blood and ISF 
during increasing or decreasing glucose concentrations, ranging from rapid 
equilibration[39, 45] to a delayed response in ISF by 18-30 min.[38, 46, 47] The 
relationship between blood and ISF is dynamic, and depends on the species,[43] the 
tissue in which the microdialysis probe is implanted[37, 48], and on the diabetic 
state.[49] Moreover, ISF glucose levels are affected by the act of probe 
implantation. Insertion of the probe into adipose tissue causes vasoconstriction at the 
site of implantation, and damages cells and capillaries surrounding the probe. 
Wientjes et al.[50] showed that ISF glucose levels are lower than blood glucose 
during the first 12 hours after implantation. Agreement between ISF and blood is 
expected to improve after tissue trauma has been mostly cleared and angiogenesis of 
new capillaries into the implantation site has been allowed to enhance delivery of 
glucose to the tissue.[51] 
We would like to reiterate that our measurement was started within a co uple of 




disruption of the endothelial barrier, a longer delay caused by the presence of tissue 
trauma and cellular debris, as well as relatively low ISF levels caused by local 
inflammation and wound healing processes. The focus of this present study is the in 
vitro/in vivo evaluation of a new microfluidic glucose sensing system incorporating 
microdialysis sampling. Fluids in the in vivo environment are very complex and 
contain many potentially interfering substances. The use of microdialysis as a 
sampling technique in this in vivo monitoring approach could thus be quite 
appealing for lab-on-a-chip glucose sensing applications.  
For further research, it would be interesting to study freely moving rats instead of 
anesthetized rats with the EMR-based system. Since the chemicals used for 
anesthesia affect rat metabolism, it is not an optimal situation in which to study the 
relationship between BG and ISF. Ultimately, microtechnology could enable the 
development of portable systems small enough to allow (small) animal studies under 
conditions in which the animals can move normally. Along with improved 
microdialysis techniques, microfluidics-based systems should enable increasingly 
reliable long-term glucose-monitoring studies in both animal and human subjects.  
 
4. Conclusion 
We have successfully demonstrated an in vivo application of a microfluidic EMR 
coupled with microdialysis for continuous subcutaneous glucose monitoring. This is 
the first example of the use of a chaotic mixing approach in a microfluidic device for 
an in vivo glucose sensing application. The results obtained show the feasibility of 
this microfluidic glucose sensing system, and its potential for further miniaturization 
and integration into an autonomous system incorporating micropumps, solution 
reservoirs and energy source. The advantage of this microfluidic glucose sensing 
system compared to commonly using immobilized enzyme sensors is the fact that 
the sensing reaction occurs in solution, which circumvents the necessity of enzyme 
immobilization and subsequent slow enzyme deactivation. Instead, a continuous 
supply of fresh, active enzyme for the sensing reaction is provided, made possible 
by the strongly reduced GOx volumes consumed in the chip. With the reaction of 
GOx and glucose, a significant amount of H2O2 is produced along the grooved 
mixing channel. Moreover, the amount of H2O2 production can be tuned by simply 
modifying the length of the mixing channel or alternatively, the flow rate. Several 
important factors have been taken into account in the current microfluidic chip 
design, as described in Moon et al.[20]. 
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Factors such as the concentration of GOx, an optimal GOx-glucose mixing ratio to 
prevent oxygen depletion and the use of longer channel lengths to increase glucose 
conversion to H2O2 and thus improve detection sensitivity were considered in this 
earlier work.  For the studies presented here, it was important to characterize flow in 
the device once coupled to the microdialysis probe, to avoid induced pressure 
differences and ultrafiltration effects. As already mentioned, the use of microdialysis 
is another advantage in terms of analyte sampling, as t he sample collected and 
reacted in the EMR is relatively clean compared to the fluid in vivo.  
For the evaluation of the EMR, electrodes coated with a PPy layer were shown to 
exhibit a less than 5% difference in measured current in the presence of added 
interferents (ascorbic acid, uric acid, acetaminophen) compared to a solution 
containing only 5.6 mM glucose. In vitro microdialysis probe recovery was 
approximately 95 % at a flow rate of 0.5 µL/min. In tissue, there are disruptions and 
capillary wound healing in the cell layers surrounding the microdialysis probe. 
Those processes in the vicinity of the probe affect glucose transport to the probe 
membrane and hence glucose recovery. However, it is possible to reach a glucose 
concentration  e quilibrium  be tween the dialysate and nearby capillaries through 
adjustment of the flow rate, as shown in a ad ipose tissue model.[32] The EMR 
coupled with microdialysis showed a good correlation coefficient in the 
concentration range of 2.1 mM to 20.6 mM (n=6 devices). In the in vivo animal 
experiments, dynamic changes in glucose levels of about 1.5 mM (15 %) increase 
and an 8.6 mM (85 %) decrease, modulated by glucose and insulin administrations, 
respectively, were observed. The trends in measured EMR levels correlated well 
with trends in blood glucose levels. Comparison of pre- and post-EMR evaluation 
data indicated that no significant biofouling of the detection electrodes had taken 
place during in vivo monitoring experiments (data not shown). It should be noted 
that since the animal study was performed on anesthetized rats, the glucose levels 
measured in ISF and blood cannot directly be compared. Under anesthetic, the 
glucose levels in ISF and blood are dependent on the glucose kinetics, location of 
the probe, up-take of glucose by cells and the condition of the animal itself. This can 
lead to quite different absolute glucose concentrations in the two compartments, as 
measured elsewhere using an ultrafiltration technique.[47] However, the in vivo 
results obtained here allow the conclusion that it is feasible to use the microfluidic 
chip coupled to microdialysis for the continuous subcutaneous monitoring of 
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The development and application of continuous glucose monitors (CGM) constitutes 
a major field in diabetes-related research. The main goal of continuous glucose 
monitoring is to provide better insight into the daily glucose fluctuations 
experienced by diabetic patients to help them achieve better management of their 
glucose levels. The existing conventional ways of discontinuous glucose monitoring, 
such as f inger-prick and HbA1c level tests, are insufficient for detection of 
hyperglycemic and, especially important, hypoglycemic episodes.[1] Various 
techniques have been investigated for the development of CGMs for diabetic 
patients, involving both invasive and noninvasive methods. Even though 
noninvasive approaches based on optical or transdermal sensing mechanisms are 
appealing because of their user-friendliness and convenience, they are still 
underdeveloped in terms of accuracy and exhibit insufficient precision for clinical 
use.[2] Invasive subcutaneous glucose monitoring methods using needle-type or 
microdialysis-based CGMs to determine glucose levels in the interstitial fluid have 
obtained promising results in clinical settings.[3, 4]  
Chapter 1 presents a general introduction to glucose biosensing, continuous 
glucose monitoring and microfluidics, and describes the scope of this thesis. The 
aim of this research is to demonstrate the development of a co ntinuous glucose 
monitor combining microdialysis sampling and microfluidics to achieve the further 
miniaturization of existing systems. Our approach to continuous glucose monitoring 
distinguishes itself in three ways. First, we have adopted microdialysis for sampling 
glucose in the interstitial fluid, a technique which has proven to be biocompatible 
and safe for use in both animals and humans.[5] Glucose diffuses over the 
microdialysis membrane and is transported to an extracorporeal sensor, where 
glucose oxidase facilitates the conversion of glucose to gluconic acid and H2O2. 
Second, we have taken a cu e from an existing subcutaneous continuous glucose 
monitoring system (SCGM), in which glucose detection is based on the reaction in 
solution of glucose oxidase (GOx) and glucose to produce H2O2.[6] The main 
advantage of a solution-based enzymatic reaction is that fresh enzyme can be 
provided for each determination, circumventing the slow loss of reactivity over time 
to which immobilized GOx is prone. An added benefit is therefore the reduced 
requirement for calibration of the solution-based system compared to approaches 
employing (micro)electrodes with immobilized GOx, since there is no ne ed to 
compensate for signal drift. However, a system based on microdialysis and solution-
based assay requires additional components such as a pump and tubing, in addition 
to a detector. Therefore, the third distinguishing feature of the system presented in 
this thesis is that it uses microfluidics technology to reduce system bulk and 
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complexity resulting from the necessity of having flow. The microfluidic system 
allows for a substantially reduced consumption of chemical reagents and short 
reaction times. This system represents a st ep forward towards a m ore fully 
miniaturized, portable monitoring system.  
In order to better understand the issues involved in continuous glucose monitoring, 
we review in Chapter 2 the technical requirements that a CGM has to satisfy and 
the physiological influences affecting accuracy, selectivity, sensitivity and 
durability. The review focuses on invasive glucose monitors based on either 
implantable needle-type sensors or microdialysis. It describes the physiological 
factors affecting the performance of these CGMs, including the sources for 
differences between interstitial fluid and blood glucose concentrations, implantation 
effects and location of the CGM. Though the studies of currently available CGMs 
showed clinically acceptable results, their performance is still sub-optimal and 
awaiting technical improvements. In this chapter, we also present our approach 
using a microfluidic enzymatic reactor with integrated electrochemical detector 
coupled to microdialysis sampling, which we envision could contribute to the further 
development of microCGM.  
The development of a microfluidic chip is described in Chapters 3 and 4. In 
Chapter 3, we demonstrate an enzymatic glucose reactor based on chaotic mixing in 
a microfluidic channel network for continuous glucose monitoring. An on-chip 
amperometric detector consisting of a thin-film Pt electrode was located at the end 
of the microreactor channel to detect the reaction product, H2O2. Chaotic mixing was 
achieved through the integration of an array of slanted microgrooves in the upper 
surface of the microchannel. The mixing characteristics of this device were 
compared to microchannels containing no microgroove arrays. A linear calibration 
curve for glucose in the clinical range of interest was obtained in both microchannels 
with slanted grooves and no grooves, using a solution-based enzymatic reaction. 
However, higher sensitivity was obtained in slanted-grooved micromixers compared 
to no-grooved micromixers, due to enhanced mixing in the former device. The flow 
rates used were selected to reduce solution consumption and because of their 
compatibility with microdialysis .  
A microfluidic system incorporating chemiluminescence (CL) detection as an 
alternative approach for glucose sensing is presented in Chapter 4. With a two-
reactor system, glucose is converted into a CL output signal detected by a si licon 
photodiode embedded in the chip. The fabricated CL microfluidic chip was 
characterized and reaction conditions optimized e.g. flow rate, pH, and 




that the silicon photodiode is not directly exposed to the sample or chemical reagents. 
This is in contrast to systems using subcutaneously implanted microelectrodes in 
direct contact with interstitial fluid, which are subject to biofouling, and as a result, 
signal drift. The system exhibited a linear calibration curve for glucose 
concentrations between 2 mM and 10 mM. With these results, it could be concluded 
that this new CL-based microfluidic system is promising for sensing glucose. 
Further investigation of how compounds in complex biological samples could 
adversely affect CL detection is required. It would also be of interest to use this 
alternative approach for in vivo glucose monitoring. Furthermore, it would be 
interesting to integrate both electrochemical and CL detection onto a single device to 
improve analytical function. Amperometric detection of H2O2 is simple and robust 
from an instrumental point of view, but is subject to signal drift over time. Because 
the photodiode is insensitive to drift, periodic CL analysis of a g lucose standard 
could be used to calibrate microelectrode response to correct for drift, thus extending 
the period of time between required replacements of the microfluidic/amperometric 
detection component.  
Chapter 5 demonstrated an in vivo application of the enzymatic microreactor 
(EMR) with integrated amperometric detection for continuous glucose monitoring. 
Introduced in Chapter 3, the EMR was further developed and coupled with a 
microdialysis probe which was inserted into the subcutaneous tissue of anesthetized 
rats. A polypyrrole (PPy)-coated microelectrode was studied with respect to its 
ability to withstand interaction with biologically interfering substances. The 
recovery of the selected microdialysis probe was also evaluated in vitro. The EMR 
coupled with microdialysis exhibited a linear calibration curve for measured current 
as a function of glucose concentration in the clinical range of interest when the 
probe was immersed in glucose solutions of different concentrations. The in vivo 
performance of the EMR was assessed by implanting the microdialysis probe in an 
anesthetized rat and modulating blood glucose concentrations with saline, glucose 
and insulin injections. Recorded glucose levels increased and decreased as expected 
with the intravenous injection of glucose and insulin, respectively. Furthermore, 
values measured with the microCGM correlated well with blood glucose values 
measured concurrently. With this newly-designed glucose sensing system, we 
concluded that it is  feasible to use the microfluidic EMR chip coupled to 
microdialysis for continuous subcutaneous measurement of glucose in rats. 
In the research leading up to this thesis, a new sensing system for continuous 
glucose monitoring based on an alternative microfluidic approach for glucose 
sensing has been developed. Two different types of sensing systems were realized 
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based on amperometric and CL detection of the hydrogen peroxide produced in the 
GOx-catalyzed reaction of glucose with oxygen. Both systems employed 
microreactors incorporating chaotic mixing channels. One future R & D goal should 
focus on the further miniaturization of the microfluidic system to achieve a true µ-
SCGM. The microfluidic EMR is a continuous flow system characterized by low 
fluid consumption, offering a promising alternative for glucose sensing. On-going 
research is required to scale down the system and integration of the system parts. An 
important consideration in this regard is the compatibility of all the system 
components with respect to materials and operating parameters. In our enzymatic 
reactor, we successfully developed an on-chip detector as a first step. The new 
compact design and realization of pumps, control valves, fluidic reservoirs, and 
electronics will also be important aspects to consider when pursuing the goal of 
business-card size devices.[7] 
Another interesting bioanalytical aspect to explore might be to use the same 
principle of solution-based enzyme assay on the microscale for the analysis of other 
analytes of interest, such as lactate, ethanol, and urea. The switch to another enzyme 
is easily accomplished, since the enzyme is simply introduced to the EMR as a 
solution via one the device inlets. This is in contrast to approaches utilizing surface-
immobilized enzymes, which require an extra immobilization step that generally 
needs to be modified for each new enzyme applied. The adjustment of microfluidic 
channel length allows the mixing/reaction time (analyte sensitivity) to be easily 
tuned for different applications. Multiple reaction channels are also possible to 
detect different substrates simultaneously.   
To gain more insight in physiological and pharmacological studies of glucose 
concentration fluctuations under different challenges, it will be important to be able 
to monitor glucose in freely moving rats instead of anesthetized rats. Animals that 
are awake provide a better representation of physiological glucose delivery than 
anesthetized rats, which should ultimately also lead to a better understanding of the 
complexities associated with glucose metabolism. Anesthesia influences metabolic 
conditions and glucose consumption in the tissue/cells during pharmacological 
challenges. Studies with freely moving rats will also provide a better means of 
investigating “the push-pull theory” as a possible explanation for observed 
differences in blood and ISF glucose levels, and rates of change in these levels, 
during periods of increasing and decreasing blood glucose levels.[8] 
Ultimately, it is very desirable to link continuous glucose monitoring to an insulin 
delivery system to achieve the so-called “artificial pancreas”. Insulin delivery in 




continuous glucose monitor. Alongside further development of highly accurate and 
reliable CGM, other components such as an insulin pump and control algorithms are 
required.[9] An insulin pump plays an important role in the delivery of fast-acting 
insulin. The control algorithms ensure the adequate delivery of insulin based on 
information from the CGM. To complete the ultimate goal of a fully automated 
system, the challenges of variable insulin absorption after administration and system 
configuration need to be addressed, and adequate control algorithms developed.  
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De ontwikkeling en toepassing van continue metende glucosesensoren zijn een 
belangrijke tak in diabetes gerelateerd onderzoek. Het voornaamste doel van het 
continue meten van glucose is om betere informatie te genereren en meer inzicht te 
verkrijgen in de dagelijkse fluctuaties van de glucosegehaltes bij diabetespatiënten, 
en op deze manier te helpen om  gezonde glucosegehaltes te kunnen handhaven. De 
bestaande methods van niet-continue glucosemetingen zoals de vingerprik en 
HbA1c-gehalte test zijn onvoldoende om bij patiënten voorvallen van hypoglykemie 
en hyperglykemie afdoende te detecteren. Om doorlopende glucose meetapparaten 
te ontwikkelen voor diabetespatiënten zijn in het recente verleden verschillende 
methods uitgeprobeerd, zowel (zo min mogelijk) invasief als volledig niet-invasief. 
De niet-invasieve methoden zijn echter nog lang niet ver genoeg ontwikkeld om alle 
problemen aan te kunnen. Onderhuidse glucosesensoren zijn de meest 
veelbelovende methode voor toekomstige klinische toepassingen. De mogelijkheid 
van mobiel gebruik, stabiliteit op lange termijn, en verhoogde nauwkeurigheid zijn 
de belangrijkste  succesfactoren bij de verdere ontwikkeling van onderhuidse 
glucosesensoren.  
 In Hoofdstuk 1 wordt het bereik van dit proefschrift beschreven samen met een 
algemene inleiding tot biosensoren en microvloeistoffenleer. Het doel van dit 
onderzoek is om een nieuw type te ontwikkelen van een continue metende 
glucosesensor gebasseerd op een alternatieve methode dat gebruik maakt van de 
microvloeistoffenleer. Er zijn drie factoren in het bijzonder waarmee onze aanpak 
zich onderscheidt van bestaande systemen voor continue glucosesensoren. Ten 
eerste hebben wij een aangepaste microdialysetechniek gebruikt dat in een andere 
context reeds als veilig wordt erkend. Glucose dat vanuit het lichaam door de porien 
van een microdialysemembraan  diffundeert wordt daarna getransporteerd naar het 
sensorische gedeelte van het meetapparaat alwaar de analytische reactie plaatsvindt. 
In tegenstelling tot gangbare in vivo methoden wordt door deze opzet het agressieve 
reactieproduct waterstofperoxide buiten het lichaam geproduceerd en ook volledig 
buiten het lichaam gehouden. Ten tweede hebben wij gebruik gemaakt van een 
onderhuidse continue glucosesensor (SCGM) waarin de analytische reactie wordt 
gekatalyseerd door glucose oxidase (GOx) dat zich vrij in oplossing bevindt. Dit in 
tegenstelling tot bestaande systemen waarbij GOx op een vaste drager wordt 
geïmmobiliseerd. Het grootste voordeel van een continue aanvoer van katalyserend 
enzym in oplossing is dat enzymactiviteit veel hoger is. Bovendien wordt 





minder calibraties nodig zijn vergeleken met een electrode waarop GOx is 
geïmmobiliseerd. Echter, het gebruik van microdialyse en een op opgelost GOx 
gebasseerde aanpak vereisen allebei aanvullende componenten zoals een minipomp, 
slangetjessysteem en een detector. Om deze nadelen te verhelpen gebruiken wij de 
alternatieve aanpak uit de microvloeistoffenleer. Het microfluidische system maakt 
het mogelijk om minder chemische stoffen te gebruiken en een snellere reactietijd te 
verkrijgen in een heel klein microfluidisch kanaaltje. Op deze manier zou het in de 
nabije toekomst mogelijk kunnen zijn om een geminiaturiseerde, compacte 
configuratie te bouwen met volledig geïntegreerde componenten. 
 Om de klinische relevantie van continue glucosesensoren te beschouwen en 
daarmee de richting van dit onderzoek vast te stellen hebben we in Hoofdstuk 2 de 
recente vooruitgangen besproken op het gebied van continue glucosesensoren 
(CGMs) en de technische uitdagingen die hierbij nog overwonnen moeten worden. 
Met name (zo min mogelijk) invasieve glucosesensoren, waaronder naaldgelijkende 
glucosesensoren en op microdialyse gebasseerde systemen worden in dit hoofdstuk 
besproken. Bovendien hebben wij uitgebreid literatuuronderzoek gedaan naar een 
aantal factoren die wellicht zorgen voor verschillen tussen de glucosegehaltes in de 
interstitiële weefselvloeistof (ISF) en die in het bloed. Deze factoren zijn onder 
andere: implantatie effecten; bioverontreiniging; bloedglucose versus 
weefselvloeistof gehaltes en de positie van geimplanteerde stoffen.  
 Hoewel uit het literatuuronderzoek is gebleken dat de recente studies naar 
verkrijgbare CGMs resultaten lieten zien die in de kliniek aanvaardbaar zijn, zijn 
hun prestaties nog sub-optimaal en vereisen de huidige beperkingen dat ze in 
technisch opzicht nog aanzienlijk worden verbeterd. Wij stelden een veelbelovende 
aanpak voor die gebruik maakt van zowel een enzymatische minireactor en een 
electrochemische detector, beide geïntegreerd op e en microfluidische chip welke 
zijn aanvoer krijgt door middel van microdialyse. 
De ontwikkeling van een microfluidische chip wordt besproken in Hoofdstuk 3-4. 
In Hoofstuk 3 hebben we de werking van een enzymatische glucose reactor 
aangetoond dat gebasseerd is op chaotische menging in een microfluidisch 
kanalennetwerk  al s essentieel onderdeel van een continue glucosesensor. Om het 
reactieproduct waterstofperoxide te meten werd een electrode (gemaakt van een dun 
laagje platina) aan het einde van het microfluidische kanaaltje gebruikt als 
amperometrische detector op de chip. In het voor klinische doeleinden interessante 
bereik werd een lineaire calibratiecurve voor glucose verkregen voor zowel het 
microkanaaltje met groeven als het kanaaltje met gladde wanden. Dit werd gedaan 




voorzien van een schuin groevenpatroon hadden een hogere gevoeligheid vergeleken 
met micromixers zonder groeven, vanwege de betere dooreenmenging van de 
vloeistofstroom. Een aanzienlijke reductie van de hoeveelheid gebruikte reagentia is 
mogelijk dankzij de combinatie van optimale doorstroomsnelheid, efficiente 
menging, en monsteraanvoer door middel van microdialyse. In Hoofdstuk 4 hebben 
we een alternatieve analytische techniek ontwikkeld waarmee glucosegehaltes 
gemeten kunnen worden, namelijk een microfluidisch systeem met detectie door 
middel vanchemoluminescentie (CL). Ten opzichte van de gangbare 
electrochemische detectie hopen we hiermee de specificiteit van het glucosesignaal 
te vergroten en de interferentie door andere stoffen in het lichaam te verminderen. In 
een systeem met twee reactoren wordt glucose door een silicium photodiode 
omgezet in een CL output signaal.. We hebben zelf microfluidische chips gebouwd 
voor CL detectie. Deze werden gekarakteriseerd en de reactieparameters, zoals 
doorstroomsnelheid, pH en concentraties van luminol en katalysator werden 
geoptimaliseerd. Het aldus aangepaste systeem genereerde een lineaire 
calibratiecurve voor glucose concentraties tussen 2 en 10 mM. Het grootste voordeel 
van dit optische systeem is dat de detector niet direct aan de chemische reactanten 
wordt blootgesteld. Het is een robust systeem vergeleken met de veelgebruikte 
electrochemische detectie waarin de naaldgelijkende electrode erg gehinderd wordt 
door bioverontreiniging en signaaldrift. Uit onze resultaten hebben wij 
geconcludeerd dat dit nieuwe CL microfluidisch systeem geschikt te maken is als 
toekomstige glucosesensor. Als verdere onderzoek is het wellicht interessant om een 
studie te doen naar verstoringen veroorzaakt door complexe biologische monsters en 
de mogelijkheid tot eleminatie van die verstoringen in diverse biomedische 
toepassingen. Met het oog op de twee onderzochte meetmethodes (hoofdstuk 3 en 4) 
zou het daarnaast interessant zijn om de beste eigenschappen van beide 
meettechnieken in één system te combineren om zowel goede nauwkeurigheid als 
lange levensduur te verkrijgen, aangezien de electrochemisch methode heel gevoelig 
is en optische detectie meer geschikt is voor stabiliteit op de langere termijn.  
 Als concrete toepassing van een microfluidisch glucose meetsysteemlaten we in 
Hoofdstuk 5 zien dat een continue en nauwkeurige registratie van glucose mogelijk 
is met een enzymatische microreactor (EMR) in een in vivo opstelling. Met 
Hoofdstuk 3 als uitgangspunt werd de EMR verder ontwikkeld en gekoppeld aan 
een microdialysesensor die in het onderhuidse weefsel van een rat (onder anesthesie) 
werd geplaatst. Een detector met een laagje polypyrrole (PPy) werd gebruikt voor 
het weren van interfererende biologisch stoffen. De EMR gekoppeld met 





concentraties van glucose in het bloed in het klinisch interessante bereik. De in vivo 
prestatie van de EMR werd uitgevoerd door bloed glucosegehaltes te moduleren met 
intraveneuze injecties van glucose (glucose omhoog), insuline (glucose omlaag) en 
een fysiologische zoutoplossing (controle; glucose blijft onveranderd). De snelle en 
nauwkeurige registratie van dynamische veranderingen van glucose gehaltes door de 
EMR  waren veelbelovend. Wij zijn van mening dat het zeer de moeite waard is om 
verdere onderzoek te doen naar continue glucosesensoren door gebruik te maken van 
microfluidische systemen. Met deze studie naar de haalbaarheid van een dergelijke 
systeem hebben we aangetoond dat het mogelijk is om veranderingen in onderhuidse 
glucosegehaltes nauwkeurig waar te nemen onder praktische in vivo 
omstandigheden. Met een pas-ontworpen microfluidisch glucose sensor hebben wij 
geconcludeerd dat het haalbaar is om op een microfluidische chip microdialyse te 
koppelen aan het doorlopende metingen van onderhuidse glucose in ratten. 
 Als alternatieve microfluidisch methode hebben we een nieuw sensorisch systeem 
ontwikkeld voor de doorlopende glucosesensor. Twee verschillende 
meetsysteemtypen werden gerealiseerd, één met electrochemische en één met een 
chemoluminiscentiemethode. Beide maken gebruik van chaotisch mengende 
microkanaaltjes. De p restaties van het uiteindelijke systeem waren uitstekend voor 
in vitro doeleinden. Voor de in vivo toepassing werd het microfluisdisch systeem 
gekoppeld met microdialyse en meette continue de onderhuidse 
glucoseconcentraties in een rat. Een voor de hand liggende uitbreiding voor dit 
onderzoek is verdere verkleining van het microfluidisch systeem naar micro SCGM. 
Aangezien het gebruik van een microfluidisch systeem ons in staat stelt een continue 
doorstroming te meten met slechts een klein vloeistofverbruik biedt een dergelijk 
systeem veel mogelijkheden. Aanvullend onderzoek zal er op gericht zijn om dit 
syteem te verkleinen en de verschillende onderdelen nog beter met elkaar te 
integreren. Dit moet opgevolgd worden met vooruitgang in zowel de technische 
aspecten van het systeem als de compatibiliteit van alle onderdelen. Hiertoe hebben 
we als eerste stap, en met succes, met onze enzymatische reactor een detector op een 
chip ontwikkeld. Het nieuwe compacte ontwerp en het realiseren van van een 
minipomp, controle ventiel, microfluidische reservoirs, werkbare accu en electronica 
vormt een verdere uitdaging in het streven naar een apparaat op bankpasformaat. 
 Een andere interessante onderzoeksvraag gebasseerd op een microfluisdisch 
systeem is het gebruik van andere enzymen dan glucose oxidase in een oplossing 
van interessante analieten. Het is mogelijk om, naast glucosegehaltes, de 
concentraties van andere stoffen te analyseren door simpelweg andere oxidsase-




zorgt voor snelle omzetting van reactieproducten vergeleken met geïmmobiliseerde 
enzymen, en een hogere gevoeligheid en snelle reactie kunnen behaald worden in 
een klein mengkanaaltje. Door de lengte van het microfluidisch kanaaltje aan te 
passen kan men de meng/reactie tijd (analietgevoeligheid) veranderen voor andere 
toepassingen. Meerdere reactiekanalen zouden verschillende substraten tegelijkertijd 
kunnen meten. 
 Om meer inzicht te verkrijgen in de fysiologische en farmacologische aspecten 
van het systeem en haar mogelijke toepassingen is het belangrijk om verder 
onderzoek te doen in vrijbewegende ratten, en uiteindelijk ook in mensen (zowel 
gezonde proefpersonen als patiënten met diabetes).  Vrijbewegende proefdieren zijn 
een beter model voor de mens omdat anethesie het glucosemetabolisme op een 
complexe manier beïnvloedt. Onderzoek in vrijbewegende ratten zal ook meer 
inzicht opleveren in de gepostuleerde push-pull theorie over de dynamische 
verschillen in glucose concentraties tussen het bloed en de interstitiële 
weefselvloeistof.  
 De ultieme geavanceerde technische toepassing is een ‘kunstmatige alvleesklier’ 
dat zelf voortdurend de glucoseconcentraties meet en zonodig precies de juiste 
hoeveelheid insuline toedient. Een dergelijke toepassing maakt doorlopende 
metingen van glucose noodzakelijk, en voor het hierbovengenoemd gesloten 
systeem is de ontwikkeling van CGM dan ook een vereiste eerste stap. Naast verdere 
ontwikkeling van zeer nauwkeurige en betrouwbare CGMs moeten andere 
onderdelen zoals een insulinepomp en controlealgoritmes nog verder ontwikkeld 
worden. Een insulinepomp speelt een belangrijke rol om gemakkelijk en geleidelijk 
insuline toe te dienen, op een manier die heel erg lijkt op een gezonde pancreas. De 
controlealgoritmen zorgen ervoor dat een passende hoeveelheid insuline toegedient 
wordt afhankelijk van de informatie verkregen uit de CGM. Daarbij spelen ook 
patiëntgebonden, en nog altijd slecht begrepen, factoren een belangrijke rol. De 
combinatie van zowel continue glucosemetingen als een goede toediening van 
insuline is belangrijk voor de verbetering van een goede glucosehuishouding bij 
patiënten. De uitdaging van een volledig geautomatiseerde systeem, de aanpak van 
variabele insuline absorptie na toediening, verbeterde systeem configuratie en goede 
algorithmen vormen belangrijke onderdelen voor een vervolgonderzoek. De 
uitdagingen van een volledig geautomatiseerd systeem, waarbij nauwkeurige en 
continue glucosemetingen de input vormen voor een adaptief regulerend systeem dat 
ook nog eens op e en prettige manier door patiënten te gebruiken is, vormen een 
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CCD:         Charge coupled device  
CE:      Counter electrode   
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CGMS:      Continuous Glucose Monitoring System  
CL:      Chemiluminescence   
EGA:      Error Grid Analysis  
EMR:      Enzymatic microreactor   
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PBS:      Phosphate-buffered saline solution   
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Re:      Reynolds  number  
RE:      Reference electrode   
SCGM:      Subcutaneous glucose monitoring system   
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